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ABSTRACT 
ABCB1, a member of the ATP binding cassette (ABC) transporter family, hydrolyses ATP as energy 
source for the translocation of substrate chemicals across the cell membrane. ABCB1-like 
transporters are found in all studied species. Typically, these transporters are abundant in tissues 
that separate compartments of the body such as the blood-brain barrier. Among the ABC 
transporters the ABCB1-like transporter proteins are of particular interest because they accept a 
broad variety of substrates and are therefore able to confer multidrug resistance (MDR) and 
multixenobiotic resistance (MXR) in wildlife, respectively. Inhibitors of the ABCB1-like transporter 
function can cause chemosensitisation, i.e. accumulation and increased sensitivity of organisms 
towards potentially harmful (natural/man-made) ABCB1-like substrate chemicals. In zebrafish 
(Danio rerio) Abcb4 was identified as functionally homologous to ABCB1.  
The aim of this study was to further characterise Danio rerio Abcb4 and to provide a database to 
approach the question to what extent ABCB1-like transporter related functions/effects are of 
ecotoxicological relevance. Main objectives are whether and how known ABCB1 ATPase stimulators 
and inhibitors interact with Abcb4 ATPase activity; to what extent ABCB1 ATPase assay data are 
transferable to Abcb4 ATPase assay data; and whether and how environmental chemicals interact 
with Danio rerio Abcb4 ATPase activity. 
In this study we established a test system – the ATPase assay with recombinant Danio rerio Abcb4 – 
to study the interaction of chemicals with the ATPase activity of the transporter protein. To relate 
obtained data to data for the well-known Homo sapiens ABCB1 and because available data for Homo 
sapiens ABCB1 were not in all cases suitable for a comparison, the ATPase assay with recombinant 
ABCB1 was adapted accordingly. Chemicals were tested up to concentrations in the range of their 
water solubilities to modulate basal and stimulator co-treated Abcb4 and/or ABCB1 ATPase 
activities. ATPase stimulators are often transported substrates. However, lipophilic compounds 
stimulating the transporter ATPase activity are not or little transported by transporter action. 
Therefore, experiments revealing whether compounds are translocated by transporters chemical 
interference with the transporter protein will not be indicated. Chemicals inhibiting the stimulator 
(here verapamil) co-treated ATPase activity compete with the verapamil to stimulate ATPase 
activity or are non-competitive inhibitors. When tested individually, these chemicals can be 
stimulators or inhibitors of basal ATPase activity, or do not interact with basal ATPase activity. 
ATPase inhibitors mitigate ATPase activity and ABCB1-like transporter mediated translocation of 
substrate chemicals. Obtained ATPase assay data were analysed with regard to concentrations at 
half-maximal effects (EC50s) and effect strengths (percent modulation). 
  
ATPase assays with recombinant Abcb4 (at 27 °C) are comparable to ABCB1 ATPase assay data 
obtained at 37 °C. Danio rerio Abcb4 seems less temperature-sensitive than ABCB1. Calculated 
activation energies for Abcb4 ATPase activities (40.75 kJ/mol for basal ATPase activity) were up to 
half as high as those for ABCB1 ATPase activities (81.61 kJ/mol for basal ATPase activity). Larger 
activation energies were previously proposed to be indicative for larger conformational 
rearrangements and hence possibly smaller rearrangements take place in Abcb4 compared to 
ABCB1. Known standard modulators of Homo sapiens ABCB1 ATPase activity interacted specifically 
with Danio rerio Abcb4 ATPase actitiy. The EC50s of the tested chemicals – 16 of 17 tested 
chemiacals interacted with the ABCB1 and the Abcb4 ATPase activity – ranged from 0.09 to 296 µM 
for ABCB1 and from 0.14 to 171 µM for Abcb4. Qualitative ATPase assay data for ABCB1, as 
interaction or not, seems transferable to Danio rerio Abcb4. Furthermore, when aligning amino acid 
sequences of mammalian ABCB1 transporter proteins and Danio rerio Abcb4 and comparing ABCB1 
residues known to bind to (lipophilic) chemicals no obvious hints were found that chemical binding 
to Abcb4 is certainly different from ABCB1. Twenty-five of 33 studied environmental chemicals 
modulated the Abcb4 ATPase activity as stimulators and/or inhibitors. Stimulation of basal Abcb4 
ATPase activity was lower for environmental chemicals than for known standard modulators. 
EC50s of environmental chemicals ranged from below 10 to 357 µM. Effects by environmental 
chemicals on Abcb4 ATPase activity with EC50s close to their water solubilities may be rather 
unspecific. 
The results of this work underline that Abcb4 function is of ecotoxicological importance as on the 
one hand several environmental chemicals were identified to inhibit Abcb4 ATPase activity – likely 
acting as chemosensitisers, while on the other hand chemicals stimulating basal ATPase activity 
suggest that these chemicals are possibly transported. A number of environmental chemicals also 
inhibited the basal Abcb4 ATPase activity. Especially non-transported inhibitors of the basal Abcb4 
ATPase activity would be of ecotoxicological relevance as organisms (here Danio rerio) exposed to 
these chemicals would not be protected by Abcb4 mediated multixenobiotic resistance and were 
moreover threatened by chemosensitisation. 
Future studies should systematically elucidate under which circumstances chemicals are 
apparently net transported by ABCB1-like transporters and relate these findings to concentrations 
of environmental chemicals and ABCB1-like transporter protein abundance in wildlife. 
 
 
 
 
 I 
CONTENT 
List of abbreviations ................................................................................................................................................................ V 
List of figures ............................................................................................................................................................................ VI 
List of tables ............................................................................................................................................................................. VII 
1 General introduction and background .................................................................................................................... 1 
1.1 ABC transporters and disposition of chemicals from cells ............................................................................................... 1 
1.1.1 Implications from interaction of chemicals with ABCB1-like transporters ............................................... 2 
1.1.2 A brief introduction to mammalian P-glycoprotein ABCB1 .............................................................................. 3 
1.2 ABCB1-like transporters and ecotoxicology .......................................................................................................................... 4 
1.3 ABCB1/4-like P-glycoproteins of fish species ........................................................................................................................ 5 
1.3.1 Danio rerio Abcb4 ................................................................................................................................................................. 7 
1.4 General Characteristics of ABCB1/4 like P-glycoproteins ................................................................................................ 9 
1.4.1 Topology ................................................................................................................................................................................... 9 
1.4.2 Function of mammalian ABCB1................................................................................................................................... 10 
1.5 Classification of chemical ABCB1- interactions ................................................................................................................. 11 
1.5.1 Methodologies to study interaction of chemicals with ABCB1 ...................................................................... 13 
1.5.1.1 ATPase assay ............................................................................................................................................................... 13 
1.5.1.2 Further test systems to study ABCB1-like transporter proteins ......................................................... 15 
1.5.1.3 Congruency of results from different test systems .................................................................................... 16 
1.6 Objectives of the thesis ................................................................................................................................................................. 17 
2 Establishment of a protocol for obtaining qualitatively and quantitatively robust 
data from ATPase assays with recombinant Danio rerio Abcb4 and Homo sapiens 
ABCB1 ................................................................................................................................................................................ 19 
2.1 Abstract ............................................................................................................................................................................................. 19 
2.2 Introduction ..................................................................................................................................................................................... 20 
2.3 Methodology .................................................................................................................................................................................... 22 
2.3.1 Chemicals............................................................................................................................................................................... 22 
2.3.2 Material .................................................................................................................................................................................. 23 
2.3.2.1 cDNA clones ................................................................................................................................................................. 23 
2.3.2.2 Generation of baculoviruses ................................................................................................................................. 25 
2.3.2.3 Sf9 cell culture ............................................................................................................................................................ 25 
2.3.2.4 Recombinant protein production....................................................................................................................... 25 
2.3.3 ATPase assays...................................................................................................................................................................... 26 
2.3.3.1 Plate design and handling ...................................................................................................................................... 26 
2.3.3.2 Data analysis ................................................................................................................................................................ 27 
2.3.3.3 Decision criteria for interaction of chemicals with ABC transporter ATPase activities ............ 28 
2.4 Optimisation of assay parameters .......................................................................................................................................... 28 
2.4.1 Optimisation of MgATP and sodium orthovanadate concentrations ......................................................... 29 
2.4.2 Abcb4 ATPase activities determined after different reaction duration .................................................... 30 
CONTENT 
II 
2.4.3 Summary of used ATPase assay conditions ........................................................................................................... 31 
2.4.4 Concentration response relationship modelling ................................................................................................. 32 
2.5 ATPase activities from Danio rerio wild-type Abcb4, mutant Abcb4 baculovirus infected, 
and native Sf9 cell membrane preparations ....................................................................................................................... 34 
2.6 Quality control ................................................................................................................................................................................ 35 
2.6.1 Immunohistochemical detection of recombinant protein in membrane preparations 
of baculovirus infected Sf9 cells .................................................................................................................................. 36 
2.6.2 Reproducibility of ATPase assay results ................................................................................................................. 36 
2.7 Conclusion ........................................................................................................................................................................................ 40 
3 Danio rerio Abcb4 and Homo sapiens ABCB1 ATPase activities at different 
temperatures .................................................................................................................................................................. 41 
3.1 Abstract ............................................................................................................................................................................................. 41 
3.2 Introduction ..................................................................................................................................................................................... 41 
3.3 Methodology .................................................................................................................................................................................... 42 
3.3.1 Tested chemicals ................................................................................................................................................................ 42 
3.3.2 Data analysis ........................................................................................................................................................................ 42 
3.4 Results ................................................................................................................................................................................................ 43 
3.4.1 Abcb4 and ABCB1 ATPase activities at different temperatures ................................................................... 43 
3.4.2 Activation energies of basal and verapamil stimulated Abcb4 and ABCB1 ATPase 
activities ................................................................................................................................................................................. 47 
3.5 Discussion ......................................................................................................................................................................................... 48 
3.5.1 Abcb4 and ABCB1 ATPase activities at different temperatures ................................................................... 48 
3.5.2 Activation energies of basal and verapamil stimulated Abcb4 and ABCB1 ATPase 
activities ................................................................................................................................................................................. 48 
3.6 Conclusion ........................................................................................................................................................................................ 50 
4 Comparison of functional properties of the multidrug transporter Abcb4 from Danio 
rerio with Homo sapiens ABCB1 based on ATPase activities of recombinant protein ........................ 51 
4.1 Abstract ............................................................................................................................................................................................. 51 
4.2 Introduction ..................................................................................................................................................................................... 52 
4.3 Methodology .................................................................................................................................................................................... 54 
4.3.1 Chemicals............................................................................................................................................................................... 54 
4.3.2 Chemical selection – additional information ......................................................................................................... 55 
4.3.3 Chemical concentrations used in ATPase assays ................................................................................................. 57 
4.3.4 ATPase assay conditions................................................................................................................................................. 57 
4.3.5 Analysis of amino acid sequences .............................................................................................................................. 57 
4.4 Results ................................................................................................................................................................................................ 58 
4.4.1 Interaction of chemicals with recombinant Abcb4 and ABCB1 ATPase ................................................... 58 
4.4.1.1 Concentration response relationships of chemicals interacting with Abcb4 and ABCB1 
ATPase activities ........................................................................................................................................................................... 62 
4.4.1.2 Overview on interaction of chemicals with Abcb4 and ABCB1 ATPase activities ....................... 66 
4.4.2 Drug binding sites of Homo sapiens ABCB1 and Mus musculus ABCB1a compared to 
Danio rerio Abcb4 amino acid sequence ................................................................................................................. 68 
4.5 Discussion ......................................................................................................................................................................................... 70 
CONTENT 
III 
4.5.1 Concentration response relationships and kinetic parameters of chemicals 
interacting with ABCB1 and Abcb4 ATPase activities ....................................................................................... 71 
4.5.1.1 Stimulation of basal ABCB1 and Abcb4 ATPase activities ...................................................................... 71 
4.5.1.2 Inhibition of basal and stimulator co-treated ABCB1 and Abcb4 ATPase activities ................... 73 
4.5.1.3 Inhibition of stimulator co-treated Abcb4 and ABCB1 ATPase activities ........................................ 74 
4.5.1.4 Chemicals with different effects on ABCB1 and Abcb4 ATPase activities ....................................... 75 
4.5.2 Drug binding sites of Homo sapiens ABCB1 and Mus musculus ABCB1a compared to 
amino acid sequence of Danio rerio Abcb4 ............................................................................................................ 78 
4.6 Significance of findings and outlook ...................................................................................................................................... 80 
5 Danio rerio Abcb4 ATPase activity modulation by potential environmental pollutants 
compared to standard modulators ......................................................................................................................... 81 
5.1 Abstract ............................................................................................................................................................................................. 81 
5.2 Introduction ..................................................................................................................................................................................... 82 
5.3 Methodology .................................................................................................................................................................................... 84 
5.3.1 Tested chemicals ................................................................................................................................................................ 84 
5.3.2 Production of recombinant protein and use in ATPase assays ..................................................................... 86 
5.3.3 Comparison of effects from standard modulators and environmental chemicals ............................... 86 
5.4 Results ................................................................................................................................................................................................ 87 
5.4.1 Modulation of Abcb4 ATPase activity by environmental chemicals ........................................................... 87 
5.4.1.1 Stimulation of basal Abcb4 ATPase activity by tested chemicals ........................................................ 89 
5.4.1.2 Inhibition of basal Abcb4 ATPase activity by chemicals .......................................................................... 90 
5.4.1.3 Inhibition of stimulator co-treated Abcb4 ATPase activity .................................................................... 95 
5.4.2 Overview of results ........................................................................................................................................................... 96 
5.5 Discussion ......................................................................................................................................................................................... 98 
5.5.1 Stimulation of Abcb4 ATPase activity ....................................................................................................................... 98 
5.5.2 Inhibition of Abcb4 ATPase activity ....................................................................................................................... 100 
5.6 Summary and outlook ...............................................................................................................................................................103 
6 Summary and implications of main outcomes of the thesis ....................................................................... 105 
7 References .................................................................................................................................................................... 111 
A Appendix ....................................................................................................................................................................... 127 
A.1 Nucleotide sequence of Danio rerio Abcb4 ........................................................................................................................127 
A.2 Protocol for recombinant protein production and the ATPase assay.....................................................................127 
A.2.1 Sf9 cell culture .................................................................................................................................................................. 127 
A.2.2 Transfection of Sf9 cells, generation of a P1 baculovirus stock, and virus 
propagation ....................................................................................................................................................................... 127 
A.2.3 Determination baculovirus titres using the plaque Assay............................................................................ 128 
A.2.4 Production of recombinant wild-type Abcb4, mutant non-functional Abcb4, and 
ABCB1 proteins in Sf9 cells ........................................................................................................................................ 128 
A.2.5 Crude membrane preparations ................................................................................................................................ 128 
A.2.6 Western blots to show presence of recombinant protein in membrane preparations ................... 129 
A.2.7 ATPase assay ..................................................................................................................................................................... 130 
A.2.8 Re-Analysis of ATPase assay data from earlier pipetting scheme ............................................................ 133 
A.2.9 Constraints in concentration response relationship modelling ................................................................ 135 
A.3 Supplemental tables and figures ...........................................................................................................................................135 
CONTENT 
IV 
A.3.1 Primer sequences ........................................................................................................................................................... 135 
A.3.2 Sf9 membrane preparations with recombinant Danio rerio Abcb4 and Homo sapiens 
ABCB1 .................................................................................................................................................................................. 135 
A.3.3 Recombinant Danio rerio Abcb4 in baculovirus infected Sf9 cell membranes after 
different infection duration ........................................................................................................................................ 136 
A.3.4 Parameters for concentration response relationships .................................................................................. 137 
A.4 References .......................................................................................................................................................................................139 
List of publications .............................................................................................................................................................. 140 
Eidesstattliche Erklärung ................................................................................................................................................. 141 
Übereinstimmungserklärung .......................................................................................................................................... 142 
Acknowledgements - Danksagung ................................................................................................................................. 143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 V 
LIST OF ABBREVIATIONS 
ABC ATP binding cassette  
Abcb4/abcb4 Danio rerio Abcb4/abcb4 (protein/gene) 
ABCB1/ABCB1 Homo sapiens ABCB1/ABCB1 (protein/gene) 
ADP Adenosine diphosphate 
ATP Adenosine triphosphate 
bA Basal ATPase activity  
Bluo-gal 5-Bromo-3-indolyl-β-D-galactopyranoside 
cA (Stimulator) co-treated ATPase activity 
CI Confidence interval 
DNA Deoxyribonucleic acid 
dpf Days post fertilisation 
E.coli Escherichia coli 
H2O Water 
hpf Hours post fertilisation 
kDa Kilodalton = 1000 Dalton (unit)  
MDR Multidrug resistance 
MDR1 (Homo sapiens) Multidrug resistance protein 1, also P-gp, ABCB1  
MgATP Magnesium adenosine triphosphate 
mg Milligram, 1·10-3 gram (unit) 
min Minute (unit) 
MXR Multixenobiotic resistance 
nf Abcb4 Non-functional Danio rerio Abcb4 
nmol Nanomole, 1·10-9 mol (unit) 
PCR Polymerase chain reaction 
PFOS Perfluorooctane sulfonate 
P-gp P-glycoprotein (Homo sapiens ABCB1-like proteins) 
Pi Inorganic phosphate 
sA Stimulated ATPase activity  
SEM Standard error of the mean 
Sf9 Insect cell line, Spodoptera frugiperda (Sf) 
WIK A Danio rerio wild-type strain 
 
 
 
 VI 
LIST OF FIGURES 
Fig. 1.1 Drug disposition processes in a hypothetical epithelial cell ................................................................................... 2 
Fig. 1.2 Schematic topology of Danio rerio Abcb4 ........................................................................................................................ 9 
Fig. 1.3 Test modes of the ATPase assays and possible interaction outcomes ............................................................. 13 
Fig. 2.1. Alignment of amino acid sequences of Danio rerio Abcb4 and Mus musculus ABCB1a at 
the ABC signature sequence and the Walker B motif .............................................................................................. 24 
Fig. 2.2 Abcb4 and ABCB1 ATPase activities with varying MgATP and vanadate concentrations ...................... 30 
Fig. 2.3 ATPase activities of recombinant Danio rerio Abcb4 after different reaction durations ........................ 31 
Fig. 2.4 Verapamil and DMSO in ATPase assays ......................................................................................................................... 32 
Fig. 2.5 ATPase activities from Danio rerio Abcb4, non-functional Danio rerio Abcb4 and native 
Sf9 cell membrane protein................................................................................................................................................... 35 
Fig. 2.6  Western blot of membrane preparations from native Sf9 cells and Sf9 cells expressing 
recombinant ABCB1, Abcb4, and non-functional Abcb4 ........................................................................................ 36 
Fig. 2.7  Basal and verapamil stimulated ATPase activities from all used ABCB1 and Abcb4 
membrane preparations ....................................................................................................................................................... 38 
Fig. 3.1 Danio rerio Abcb4 and Homo sapiens ABCB1 ATPase activities at 27 °C and 37 °C ................................... 44 
Fig. 3.2  Arrhenius plot for ABCB1 and Abcb4 ATPase activities......................................................................................... 47 
Fig. 4.1 Concentration response relationships for chemicals interacting with Danio rerio 
Abcb4 and Homo sapiens ABCB1 ATPase activity ..................................................................................................... 61 
Fig. 4.2 Multiple amino acid sequence alignment of Abcb4, ABCB1, and ABCB1a...................................................... 70 
Fig. 5.1 Concentration response relationships of environmental chemicals modulating the 
Abcb4 ATPase ............................................................................................................................................................................ 88 
Fig. 5.2 Comparison of Danio rerio Abcb4 ATPase activity modulation by standard modulators 
and environmental chemicals ............................................................................................................................................ 94 
Fig. A.1 Pipetting scheme for ATPase assays ............................................................................................................................ 132 
Fig. A.2 Pipetting scheme used in early ATPase assays ........................................................................................................ 133 
Fig. A.3 Early ATPase assay data before and after re-analysis .......................................................................................... 134 
Fig. A.4 Re-analysis of example data ............................................................................................................................................. 134 
Fig. A.5 Western blots from seven membrane preparations of Abcb4 and ABCB1 each ...................................... 135 
Fig. A.6 Western blots of protein extracts from Sf9 cells with recombinant Abcb4 ................................................ 136 
Fig. A.7 Modulation of ABCB1 ATPase activity by colchicine and verapamil ............................................................. 138 
Fig. A.8 Endosulfan modulating stimulator co-treated Abcb4 ATPase activity ......................................................... 138 
 
 
 
 
 
 
 
 
 
 
 VII 
LIST OF TABLES 
Table 2.1 Overview of ATPase assay conditions for recombinant Abcb4 and ABCB1 in this 
work ........................................................................................................................................................................................... 32 
Table 2.2 Kinetic parameters from different equations to describe ABCB1 ATPase activity 
stimulation .............................................................................................................................................................................. 34 
Table 2.3 Overview on variability of ATPase activities from the used membrane preparations ......................... 39 
Table 3.1 Kinetic parameters of concentration response relationships from recorded Abcb4 
and ABCB1 ATPase activities at 27 °C and 37 °C .................................................................................................... 46 
Table 4.1 Characteristics of chemicals tested to interact with ABCB1 and Abcb4 ATPase 
activities.................................................................................................................................................................................... 56 
Table 4.2 Kinetic parameters of chemicals modulating of Danio rerio Abcb4 and Homo sapiens 
ABCB1 ATPase activities ................................................................................................................................................... 64 
Table 4.3 Overview on interaction of chemicals with ABCB1 and Abcb4 ATPase activities ................................... 67 
Table 4.4 Overview on amino acid sequence comparison of Abcb4, ABCB1, and ABCB1a ..................................... 69 
Table 5.1 Characteristics of environmental chemicals studied for Danio rerio Abcb4 ATPase 
modulation .............................................................................................................................................................................. 85 
Table 5.2 Kinetic parameters for modulation of Danio rerio Abcb4 ATPase activity by 
environmental chemicals .................................................................................................................................................. 91 
Table 5.3 Overview of environmental chemicals tested for interaction with the Danio rerio 
Abcb4 ATPase activity ........................................................................................................................................................ 97 
Table A.1 Primer sequences .............................................................................................................................................................. 135 
Table A.2 MgATP modulating basal and 22.2 µM verapamil stimulated ABCB1 and Abcb4 
ATPase activities. ............................................................................................................................................................... 137 
Table A.3 Verapamil and cyclosprorin A modulating basal and verapamil co-treated Abcb4 
ATPase   activities. A, verapamil. B, Cyclosporin A. ............................................................................................ 137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
1 GENERAL INTRODUCTION AND BACKGROUND 
1.1 ABC TRANSPORTERS AND DISPOSITION OF CHEMICALS FROM CELLS  
Organisms have developed mechanisms to cope with natural and anthropogenic toxins they are 
exposed to. Thereby, toxicokinetic processes – absorption, distribution, metabolism, excretion 
(ADME) – are determined by active transport, enzymatic modification, and by physicochemical 
properties of biological molecules and the chemical (Fig. 1.1). Detoxification is mediated by 
transporter proteins in the cell membrane which contribute to the absorption, distribution, and 
excretion of a chemical (Leslie et al., 2005). Important transporter proteins, besides organic anion 
transporter proteins (OATP) (Kalliokoski & Niemi, 2009), are members of the ATP (Adenosine 
triphosphate) binding cassette (ABC) transporter subfamilies ABCB (ABCB1), ABCC (ABCC1-5), and 
ABCG (ABCG2) (reviewed in Leslie et al., 2005; Renes et al., 2000; Dietrich et al., 2003). ABCB1 
(MDR1, P-glycoprotein) modulates the absorption and distribution of chemicals as it transports 
unmodified substrate chemicals across the membrane out of the cell (Ayrton & Morgan, 2001; 
Schinkel et al., 1995; Schinkel et al., 1997; Darwich et al., 2010; Aller et al., 2009). ABCC1-5 (MRP1-
5) transport anions as phase II metabolites and contribute to the elimination and distribution of 
chemicals (Leslie et al, 2005; Ayrton & Morgan, 2001; Cole & Deeley, 1998; Deeley, 2006). ABCG2 
transports unmodified (reviewed in König et al., 2013) and sulphate conjugated chemicals (Suzuki 
et al., 2003). Members of the subfamilies ABCC and ABCG are beyond the scope of this work. An 
overview on substrates and function of ABC transporter proteins is given in e.g. Deely (2006) and 
Stein & Litman (2014).  
Biotransformation is facilitated by phase I enzymes (e.g. cytochrome P450 family) that modify 
unpolar functional groups of molecules to more polar and hydrophilic functional groups and 
thereby prepare for conjugation of phase I metabolites to glutathione, sulphate or gluconates by 
phase II biotransformation enzymes. As a consequence, the obtained more hydrophilic and higher 
molecular weight chemical can be excreted. However, besides detoxifying processes, phase I 
enzymes can also lead to bioactivation with the consequence that the metabolised chemical is more 
toxic than the parent compound. As an example, benzo[a]pyrene metabolism by cytochrome P450 
results in a more toxic benzo[a]pyrene-7,8-dihydroxy-9,10-epoxid (Jiang et al., 2007).  
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Fig. 1.1 Drug disposition processes in a hypothetical epithelial cell 
(1) Unpolar chemicals (filled circles) may enter the cell via passive diffusion. (2) Hydrophobic chemicals may 
be effluxed by ABC transporters (T), as ABCB1 and ABCG2, which are abundant on the apical side of polarised 
epithelial cells. (3) Chemicals in the cytoplasm may be subjected to biotransformation processes and are 
modified to more polar chemicals (open circles) by phase I enzymes, which enables further conjugation of 
endogenous anionic moieties (triangles) by phase II enzymes. (4) ABCC2 (apical) and ABCC3 (basolateral) 
transporters translocate organic anions and conjugated metabolites. ABCG2 also transports sulphate 
conjugated chemicals. The schematic is based on the mammalian intestine, modified from Chan et al. (2004) 
and is taken from Luckenbach et al. (2014), with permission. 
 
1.1.1 Implications from interaction of chemicals with ABCB1-like transporters 
ABCB11, a member of the ATP binding cassette (ABC) transporter family, and all other proteins with 
the conserved ATPase domain (ATP binding cassette) hydrolyse ATP as energy source for their 
biological processes (Bouige et al., 2002), such as translocation of substrate chemicals by ABCB1 
(Horio et al., 1988; Hyde et al., 1990). ABCB1 facilitated translocation of substrate chemicals across 
membranes influences the bioavailability of compounds acting as substrates (reviewed in Staud 
et al., 2010; Ayrton and Morgan, 2001; Mayer et al., 1997; Bard, 2000). Hence, ABCB1 mediated 
efflux of chemicals counteracts the accumulation of potentially harmful chemicals in a cell or 
organism leading to multidrug/multixenobiotic resistance (MDR/MXR).  
                                                             
1 The name ABCB1 is reflecting its affiliation to the ABC transporter family. Further terms are P-glycoprotein, 
for permeability glycoprotein, and MDR1, point to its role in multidrug resistance and are more historic. 
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The translocation of chemicals across membranes by ABCB1-like transporters can be inhibited by 
further chemicals which may lead to decreased efflux/increased accumulation of (possibly harmful) 
substrates and subsequent increased sensitivity of the organism toward the substrate chemical, i.e. 
to so called chemosensitisation (Gottesman & Pastan, 1988; Cornwall et al., 1995; Galgani et al., 
1996; Kurelec et al., 1997; Luckenbach et al., 2005). Chemosensitising chemicals inhibit the ABCB1-
like mediated translocation of substrate chemicals via competition for substrate binding sites or via 
non-competitive inhibition (Kurelec, 1997; Bard, 2000; Sarkadi et al., 2006). (Terms “substrate” 
and “inhibitor” are described in detail in section 1.5) 
ABCB1-like proteins generally show a broad specificity with regard to transported substrates as 
well as to chemosensitisers/inhibitors. The reason for this multi-specificity is the rather large 
binding cavity of ABCB1 and its flexibility (Aller et al., 2009) (Functional details for ABCB1-like 
proteins are given in section 1.4.2.). Substrates of Homo sapiens ABCB1, the so far most studied ABC 
transporter, comprise endogenous substances (e.g. testosterone [Von Richter et al., 2009], estradiol 
[Rao et al., 1994]), membrane constituents (Masuda et al., 2008), and un-metabolised chemicals of 
natural (e.g. colchicine [Sarkadi et al., 1992]) and artificial origin (e.g. verapamil [Sarkadi et al., 
1992]).  
Substrates are suggested to be moderately hydrophobic, have a low molecular weight and positive 
or neutral residues (Gottesman und Pastan, 1988; Higgins et al., 2007; Litman et al., 2001; McDevitt 
et al., 2007). Common characteristics of inhibitors are a molecular weight > 300 g/mol, moderate to 
high lipophilicity, a basic nitrogen atom as and a positive charge at physiological pH (Bain et al., 
1997; Smital et al., 2004). However, common physicochemical characteristics of ABCB1 inhibitors, 
as described by e.g. Bain & LeBlanc (1996), Higgins et al. (2007), and Gottesman & Pastan (1988), 
could not be confirmed by Kurth et al., (2015), who reviewed literature data on the 
chemosensitisation potential of the so far tested chemicals. 
Also artificial, environmental chemicals can be transported substrates or act as chemosensitisers 
(Kurelec, 1997; Smital et al., 2004; Nicklisch et al., 2016).  
 
1.1.2 A brief introduction to mammalian P-glycoprotein ABCB1 
Most research articles on ABCB1 focus on its function and role in human or mammalian physiology 
– especially in cancer, multidrug resistance, and in pharmacokinetics – starting about 40 years ago. 
Following, a brief profile of mammalian ABCB1 is provided. 
In the late 1960s researchers discovered cell lines that are resistant to drugs and subsequently 
found that these cell lines exhibit increased drug efflux (Kessel et al., 1968; Danø, 1973). In 1976 
Juliano & Ling demonstrated that a membrane protein, ABCB1, in the cell membrane of drug 
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resistant cancer cells is responsible for pleiotropic cross-resistance of these cells against a range of 
pharmaceuticals and coined the term multidrug resistance (MDR). 
ABCB1 is abundant in the apical membrane of epithelial cells of the intestine, liver, kidney, and in 
endothelial cells of capillary blood vessels at the blood-brain-barrier (Thiebaut et al., 1987; 
Schinkel & Jonker, 2003; Sarkadi et al., 2006). For a detailed overview on expression of mammalian 
ABCB, ABCC and ABCG transporters in different organs see König et al. (2013). 
ABCB1 was identified to prevent ivermectin and vinblastine crossing the blood-brain barrier in 
rodents by demonstrating increased concentrations of these chemicals in ABCB1 knockout mice 
(mdr1a (-/-)) brains (Schinkel et al., 1994). Similar results were obtained for loperamide, 
cyclosporin A, saquinavir, indinavir and others compounds (Schinkel et al., 1996; Kim et al., 1998). 
In human, ABCB1 is proposed to be involved in side effects of antihistamines (Polli et al., 2003; 
Chen et al., 2003), efficacy of antidepressants (reviewed in O’Brien et al., 2012) and blood-tissue 
barriers permeability for ABCB1 substrates (reviewed in Fromm et al., 2004). 
Goldstein et al. (1989) reported elevated levels of ABCB1 RNA in > 400 human cancers, amongst 
them in untreated, intrinsically drug-resistant tumours of the colon, kidney, adrenal gland, liver, 
and pancreas. ABCB1 expression is detected in 39 of 60 cell lines derived from cancer tissue 
including renal and colon carcinomas, melanomas and central nervous system tumours (Alvarez 
et al., 1995). Expression of ABCB1 in cell lines from renal and colon carcinomas are highest with 
expression levels ranging from the reference cell line SW620 with a value of 10 to 749 in renal cells 
and to 457 in colon cells, respectively (Alvarez et al., 1995). A correlation is reported between 
increased ABCB1/ABCB1 expression levels and decreased drug permeability at the lower 
concentration range in ABCB1 expressing cells (Shirasaka et al., 2008). (At higher concentrations 
permeability reaches a maximum.) In a quantitative PCR analysis of clinical samples ABCB1 
negative samples are preferably seen for drug responsive tumour types (Noonan et al., 1990).  
 
1.2 ABCB1-LIKE TRANSPORTERS AND ECOTOXICOLOGY 
Studies on ABC transporter function of aquatic species are important from at least two 
perspectives. One viewpoint is the role of active transport by cellular transporter proteins in 
toxicokinetics of e.g. the zebrafish in general (i). Another one concerns chemosensitisation, 
especially of relevance in scenarios in which organisms are exposed to a variety of chemicals (ii).  
It is not yet unravelled completely how the ABCB1 mediated translocation of chemicals is working 
exactly, e.g. from where to where substrate chemicals are translocated (Sharom, 2014; Stein & 
Litman 2014). However, parameters from in vitro data on ABCB1 mediated efflux and challenges for 
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their use in physiologically based toxicokinetic (PBTK2) models are under discussion (reviewed in 
Sjöstedt et al., 2014). (Homo sapiens) ABCB1 function becomes predominantly visible with regard 
to blood-tissue barrier (non-) permeability and in scenarios with moderate to high expression of 
the transporter(s) as in multidrug resistant cancer cells (see section 1.1.2). Similarly, for wildlife 
organisms ABCB1-like function might be involved in limited blood-brain barrier permeability of 
ABCB1-like transporter substrates. Concentration of these chemicals in the brain could be 
dependent on ABCB1-like efflux in organisms with physiological protein expression. Effects of 
ABCB1 mediated transport on overall bioavailability of MDR/MXR transporter substrates as well as 
effects by chemosensitisation could be limited to organisms/cells with high expression levels of the 
transporter or in a mixture scenario. In the end, further transporter proteins and biotransformation 
enzymes may contribute to bioavailability/concentrations of a chemical at target sites as well (i). 
Although several studies on the chemosensitisation potential of chemicals have been performed, it 
is still not known to what extent chemosensitisation is ecotoxicologically relevant with respect to 
the overall number of man-made chemicals acting as chemosensitisers and their concentrations in 
the environment (Kurth et al., 2015). At the same time, elevated levels of ABCB1-like protein and 
ABCB1 related function in organisms from polluted environments point to a function of the ABCB1-
like proteins to prevent potentially harmful chemicals to accumulate in cells or organisms (Scott 
et al., 1999; Lu et al., 2015; Smital et al., 2003; Bard et al., 2002a). Further, experiments with 
samples from contaminated environments revealed a chemosensitising potential of chemicals in 
those samples (Zaja et al., 2013, Nicklisch et al., 2016). These studies suggest that ABCB1-like efflux 
transporters are indeed involved in detoxifying environmental pollutants and that transporter 
function can indeed be compromised by chemosensitising chemicals (ii).  
Both perspectives join at chemical and pharmaceutical safety, the associated risk assessment and 
the thereby needed improvement of test strategies. The improvement of test strategies involves the 
use of mechanistic understanding of toxicodynamic and toxicokinetic processes, as the role of 
active transport. Moreover, by use of in vitro models chemical testing can be developed further with 
respect to the 3R approach (reduce, replace, refine of animal testing) (Nichols et al., 2009; Russel & 
Burch, 1959). 
 
1.3 ABCB1/4-LIKE P-GLYCOPROTEINS OF FISH SPECIES  
Abcb1/4 cDNA and/or protein were confirmed in various fish species, reviewed in Ferreira et al. 
(2014a). The first evidence for an ABCB1-like transporter in fish on the genomic level was reported 
for Pleuronectes americanus (winter flounder) (Chan et al., 1992). Subsequently, ABCB1-like 
                                                             
2 PBTK models are extended toxicokinetic models that base on physiological data as e.g. composition and 
volumes of main organs, blood flow, and physicochemical propteries of the chemicals of interest. 
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expression (gene and/or protein) was confirmed in Barbus barbus (barbel), Leuciscus cephalus 
(chub), Chondrostoma nasus (sneep), Carassius auratus gibelio (Prussian carp, Sauerborn Klobucar 
et al., 2010), Chelon labrosus (grey mullet, Diaz de Cerio et al., 2012), Dicenthrarchus labrax 
(European seabass, Ferreira et al., 2014b), Fundulus heteroclitus (killifish; Bard et al., 2002b; Miller 
et al., 2002,), Mullus barbatus (red mullet), Oncorhynchus mykiss (rainbow trout, Loncar et al., 
2010), Oreochromis niloticus (Nile tilapia, Costa et al., 2012), Ictalurus punctatus (channel catfish, 
Doi et al., 2001) Scophtal musmaximus (turbot, Tutundjian et al., 2002), and Trematomus bernacchii 
(rock cod, Zucchi et al., 2010), reviewed in Ferreira et al. (2014a). 
ABCB1-like protein expression is evident in Channel catfish (Ictalurus punctatus) bile canaliculi or 
bile pre-ductules of the liver, extratubular kidney, and the columnar epithelia of the intestine using 
the monoclonal antibody (mAb) C2193 (Kleinow et al., 2000). Presence of ABCB1-like transporters 
in fish species was further confirmed in brain (Diaz de Cerio et al., 2012, Miller et al., 2002) and 
gonads (Loncar et al., 2010). Expression of fish ABCB, ABCC and ABCG transporters in various 
organs is described in detail in Loncar et al. (2010), and Luckenbach et al. (2014). 
Multiple sequence alignment within Clustal W of amino acid sequences of ABCB1-like transporters 
in fish give 87 % to 98 % similarity of amino acid sequence for common carp compared to other 
fish species (Sauberborn Klobucar et al., 2010). Fish species genome assemblies are available for 
Danio rerio (zebrafish), Gasterosteus aculeatus (stickleback), Gadus morhua (cod), Oreochromis 
niloticus (tilapia), Oryzias latipes (medaka), Takifugu rubripes (fugu), Tetraodon nigroviridis (green 
dotted puffer), and Latimeria chalumnae (coelacanth) and were used for phylogenetic analysis of 
the ABCB4/1 subfamily in these fish species, Homo sapiens, and Gallus gallus (chicken) (Luckenbach 
et al., 2014). It is suggested that human ABCB1 and ABCB4 arose from gene duplication and that 
(teleost) fish sequences are not one-to-one orthologues to either ABCB1 or ABCB4, but co-
orthologues of both (Luckenbach et al., 2014). In the studied teleost fish species at least one ABC 
transporter of the Abcb1/Abcb4 clade is present (Luckenbach et al., 2014).  
In general, function and physiological roles of ABC transporters are similar between teleost fish 
species and mammals, indicated by similar expression patterns in tissues, as apical localisation of 
ABCB1/4-like proteins in diverse fish species (reviewed Ferreira et al., 2014a) and functional 
analyses using fluorescent substrates (reviewed in Luckenbach et al., 2014). However, genome 
organisation is not homogeneous in the studied fish species resulting in exceptions, as e.g. presence 
of multiple isoforms of Abcg2 in fish (e.g. four in Danio rerio, two in Oryzias latipes) and the missing 
Homo sapiens ABCB1 homolog in Danio rerio (Luckenbach et al., 2014). 
Chemicals studied to interact with ABCB1-like proteins of e.g. Killifish (Fundulus heteroclitus) and 
channel catfish (Ictalurus punctatus) are amongst others fluorescent derivates of verapamil and 
                                                             
3 C219 is specific to epitope VQEALD present in ABCB1/4/11 transporters (Georges et al., 1990; Childs et al., 
1995; Van den Elsen et al., 1999)  
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cyclosporin A (Miller et al., 2002) and verapamil and vinblastine (Doi et al., 2001), respectively. An 
analysis of mRNA expression and activity of ABC transporters in cell lines derived from different 
rainbow trout (Oncorhynchus mykiss) tissues – liver, liver hepatoma, gill, gonad, gut, and brain – 
shows that Abcb1a is only moderately expressed in the RTbrain cell line whereas only weak 
expression was observed in cell lines from other tissues for Abcb1a and Abcb1b. Rainbow trout 
Abcc1 is moderately expressed in all cell lines and strongest expression was seen for Abcc2 (Fischer 
et al., 2011). Efflux of the fluorescent Abcb1 and Abcc substrate calcein-acetoxymethyl ester 
(calcein-AM) is inhibited in a concentration dependent manner in all studied cell lines by 
cyclosporin A, PSC833, and MK571 leading to an increase in fluorescence of up to three-fold. 
(Cyclosporin A, PSC833, and MK571 act as competitive substrates for or as inhibitors of - due to 
higher expression levels - probably Abcc1 and Abcc2 in the studied cell lines.) 
Further, a study on ABCB1-like activity in the doxorubicin resistant fish hepatoma cell line PLHC-
1/dox – derived from the clearfin livebearer (Poeciliopsis lucida) PLHC-1 cell line – shows that 
PLHC-1 Abcb1 exhibits similar interaction with some human ABCB1 ATPase stimulators 
(verapamil, testosterone, and colchicine) (Zaja et al., 2007; Zaja et al., 2011). Otherwise vinblastine, 
etoposide, and dexamethasone do not stimulate the PLHC-1 Abcb1, but Homo sapiens ABCB1 
ATPase activity. Interestingly, doxorubicin which was used for the selection of the PLHC-1/dox cell 
line is not interacting with the PLHC-1/dox Abcb1 ATPase (Zaja et al., 2011). 
 
1.3.1 Danio rerio Abcb4 
In zebrafish (Danio rerio) two ABCB1-like transporters are present and were previously annotated 
Abcb1a and Abcb1b (Annilo et al., 2006). Later, Fischer et al. (2013) and Luckenbach et al. (2014) 
revealed by phylogenetic analyses that ABCB1 and ABCB4 are rather co-orthologues than one-to-
one orthologues and based on synteny Danio rerio Abcb1a and Abcb1b are annotated Abcb5 and 
Abcb4, respectively, while Abcb1 is not present in this species.  
Danio rerio Abcb4 has a 64 % similar peptide sequence compared to Homo sapiens ABCB1 and 
ABCB4 and 56 % similarity to Danio rerio Abcb5 (Fischer et al., 2013). The most similar amino acid 
sequence to Danio rerio Abcb4 has Oncorhynchus mykiss Abcb1 (partial) with 77 %. Poeciliopsis 
lucida Abcb1 and Danio rerio Abcb4 are 73 % similar with respect to their amino acid sequences. 
Fischer et al. (2013) demonstrate that Abcb4, but not Abcb5, is acting as multixenobiotic 
transporter. Accumulation of the fluorescent substrate dyes rhodamine B and calcein-AM in Danio 
rerio embryos is increased after co-exposure to the ABCB1-like inhibitors cyclosporin A and 
PSC833 compared to embryos without co-exposure to inhibitors, and is moreover similar to 
increased accumulation of rhodamine B and calcein-AM in Abcb4 morpholino knockdown Danio 
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rerio embryos. Abcb5 knockdown in Danio rerio embryos is not accompanied by increased 
accumulation of the substrate dyes (Fischer et al., 2013).  
Function of zebrafish Abcb4 and probably also of Abcb4 proteins from other fish species differs to 
that of mammalian ABCB4. The mammalian ABCB4 protein is a phosphatidylcholine translocator 
specifically active in liver; its dysfunction is associated with liver diseases (Rosmorduc et al., 2001). 
Unlike ABCB1 the protein does not confer multidrug resistance (Smith et al., 2000) although the 
cancer drugs and ABCB1 substrates paclitaxel, digoxin and vinblastine are transported by ABCB4 at 
a low rate (Smith et al., 2000). Biliary phospholipid levels in fish, reptiles and birds are generally 
low indicating a lack of phospholipid translocation into the bile in those taxa. It is therefore 
assumed that the ABCB4-specific function in biliary phospholipid excretion is evolutionary young 
whereas transport of toxicants by Abcb1/Abcb4 orthologues is more ancient (Elferink et al., 2004; 
Luckenbach et al. 2014). 
mRNA transcripts of Abcb4 are found in Danio rerio embryos from early development on, i.e. 
throughout the first 48 hours post fertilisation (hpf). At 120 hpf expression is confirmed by in situ 
hybridisation in the intestine and intestinal bulb (Supplemental material from Fischer et al., 2013). 
In 96 hpf zebrafish embryos expression of Abcb4 is seen in the intestine (Lu et al., 2015) as seen at 
120 hpf in Fischer et al. (2013). In adult zebrafish Abcb4 expression (qPCR analysis) is highest in 
the intestine and liver, followed by muscle, gill, eye, ovary and low expression levels in testis, brain, 
kidney, heart (Lu et al., 2015). Furthermore, elevated Abcb4 expression (qPCR analysis) is seen in 
96 hpf zebrafish embryos exposed to microcyctin-LR in a concentration dependent manner with up 
to two-fold elevated Abcb4 levels at 10 µg/l microcystin-LR (1.5 fold elevated level at 0.01 µg/l) (Lu 
et al., 2015). 
In a study on functional aspects of Danio rerio blood-brain barrier maturation in developing 
zebrafish embryos and larvae up to 10 dpf (days post fertilisation) the expression of blood-brain 
barrier marker genes Claudin-5 and ZO-1, formation of vascular epithelium, expression of Abcb4 
and Abcb5 and active efflux of the fluorescent human ABCB1, ABCB4, and ABCB5 substrate 
rhodamine 123 were analysed (Fleming et al., 2013). Maturation of the zebrafish blood-brain 
barrier occurs between 3 dpf and 10 dpf as marker gene expression (Claudin-5 and ZO-1) was 
found from 3 dpf on, whereas other blood-brain barrier features – as presence of a vascular 
endothelium and tight junctions indicated by double membrane – was only seen later than 8 dpf 
and 10 dpf, respectively. Abcb4 function, i.e. active efflux of rhodamine 123 out of the zebrafish 
brain, was earliest seen at 8 dpf. Additionally, distribution of the human ABCB1 substrate 
desloratadine was effected by Danio rerio Abcb4 function from 8 dpf on (Fleming et al., 2013). 
Danio rerio Abcb4 is part of the zebrafish blood-brain barrier (from 8 dpf on) as it is ABCB1 in 
Homo sapiens blood-brain barrier.  
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Interaction of chemicals with Danio rerio Abcb4 on the qualitative level was reported for 
prototypical ABCB1 modulators (rhodamine B, calcein-AM vinblastine, vincristine, doxorubicin, 
verapamil, cyclosporin A, PSC833, and MK571) as well as three environmental chemicals 
(phenanthrene, galaxolide, tonalide) using ATPase assays (Fischer et al., 2013). Further, Danio rerio 
Abcb4 is involved in active efflux of the natural toxin microcystin-LR from in Danio rerio embryos 
and moreover from LLC-PK1 cells expressing Danio rerio Abcb4 (Lu et al., 2015). First quantitative 
ATPase assay data for Danio rerio Abcb4 are published in Fischer et al. (2013), Keiter et al. (2016) 
and Cunha et al. (2017). 
 
1.4 GENERAL CHARACTERISTICS OF ABCB1/4 LIKE P-GLYCOPROTEINS 
1.4.1 Topology 
The actual molecular weight of Homo sapiens ABCB1 – expressed in human cells – is about 170 kDa 
(Germann et al., 1990). Homo sapiens ABCB1, expressed in insect cell using baculoviruses, has a 
lower molecular weight, ca. 130 kDa, due to under-glycosylation (Sarkadi et al., 1992, Germann 
et al., 1990). Danio rerio Abcb4, obtained with the baculovirus expression system, has a molecular 
weight of about 140 kDa (Fischer et al., 2013). No information on the glycosylation status of Danio 
rerio Abcb4 is available. However, both, Homo sapiens ABCB1 (Chen et al., 1986) and Danio rerio 
Abcb4 (Fig. 1.2), have 3 putative glycosylation sites suggesting that glycosylation could affect the 
molecular weight of Abcb4 in a similar fashion as ABCB1. 
 
Fig. 1.2 Schematic topology of Danio rerio Abcb4 
Topology of Danio rerio Abcb4 with membrane spanning domains (MSDs) and nucleotide binding domains 
(NBDs) which are indicated by A loop, Walker A and B, and the ABC signature motifs. GS marks 
N-glycosylation sites. Topology was predicted using the Consensus Constrained TOPology prediction web 
server (CCTOP): http://cctop.enzim.ttk.mta.hu/?_=/jobs/result/588dec8f9a4471e1e6925b64ae5b54d1 and 
Abcb4 amino acid sequence from http://www.uniprot.org/uniprot/E7F1E3. By courtesy of T. Luckenbach 
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The topology of ABCB1-like proteins in general – for Danio rerio Abcb4 given in Fig. 1.2 – comprises 
two cytosolic nucleotide binding domains (NBD) and two membrane spanning domains (MSD) of 
six alpha helices each (Hyde et al., 1990). The NBD is conserved among ABC transporters and 
contains the catalytically active Walker A and Walker B motifs. Another unique ABC transporter 
motif is the ABC signature (amino acid sequence LSGGQ) which is located between the Walker A 
and Walker B motifs (Walker et al., 1982; Rees et al, 2009).  
While ABCB1 is a full transporter consisting of two homologous half-transporters, other ABC 
transporters as ABCC and ABCGs have different topologies, e.g. are half-transporters (ABCG2) or 
consist of three MSDs and two NBDs (ABCC1-3) (Dean et al., 2001; Deeley et al., 2006). All ABC 
transporters have a conserved ATPase domain (ATP binding cassette), consisting of the Walker A, 
Walker B and the ABC signature (linker peptide) motif and hydrolyse ATP as energy source for 
their biological processes (Bouige et al., 2002). 
 
1.4.2 Function of mammalian ABCB1 
ABCB1 has at least two substrate binding sites (H and R sites) and a modulator/inhibitor binding 
site, proposed in Ferreira et al. (2013). H (Hoechst 33342) and R (Rhodamine 123) binding sites 
were first identified by Shapiro and Ling (1998). Further early works on binding sites of ABCB1 
also propose more than one binding site for chemicals within ABCB1: Orlowski et al. (1996) 
revealed different modulating sites for progesterone, deoxycorticosterone, corticosterone and 
verapamil which are independent but interacting; Litman et al. (1997c) described two binding sites, 
one high affinity activating and one low affinity inhibiting site causing bell shaped concentration 
response curves for e.g. verapamil. More recent studies show that ABCB1 rather has a large flexible 
cavity in the transmembrane domain holding several sites to which chemicals bind (Aller et al.; 
2009; Chufan et al., 2013). Further, it was demonstrated that when primary binding sites are 
mutated secondary binding sites are occupied by substrates and modulators, and substrates are 
still transported (Chufan et al., 2013). Chufan et al. (2016) propose that hydrogen bonds between 
chemical (inhibitors) and the P-glycoprotein (phenylalanine-tyrosine structural motifs) mediate 
inhibition of ATPase activity and transport. Upon mutation of these sites inhibitors bind with lower 
affinity and stimulate ATPase activity. 
The catalytic cycle of ABCB1 was first described by Ambudkar et al. (2006) and the current state of 
knowledge can be read in Stein & Litman (2014). In the catalytic cycle one ATP molecule is bound 
to one NBD while the other NBD is empty. Upon chemical binding to the MSD an ATP molecule 
binds to the vacant NBD, the two NBDs dimerise (occluded “ATP sandwich”) and ATP is hydrolysed. 
The MSDs form an outward-facing, low-affinity conformation which allows the release of the 
substrate chemical, the inorganic phosphate, and ADP. The release of ADP, the rate limiting step, 
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resets ABCB1 from the low-affinity outward facing to the high-affinity inward-facing conformation 
and the NBD are no longer dimerised (reviewed in Stein & Litman, 2014, Senior et al., 1995; Sauna 
et al., 2007, Ambudkar et al., 2006). 
Also, ABCB1 possesses a basal ATPase activity which is described as intrinsic mechanistic property 
(Al-Shawi et al., 2003)/ to maintain a transport-competent conformation (Sarkadi et al., 2006) or to 
be related to translocation of endogenous substrates (described in Stein & Litman, 2014). 
Membrane constituents (lipids) or chemicals similar to those interact with ABCB1, reviewed in 
Sharom (2014), and previous work emphasise the influence of membrane constituents on ABCB1 
ATPase activity and activation energy (Al-Shawi et al., 2003; Romsicki & Sharom, 1998). 
How substrate chemicals are translocated by ABCB1 is not yet unravelled completely. The most 
discussed and favoured models are the flippase model and the hydrophobic vacuum cleaner model 
(Stein & Litman, 2014; Sharom, 2014). In the flippase model a hydrophobic chemical intercalates in 
the inner leaflet of the membrane and is translocated from the inner to the outer leaflet of the 
membrane and from there it equilibrates to the extracellular space (Higgins & Gottesman, 1992; 
Siarheyeva et al., 2006). In the hydrophobic vacuum cleaner model the chemical also partitions into 
the inner leaflet but is translocated to the extracellular space (Raviv et al., 1990). The two models 
are not mutually exclusive, suggested in Sharom (2014). Nonetheless, so far it is not possible to 
distinguish these two models experimentally as the same equilibrium state is reached (Sharom, 
2014).  
 
1.5 CLASSIFICATION OF CHEMICAL ABCB1- INTERACTIONS  
Following, classifications of chemical ABC transporter interactions – stimulator, substrate, and 
inhibitor – are explained.  
In general, chemical interactions with ABC transporter ATPase activity depend on the assay 
conditions. If tested individually, a chemical which increases basal ATPase activity acts as 
stimulator4 ; a chemical which decreases basal ATPase activity (bA) acts as inhibitor (inhibitor of 
bA). High affinity inhibitors of basal ATPase activity are also high affinity transport inhibitors 
(Chufan et al., 2016).  
Some chemicals – which can also be stimulators if assayed individually – decrease ATPase activity if 
tested along with another stimulator and act as inhibitors of stimulator co-treated ATPase activity 
(cA – inhibitor of cA). For example, vinblastine is a stimulator of basal ABCB1 ATPase activity 
(Sarkadi et al., 1992), but acts as inhibitor if assayed along with the stimulator verapamil as it 
decreases the stimulator co-treated ABCB1 ATPase activity (Litman et al., 1997b). Furthermore, 
                                                             
4 In some studies stimulators are termed catalytic substrates (Stein & Litman, 2014). 
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there are chemicals which do not stimulate nor inhibit basal ATPase activity but act as inhibitor of 
the stimulator co-treated ATPase activity (Von Richter et al., 2009; Glavinas et al., 2008). 
Stimulation of the basal ATPase activity and inhibition of the stimulator co-treated ATPase activity 
points to properties of a chemical as high turnover and low turnover transported substrate, 
respectively (Von Richter et al., 2009; Glavinas et al., 2008). The latter can also act as competitive 
inhibitor, as cyclosporine A (Litman et al., 1997b). 
Chemicals which are transported by ABCB1 – demonstrated e.g. by transport studies, are termed 
(transport) substrates. In the same manner, chemicals which inhibit transport of a chemical are 
(transport) inhibitors.  
Obtained characteristics of tested chemicals as substrate, inhibitor may depend on the used test 
system (Polli et al., 2001, see section 1.5.1, especially 1.5.1.3) and are not mutually exclusive 
(Luckenbach et al., 2014), as underlined by a survey of available literature: 
Cyclosporin A, inhibiting ABCB1-like mediated efflux of chemicals (Twentyman, 1992, Fischer et al., 
2013), is also a transported substrate of ABCB1 when tested individually (Goldberg et al., 1988; 
Polli et al., 2001). The human ABCB1 and mouse ABCB1a transported substrate5 ivermectin 
(Pouliot et al., 1997; Schinkel et al., 1994; Schinkel et al., 1996) acts as inhibitor of mammalian 
ABCB1 mediated MDR (Pouliot et al., 1997; Didier and Loor, 1996).  
However, the potent ABCB1 transport inhibitors tariquidar and elacridar6 (also known as 
GF120918) (Chufan et al., 2016) are not transported by Homo sapiens ABCB1 (Kannan et al., 2011; 
Loo et al., 2012).  
Overall, chemosensitisers (also called reversal agents) decrease or prevent ABCB1-like mediated 
substrate translocation due to competitive binding to the substrate binding site, high affinity to 
binding sites, fast passive diffusion across the cell membrane and/or low transport rate (i.e. are 
substrates themselves), due to inhibition of ATPase activity or due to alteration of membrane 
fluidity and permeability (Bard, 2000; Kurelec et al., 1998; Sharom, 2014, Chufan et al., 2016). 
ATP is the enzymological ABCB1 substrate as it is converted to ADP and Pi by the ABC transporter 
intrinsic ATPase activity of the NBDs.  
 
 
 
 
                                                             
5 Even though ABCB1 mediated transport of ivermectin is described, these results appear rather qualitative. 
When surveying quantitative or comparative data, an efflux ratio for ivermectin of only 1.13 (using murine 
B16 cells expressing human ABCB1 versus non-transfected B16 cells) is described (Bain & LeBlanc, 1996). 
Further, ivermectin was less efficiently transported than vinblastine (Pouliot et al., 1997). 
6 Elacridar is reported to accumulate in MDCKII-MDR1 (expressing human ABCB1) cells (Polli et al., 2001) 
but no transport was demonstrated so far. 
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1.5.1 Methodologies to study interaction of chemicals with ABCB1 
From the experimental point of view mainly7 two aspects of the ABCB1 chemical interaction are 
investigated: is a chemical interacting with the catalytic (ATPase) activity and is a chemical 
transported (or is inhibiting the transport of another), reviewed in Luckenbach et al. (2014).  
This work focuses on the type of interaction of chemicals with Danio rerio Abcb4 and Homo sapiens 
ABCB1 ATPase activity using the ATPase assay. However, as studies on ABCB1 mediated chemical 
transport complete the understanding of ABC transporter function (Stein & Litman, 2014) test 
systems to study transport and transport inhibition are introduced as well. 
 
1.5.1.1 ATPase assay 
As the translocation of substrates by ABCB1 is unambiguously coupled to ATP cleavage (Ambudkar 
et al., 1992), the ATPase assay has been proposed to assess the interaction of chemicals with the 
ABCB1 catalytic activity, serving as proxy for ABCB1 modulation by chemicals (Sarkadi et al., 1992). 
Effects of chemicals on the ABCB1 ATPase activity indicate interaction with and affinity for ABCB1 
(Stein and Litman, 2014). Chemicals can act as stimulators or inhibitors of basal (e.g. ABCB1) 
ATPase activity (or do not interact). In addition, chemicals can inhibit the stimulator co-treated 
ATPase activity. It is suggested studying effects of chemicals on basal (Fig. 1.3 A) and stimulator 
(e.g. verapamil) co-treated ATPase activity (Fig. 1.3 B) (Glavinas et al., 2008; Von Richter et al., 
2009). 
 
Fig. 1.3 Test modes of the ATPase assays and possible interaction outcomes 
Chemical-sensitive ABCB1-like transporter ATPase activity versus concentration of a tested chemical; 
b/s = levels of basal /stimulator treated P-gp ATPase activity serve as controls; basal ATPase activity does not 
equal zero (e.g. Von Richter et al., 2009). A: Chemicals can stimulate (I) or inhibit (II) basal ATPase activity. B: 
Chemicals inhibiting the stimulator (in this work verapamil) co-treated ATPase activity (III) can be 
stimulators or inhibitors of basal ATPase activity when tested individually, or do not interact with basal 
ATPase activity. Please note that non-interaction is not depicted. It is in principle possible that chemicals 
increase verapamil co-treated ATPase activity (not depicted), as described e.g. in Litman et al. (1997b). 
                                                             
7 Further methods are applied to study functional and structual aspects of ABCB1 as e.g. photoaffinity labeling 
and X-ray analyses (Loe & Sharom, 1993; Aller et al., 2009). 
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In ATPase assays the interaction of a chemical with the ATPase activity of the ABC transporter is 
recorded by (e.g. colorimetric) quantification of the liberated inorganic phosphate originating from 
hydrolysis of ATP by the ABCB1 inherent ATPase in presence and absence of (sodium) 
orthovanadate. Sodium orthovanadate is used in ATPase assays to derive ABCB1-specific ATPase 
activities by trapping nucleotides in a single catalytic site of the protein (Cantley et al., 1977; 
Urbatsch et al., 1995; Senior et al., 1995). Further constituents (EGTA, sodium azide) are present in 
the assay constituents which inhibit endogenous ATPases (Germann, 1998). For studying the 
modulation of transporter ATPase activity by chemicals cellular or artificial membranes containing 
high titres of the transporter protein of interest are used (overview given in e.g. Glavinas et al., 
2008). The baculovirus expression system has proven to be a useful system to obtain comparatively 
large amounts of functional recombinant transporter protein, allowing for close to high throughput 
testing. Sarkadi et al. (1992) and Germann (1998) published pioneering works in which membrane 
fractions containing recombinant human ABCB1 are used in an ATPase assay. For this methodology 
the permanent Sf9 (Spodoptera frugiperda) insect cell line is used which is a relatively rapidly 
growing cell line and which can be cultivated in suspension culture. Upon infection with 
baculoviruses, containing the genetic information of the protein of interest, the cells are harvested 
and cell membranes containing the recombinant protein are isolated and subsequently used in the 
ATPase assay. The percentage of ABCB1 of the overall protein in membrane preparations used in 
ATPase assays varies between 3 % and 32 % (Sarkadi et al., 1992, Al-Shawi & Senior 1993). A 
survey of ABCB1 expression levels in two batches of commercially available Homo sapiens ABCB1 
Sf9 cell membrane preparations reveals yields of ≈ 61.4 and ≈ 85.4 fmol ABCB1/µg protein (Zhang 
et al., 2011)   ̶ which equal 0.9 to 1.2 % of total membrane protein. 
Homo sapiens ABCB1 has a lower molecular weight expressed in Sf9 insect cells (120 to 140 kDa) 
than Homo sapiens ABCB1 isolated from human cells due to under-glycosylation (Germann, 1998). 
The actual size of Homo sapiens ABCB1 is around 170 kDa. Gottesmann and Pastan (1993) argue 
that glycosylation does not affect function of ABCB1. Their arguments have been different 
glycosylation status and sites of mouse ABCB1a and human ABCB1 (Chen et al., 1986; Gros et al., 
1986), blocking of N-glycosylation did not abolish drug resistance in multidrug resistance cells 
(Beck and Cirtain, 1982) and the possibility to isolate multidrug resistance cells from a 
glycosylation deficient mutant (Ling et al., 1983). The described method has been applied in a 
number of studies (Polli et al., 2001; Von Richter et al., 2009; Fischer et al., 2013; Fekete et al., 2015; 
Keiter et al., 2016, Cunha et al., 2017).  
Advantages of the ATPase assay are that it is a quantitative, standardisable assay which is suitable 
to test many chemicals, e.g. for screening purposes. Data from ATPase assays provide a first 
indication of chemical-transporter interaction at all and give information on type of interaction at 
the molecular level (Stein & Litman, 2014). ATPase assays are appropriate to compare chemicals 
1 GENERAL INTRODUCTION AND BACKGROUND 
15 
and chemical-ABC transporter interaction among different species. A disadvantage of the ATPase 
assay is that obtained results do not necessarily answer the question whether a chemical is 
apparently net transported (Stein & Litman, 2014). Highly lipophilic ATPase activity stimulators are 
often not net transported as they permeate to the cell membrane quickly. Further, especially slowly 
partitioning chemicals are often not identified as ATPase stimulators (Polli et al., 2001). However, 
these slowly partitioning chemicals probably act as inhibitors of stimulator co-treated ATPase 
activity (see section 1.5.1.3). Inhibitors of basal ATPase activity with high affinity (IC50 values at 
the nM level) are also high affinity transport inhibitors (Chufan et al., 2016). 
 
1.5.1.2 Further test systems to study ABCB1-like transporter proteins 
Transport and transport inhibition studies 
In order to study ABCB1 mediated transport of a chemical, vesicles of ABCB1 containing 
membranes or ABCB1 expressing cell lines are used. When using inside-out vesicles accumulation 
of chemicals of interest inside the vesicles can be studied (Horio et al., 1988). Epithelial cell lines, as 
Caco2 (heterogeneous epithelial colorectal adenocarcinoma cells), LLC-PK1 (pig kidney epithelial 
cells) or MDCK (Madin-Darby canine kidney cells) cells, are commonly used to study transport or 
transport inhibition of a test chemical. MDCK and LLC-PK1 cell lines form a polarised monolayer 
and can be transfected with the transporter(s) of interest, e.g. ABCB1. They are cultured on a 
porous membrane in a trans-well chamber with an apical and basolateral compartment and 
apparent permeabilities (Papp) for a chemical in apical (A) to basolateral (B) direction and vice versa 
can be obtained by analytical or radioactivity determination (Cho et al., 1989; Cho et al., 1990; Kim 
et al., 1998; Polli et al., 1999). Efflux ratios (= Papp B to A / Papp A to B) can be obtained for 
transporter transfected cell lines which can be compared to those of the parental cell line (e.g. in 
Feng et al., 2008).  
Besides the advantage of studying apparent transport and/or transport inhibition there are also 
disadvantages: Further endogenous transporter proteins could be expressed in cell lines used in 
transport assays which may blur the ABCB1 specific contribution (Stein & Litman, 2014; Sjöstedt 
et al., 2014). Studied cell lines should be evaluated carefully with respect to expression of 
endogenous transporters, which differ between parental and transfected cell lines or between cell 
line clones (Kuteykin-Teplyakov et al., 2010; Maubon et al., 2007) (1). Moreover, ABCB1 mediated 
chemical transport has been described to be concentration-dependent (Shirasaka et al., 2008) 
implying that chemical concentrations used in the test system should be chosen carefully (2). 
Chemical transporter interactions might be overlooked in transport studies as transport of highly 
permeable /fast diffusing chemicals may be difficult to identify as these chemicals equilibrate to the 
membrane very fast (Sjöstedt et al., 2014) (3). 
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Dye efflux assays 
Another methodology to assess transport inhibition, are accumulation studies with fluorescent 
substrate probes as e.g. rhodamine B (there are further rhodamine dyes). If ABCB1 is translocating 
its fluorescent substrate little fluorescence is detected in the cells or test system (i.e. Danio rerio 
embryo, gill tissue of bivalves, and others) whereas if co-exposed to a transport inhibiting chemical, 
increased fluorescence is detected (Homolya et al., 1993). In a similar assay calcein-AM, a non-
charged, non-fluorescent substrate of ABCB1 and ABCCs, is used. If efflux of calcein-AM is inhibited 
by a chemical and consequently reaches the cytoplasm intracellular esterases hydrolyse the AM 
moiety and fluorescent calcein is formed which is not a substrate of ABCB1 (Holló et al., 1994; 
Essodaïgui et al., 1998).  
In dye efflux assays not all ABCB1-chemical interactions may be discovered but competitive (same 
binding site) and non-competitive (different/overlapping binding sites) interactions with 
calcein-AM, rhodamine B, or any other fluorescent substrate used (Stein & Litman, 2014).  
 
1.5.1.3 Congruency of results from different test systems  
Some chemicals, as vinblastine and colchicine, slowly diffusing across the membrane, are easily 
identified as transported substrates in transport studies and also stimulate ATPase activity (Stein & 
Litman, 2014). However, not all results obtained with the above mentioned methodologies seem 
congruent. Interaction of highly permeable, i.e. very lipophilic, chemicals (e.g. verapamil [Glavinas 
et al., 2008; Polli et al., 2001; Stein & Litman, 2014] with ABCB1 is prone to be overlooked in 
transport studies as they equilibrate quickly back to the membrane whereas in ATPase assays often 
quite strong stimulation is seen for lipophilic substrates. Indeed, verapamil is transported by 
ABCB1, demonstrated with radio-labelled or BODIPY-verapamil (Stein & Litman, 2014). Otherwise, 
cyclosporin A was shown to be a transported substrate of ABCB1 (Goldberg et al., 1988, Polli et al., 
2001) and is not stimulating basal ATPase activity of ABCB1 (Watanabe et al., 19978; Von Richter 
et al., 2009), but is inhibiting stimulator co-treated ABCB1 ATPase activity (e.g. Glavinas et al., 
2008). An explanation for the inhibition of stimulator co-treated ABCB1 ATPase activity by 
cyclosporin A might be its high molecular weight (≈ 1200 g/mol), slowing down turnover rate on 
the catalytic level (Stein & Litman, 2014).  
Furthermore, physicochemical properties of the constituents of the test system (tested chemical, 
membrane environment), permeation/binding of a chemical to lipids and proteins, pH of the test 
system, and biotransformation of the chemical of interest (only when cellular systems as MDCK cell 
                                                             
8 Cyclosporin A is shown to inhibit basal ABCB1 ATPase activity in Watanabe et al. (1997), but not in Glavinas 
et al. (2008). 
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lines are used) could further contribute to an observed effect (transport/transport inhibition, 
modulation of ATPase activity). 
Many ABCB1 ATPase stimulators increase ATPase activity at low, and subsequently decrease at 
higher concentrations (Litman et al., 1997c). Certainly, the used concentrations of chemicals in a 
test system can determine the observed effect.  
 
1.6 OBJECTIVES OF THE THESIS  
The overall aims of this work are to characterise further Danio rerio Abcb4 and to provide a 
database to approach the question to what extent ABCB1-like transporter related functions/effects 
are of ecotoxicological relevance.  
 
In the following, the objectives of each chapter are outlined. 
 
A test system is established to obtain consistent data on ABC transporter chemical interaction: The 
ATPase assay is adapted to study Danio rerio Abcb4 ATPase activities, providing information on 
types of interaction as well as quantitative data, i.e. affinities for the ABC transporter and 
information on strength of interaction. Reproducible ATPase assay data are prerequisite to relate 
chemical ABCB1-like interactions to physicochemical properties of chemicals. 
As the available ATPase assay data for Homo sapiens ABCB1 – used as reference ABCB1-like 
transporter – are not in all cases suitable for a comparison, production of recombinant ABCB1 and 
use in the ATPase assay is optimised for comparison to Abcb4 ATPase assay data. The 
estalblishment of the test systems comprises the tasks:  
- Production of recombinant Danio rerio Abcb4, non-functional Danio rerio Abcb4, and Homo 
sapiens ABCB1 in Sf9 cells using baculoviruses.  
- Revised protocol for ATPase assay for recombinant P-glycoproteins ABCB1 and Abcb4.  
- Comparability of replicates and batches of membrane preparations 
- Non-functional Danio rerio Abcb4 with native Sf9 cell level ATPase activity as proof that 
recorded ATPase activities originate from recombinant Abcb4.  
- Data analysis (Chapter 2) 
 
Danio rerio are found in habitats of temperatures from 16 to 38 °C (Engeszer et al., 2007; Spence 
et al., 2006) and ecotoxicological tests with Danio rerio are run at ca. 27 °C (OECD 236 guideline 
ISO 7346-3). Homo sapiens have a constant body temperature of about 37 °C. If chemicals are tested 
to modulate ABCB1 and Abcb4 ATPase activities – to what extent do the different incubation 
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temperatures influence ATPase activities and kinetic parameters? Are these tests run at different 
temperatures comparable? 
Therefore ATPase assays with recombinant ABCB1 and Abcb4 are performed at 27 °C and 37 °C 
and the effect of the different incubation temperatures on ATPase activities and EC50s are 
investigated (Chapter 3). 
 
Danio rerio Abcb4 is a known MDR/MXR transporter with 64 % amino acid similarity to Homo 
sapiens ABCB1 (Fischer et al., 2013). It is of question whether and to what extent Abcb4 and ABCB1 
stimulators and inhibitors differ. Chemicals are explored for their interaction with Homo sapiens 
ABCB1 and Danio rerio Abcb4 ATPase activities and quantitative parameters are obtained, using 
the methodology established in chapter 2. Homo sapiens ABCB1 and Mus musculus ABCB1a amino 
acid residues known to be involved in chemicals binding or protein function were aligned to and 
compared to their Danio rerio Abcb4 counterparts (Chapter 4). 
 
Do environmental chemicals – released to the environment accidentally or on purpose – interact 
with Danio rerio Abcb4 ATPase activity? Are these chemicals stimulators or inhibitors of Danio rerio 
Abcb4 ATPase activity? Further, are effects on Abcb4 ATPase activity modulation by environmental 
chemicals comparable and similar to those by standard modulators – natural compounds and/or 
pharmaceuticals known to modulate ABCB1-like function? The bioavailability of Abcb4 ATPase 
activity stimulators could be affected by Abcb4-mediated active transport. Further, chemicals 
inhibiting Danio rerio Abcb4 basal or stimulator co-treated ATPase activity could act as 
chemosensitisers in mixture scenarios and cause accumulation of Abcb4 substrates. Using the 
established test system from chapter 2, consistent data on the interaction of environmental 
chemicals with Danio rerio Abcb4 ATPase activity is obtained (Chapter 5). 
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2 ESTABLISHMENT OF A PROTOCOL FOR OBTAINING 
QUALITATIVELY AND QUANTITATIVELY ROBUST DATA FROM 
ATPASE ASSAYS WITH RECOMBINANT DANIO RERIO ABCB4 
AND HOMO SAPIENS ABCB1 
2.1 ABSTRACT 
ABCB1-like transporter proteins belong to the ATP binding cassette (ABC) transporter family and 
mediate the translocation of a wide range of chemicals across cellular membranes. These 
membrane proteins couple ATP hydrolysis – facilitated by the proteins immanent catalytic domain 
– to the translocation of substrate chemicals. The ATPase activity can serve as a measure for 
interaction of chemicals with the transporter protein as stimulator and/or inhibitor. ATPase assays 
with membrane preparations from cells overexpressing a certain ABC transporter, derived e.g. with 
the baculovirus system, have been frequently used to study chemical-transporter interaction.  
Nevertheless, it has remained challenging to decide for reference ATPase assay data (e.g. 
Homo sapiens ABCB1), to relate obtained results from Danio rerio Abcb4 ATPase assays to. 
Available data differed with respect to quantitative results and ATPase assay protocols. 
Furthermore, not for all chemicals studied with Abcb4 respective data for ABCB1 are available. 
The objective of this chapter is to provide a protocol to obtain ATPase assay data for recombinant 
Danio rerio Abcb4 and for the reference transporter Homo sapiens ABCB1, which are reproducible 
across different batches of membrane preparations. Recombinant Danio rerio Abcb4, mutated 
non-functional Danio rerio Abcb4 and Homo sapiens ABCB1 were produced in Sf9 cells using the 
baculovirus expression system. A recombinant non-functional Danio rerio Abcb4 was generated by 
mutation of two conserved residues – one in the ABC signature sequence and one in the Walker B 
motif of ABC transporters – which was previously described for a Mus musculus ABCB1a mutant 
with zero level ATPase activity. Revised ATPase assay parameters were concentrations of MgATP, 
sodium orthovanadate and the pipetting scheme. Incubation temperatures of the ATPase assays 
were 27 °C for Abcb4 and 37 °C for ABCB1. The ATPase assay data were analysed using non-linear 
regression to the four parameter logistic equation.  
Kinetic parameters for ABCB1 ATPase activity stimulation by MgATP and verapamil were in 
accordance with previous findings. Basal and stimulated ATPase activities of Danio rerio Abcb4 
were ca. half as high as those from ABCB1 probably due to lower assay temperature, resembling 
temperatures at which zebrafish are bred, and kinetic parameter for ATPase stimulation by MgATP 
2 ESTABLISHMENT OF A PROTOCOL FOR OBTAINING QUALITATIVELY AND QUANTITATIVELY ROBUST DATA FROM ATPASE ASSAYS 
20 
and verapamil were similar to those of ABCB1. The mutated non-functional Abcb4 was not 
stimulated by verapamil and basal ATPase activities were in the range of native Sf9 cell membrane 
protein.  
The described ATPase assay protocol is standardisable and appropriate to study novel ABC 
transporters, as Danio rerio Abcb4. Obtained ABCB1 ATPase assay data were in line with previous 
findings and overall of low variability. Variability of Abcb4 ATPase assay was higher, due to the 
conduct of membrane preparations and ATPase assay over a three times longer time period by 
three different experimenters. Hence, membrane preparations should be pooled. The here 
described protocol is suitable to screen chemicals for ABCB1-like ATPase stimulating and/or 
inhibiting properties and to further compare chemicals for interaction with Homo sapiens ABCB1 
and Danio rerio Abcb4.  
 
2.2 INTRODUCTION 
Homo sapiens ABCB19 (ABCB1) and Danio rerio Abcb4 (Abcb4) use ATP hydrolysis as energy source 
to mediate the transition of a broad variety of chemicals across cellular membranes (Ambudkar 
et al., 1992; Ambudkar & Gottesman 1998). The transporter ATPase activity can thus serve as a 
measure for the interaction of chemicals with transporter protein function (Sarkadi et al., 1992). 
Transporter ATPase assays are used to study whether chemicals interact with the basal ATPase 
activity and/or stimulator co-treated ATPase activity. Using the baculovirus expression system, 
reasonable amounts of the protein of interest can be produced and subsequently used in the 
ATPase assays which can be run as screening method in multi-well-plates with a high potential for 
standardisation. Nevertheless, no conclusion about apparent net transport of a chemical can be 
drawn from ATPase assays, but on a chemical’s affinity for and kind of (and extent of) interaction 
with ABCB1-like proteins (Stein & Litman 2014; see section 1.5).  
Chemicals should be screened to modulate basal and stimulator (in this study verapamil) 
co-treated ATPase activity (Von Richter et al., 2009; Glavinas et al., 2008). If tested individually, 
chemicals either stimulate or inhibit basal ATPase activity, or do not interact. Chemicals stimulating 
basal ATPase activity, i.e. provoking an increase in liberated inorganic phosphate, were defined 
stimulators (of basal ATPase activity). Many but not exclusively all ATPase stimulators are 
apparently net transported ABCB1-like substrates (Von Richter et al., 2009, Polli et al., 2001; see 
section 1.5.1.3). Additionally, when assayed along with another stimulator (as verapamil), many 
stimulators of basal ATPase activity also inhibit co-treated ATPase activity (while there are other 
                                                             
9 The designation of gene and protein names is based on the Zebrafish Nomenclature Guidelines 
https://wiki.zfin.org/display/general/ZFIN+Zebrafish+Nomenclature+Guidelines. zebrafish: abcb4/Abcb4,  
human: ABCB1/ABCB1, mouse: Abcb1a/ABCB1a (gene/protein). 
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chemicals which only inhibit the co-treated ATPase activity). When testing for inhibition of the 
stimulator co-treated ATPase activity the stimulator verapamil (in the assay constituents), the 
tested chemical, and finally – to start the reaction – MgATP were subsequently added. Hence in this 
work the term stimulator co-treated ATPase activity was used whereas in previous studies the 
co-treated ATPase activity is frequently termed “verapamil/stimulator stimulated” and hence 
chemicals “inhibited verapamil stimulated ATPase activity”. Studying interaction of chemicals with 
the stimulator co-treated ATPase activity is in fact a mixture experiment and it is not known 
whether ATPase activity is stimulated by verapamil and subsequently inhibited by the tested 
chemical.  
To characterise a novel transport protein, as Danio rerio Abcb4, it is difficult to decide for reference 
data – likely for the very well-studied Homo sapiens ABCB1 – because they are not always 
consistent.  
Cyclosporin A was shown to inhibit basal (and drug-stimulated) Homo sapiens ABCB1 ATPase 
activity (Watanabe et al., 1997) and to not interact with basal (but to inhibit stimulator co-treated) 
ABCB1 ATPase activity (Von Richter et al., 2009). Tariquidar (Chufan et al., 2016) is reported to 
inhibit (Chufan et al., 2016) and to stimulate basal ABCB1 ATPase activity (Loo et al., 2012), 
depending the study. Concentrations of colchicine at half-maximal ABCB1 stimulation were 20 µM 
in Sarkadi et al. (1992), 227.6 µM in Aänismaa & Seelig (2007), and 321 ±80 µM in Fekete et al. 
(2015). Also protocols of ATPase assays are diverse – varying in amount of membrane protein, 
concentrations of vanadate and MgATP (reviewed in Shapiro & Ling, 1994). In pioneering ATPase 
assays with Homo sapiens ABCB1 a concentration of 5 mM MgATP and 0.1 mM vanadate were used 
along with different amounts of membrane protein – 10 µg and 100 µg, respectively (Sarkadi et al., 
1992; Germann, 1998). Recent works (Bircsak et al., 2013; Fekete et al., 2015) use commercial 
ABCB1 membrane preparations. The percentage of ABCB1 protein in Sf9 cell membrane 
preparations varies between 3 % (Sarkadi et al., 1992) and 61.4 and ≈ 85.4 fmol/µg protein for a 
commercially available human ABCB1 (Zhang et al., 2011), which equal 0.9 to 1.2 %. 
Also, not all chemicals tested to modulate the Abcb4 ATPase activity were tested in ABCB1 ATPase 
assays. Furthermore, consistent ATPase assay data are also needed to define physicochemical 
properties of stimulators or inhibitors. These quantitative structure activity relationships (QSAR)-
like information could help to further improve in silico methods for risk assessment. 
The objective of this work is to provide a standardised protocol for the production of recombinant 
transporter proteins, the conduct of the ATPase assay, and the analysis of ATPase assay data to 
obtain consistent information on the kind of and strength of interaction of chemicals with 
recombinant Abcb4 and ABCB1 ATPase activities.  
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Recombinant protein production and use in the ATPase assay  
Protocol parameters of the Abcb4 ATPase assay were revised with regard to MgATP and sodium 
orthovanadate concentrations as well as the duration of the reactions. The same procedure as for 
Abcb4 was followed for the optimisation of the ABCB1 ATPase assay protocol (MgATP, sodium 
orthovanadate concentrations). Further, a mutant non-functional Danio rerio Abcb4 was generated 
serving as proof that recorded ATPase activities originate from the expressed transporter protein 
(Abcb4) and not from Sf9 cell transporters. The mutations introduced into the Danio rerio abcb4 
correspond to those of a mutant mouse Abcb1a with two conserved residues interchanged to 
alanine (Tombline et al., 2004). These residues are at position 552 (E552) of the walker B motif and 
528 (S528) of the ABC signature sequence (LSGGQ) in the murine ABCB1a amino acid sequence. 
Mutation of these amino acids to alanine results in a nearly zero level Mus musculus ABCB1a 
ATPase activity by interference with the formation of the correct interdigitated nucleotide binding 
domain dimer interface, which is necessary to generate a closed conformation, which is necessary 
for the progress of the catalytic cycle (Tombline et al., 2004). Accordingly, the two respective amino 
acids in Danio rerio Abcb4 were altered to alanine using side directed mutagenesis.  
 
ATPase assay setup and data analysis 
In some studies chemicals were screened for interaction with ABC transporter ATPase activity at a 
certain concentration (Polli et al., 2001) or up to concentrations which were in part – depending the 
chemical – below or above the chemical’s water solubilities (e.g. in Bircsak et al., 2013; Sarkadi 
et al., 1992). To discover chemical-ABCB1 or -Abcb4 interactions, chemicals were tested up to the 
range of their water solubility (≥ 6 concentrations) to modulate basal and stimulator (verapamil) 
co-treated ATPase activities. Plate design and handling ensured that all reactions (wells) have the 
same conditions with respect to duration and temperature during incubation. 
As kinetic parameters of ATPase assay data (Km, EC50) were obtained using different equations – 
often Michaelis-Menten equation or versions of the four parameter logistic equation – data from 
verapamil and colchicine were accordingly compared. 
 
2.3 METHODOLOGY 
2.3.1 Chemicals  
All chemicals were ordered as followed and were stored according to the supplier’s instructions.  
Tris (hydroxymethyl) aminomethane (Tris Base), ethylene glycol tetraacetic acid (EGTA), 
tetracycline, and ascorbic acid were ordered from Applichem (Darmstadt, Germany). Grace Insect 
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media unsupplemented, 4 % agarose gel (low melting, Cat.-no. 18300-012), and Sf 900 1.3x, Sf9 
Cells (Cat No. 11496-015; Lot No 644282) were ordered from Gibco life technology (Thermo 
Fischer Scientific, Waltham, USA). IPTG, Bluo-gal and Sf-900 II SFM medium were ordered from 
Invitrogen (Thermo Fischer Scientific, Waltham, USA). Potassium chloride, potassium dihydrogen 
phosphate (KH2PO4), and 2-mercaptoethanol were ordered from Merck Chemicals GmbH 
(Darmstadt, Germany). Penicillin/Streptomycin 100x in 0.9 % NaCl, Dulbecco’s PBS (1x) with 
calcium/ magnesium were from PAA (GE Healthcare, Little Chalfont, UK). Magnesium chloride and 
D-Mannitol were from Riedel-de Haën (Honeywell Specialty Chemicals Seelze GmbH). 3-
morpholinopropane-1-sulfonic acid (MOPS), sodium hydroxide, gentamycin, and kanamycin 
sulphate were from Roth (Karlsruhe, Germany). 
Sodium dodecyl sulphate (SDS) was ordered from Serva (Heidelberg, Germany). Sodium azide, 
dithiothreitol (DTT), sodium orthovanadate, adenosine triphosphate (ATP), verapamil 
hydrochloride, cyclosporin A, zinc acetate, ammonium molybdate, Trypan blue solution (0.4 %), 
fetal bovine serum (FBS, Cat. No. F7524), 0.3 g/l Neutral red solution, and protease inhibitor (Cat. 
No. P8340) were ordered from Sigma Aldrich (Deisenhofen, Germany). Stock solutions of verapamil 
and cyclosporin A were prepared in dimethyl sulfoxide (DMSO); concentrations used in the tests 
did not exceed 2 % DMSO. 
 
2.3.2 Material 
2.3.2.1 cDNA clones 
Danio rerio Abcb4  
Danio rerio cDNA was obtained by RT-PCR of RNA isolated from 48 hpf embryos of Danio rerio 
wild-type strain WIK bred according to standard protocols (Westerfield, 2000; Nagel, 2002). The 
open reading frame of abcb4 (Gene ID: 100136865-GENE-080204-52) was amplified from Danio 
rerio cDNA via PCR using the Phusion High Fidelity Polymerase (New England Biolabs) and 
respective primers (Table A.1 [primer 1, 2]) and standard procedure protocols. The PCR product 
was gel purified (GeneJET Gel Extraction Kit, Thermo Scientific) and ligated into the vector 
pJet1.2/blunt (CloneJET PCR Cloning Kit, Thermo Scientific). For propagation electro-competent 
Escherichia coli (E. coli) cells [Invitrogen, MegaX DH10B T1 Electrocomp Cells] were transformed 
according to the instructions of the supplier. Positive E. coli colonies were identified using colony 
PCR (Zon et al., 1989), plasmids from a positive clone were isolated (GeneJET Plasmid Miniprep Kit, 
Thermo Scientific), and sequenced (ABI 3100 sequencer using standard cycle sequencing 
protocols). 
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Mutated Danio rerio abcb4 cDNA/Abcb4 protein 
For obtaining non-functional Danio rerio Abcb4 protein (nf Danio rerio Abcb4) a wild-type abcb4 
clone was mutated with the QuikChange II XL Site-Directed Mutagenesis Kit (Strategene Cloning 
Systems). In a study on Mus musculus Abcb1a/ABCB1a replacements of S528 in the ABC signature 
and of E552 in the Walker B motifs by alanine resulted in zero level ATPase activity of the protein 
(Tombline et al., 2004) (Fig. 2.1; positions altered in mouse Abcb1a are marked in bold). ABC 
signature and Walker B motifs were identified in zebrafish Abcb4 (UniProtKB-K9M7F0) and 
positions to be mutated confirmed by alignment of Danio rerio Abcb4 and mouse ABCB1a 
(UniProtKB - P21447) amino acid sequences. 
 
 
A                                    ABC signature sequence              Walker B    
                   LSGGQ               ΦΦΦΦDE   
Mus musculus ABCB1a       LVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALD 
Danio rerio Abcb4        pos.528   LVGDRGTQMSGGQKQRIAIARALVRNPKILLLDEATSALD   pos.567 
B 
wt Danio rerio Abcb4    pos.536               M S G G Q             I L L L D E     pos.561 
wt Danio rerio Abcb4    nt. 1606    ATGAGTGGCGGACAA … ATCCTTCTTCTCGATGAG                  bp 1682 
C 
nf Danio rerio Abcb4    pos.536          M A G G Q              I L L L D A      pos.561 
nf Danio rerio Abcb4    nt. 1606     ATGGCTGGCGGACAA … ATCCTTCTTCTCGATGCG                  bp 1682 
 
Fig. 2.1. Alignment of amino acid sequences of Danio rerio Abcb4 and Mus musculus ABCB1a at the ABC 
signature sequence and the Walker B motif 
Given amino acid positions (pos.) and nucleotide positions (nt.) mark begin and end of shown amino acid or 
nucleotide sequences. LSGGQ (ABC signature sequence) and Walker B motifs are underlined. Φ is an aliphatic 
amino acid. A: Amino acid sequences were retrieved from www.uniprot.org and alignments performed with 
ClustalW. Mus musculus ABCB1a (P21447) and Danio rerio Abcb4 (K9M7F0) amino acid sequences are given. 
Positions which were altered to alanine are highlighted in bold (Mus musculus ABCB1a from Tombline et al., 
2004; Danio rerio Abcb4 this study). B: Nucleotide codons and amino acids (both underlined) of wild-type 
(wt) Danio rerio Abcb4 which were mutated. C: Mutated non-functional (nf) Danio rerio Abcb4 with amino 
acid serine at position 537 mutated to alanine and amino acid glutamate at position 561 mutated to alanine 
(highlighted in grey background).  
 
The amino acid sequence LSGGQ within the ABC signature motif in Mus musculus ABCB1a 
corresponded to MSGGQ at the respective positions in Danio rerio Abcb4 (Fig. 2.1). Walker B motif 
sequences were identical in both proteins (ILLLDE). Amino acid positions of Danio rerio Abcb4 
(S537 and E561) corresponding to mouse ABCB1a S528 and E552 were replaced by alanine (Fig. 
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2.1, marked in bold). The two codons of Abcb4 E537 and S561 were consecutively changed to 
alanine codons by PCR using primers 3-6 (Table A.1 [primer 3 to 6]) according to the 
manufacturer’s instructions. Primers were designed on the webpage 
http://www.genomics.agilent.com/primerDesignProgram.jsp and ordered from MWG Eurofins 
(City, Country) in HYPUR quality. Mutations were confirmed by sequencing. 
Homo sapiens ABCB1  
The cDNA of the Homo sapiens ABCB1 (NCBI Gene ID: 5243; Ensembl: ENSG00000085563) was 
obtained from ATCC (MDR1.1 [pGEM3Zf(-)Xba-MDR1.1]; plasmid in E. coli, freeze-dried; ATCC 
number 65704) and control sequenced. 
 
2.3.2.2 Generation of baculoviruses  
The Bac-to-Bac expression system (Invitrogen) was used according to the manufacturer’s manual 
to generate recombinant baculovirus: The cDNAs containing the open reading frame (ORF) of 
wild-type Danio rerio abcb4, mutant Danio rerio abcb4, or Homo sapiens ABCB1 were cloned into the 
pFastBac1 vector using the restriction endonucleases NotI, XbaI (Abcb4) and XbaI (ABCB1), 
respectively. pFastBac1 clones containing correct OFR sequences of wild-type Abcb4 or ABCB1 were 
used to transform E. coli DH10BAC (MAX Efficiency DH10Bac Competent Cells (Invitrogen) 
according to the supplier’s protocol. Bacmids isolated from positive clones were chosen for 
transfection of Sf9 cells according to the manufacturer’s instructions. 
 
2.3.2.3 Sf9 cell culture 
The permanent insect cell line Sf9 (Vaughn et al., 1977) – derived from the moth Spodoptera 
frugiperda – can be cultured adherently or in suspension and is used for recombinant protein 
production. Sf9 cells adapted to serum free conditions cells (Gibco life technology; Sf9 Cells; Cat No. 
11496-015; Lot No 644282) were cultured according to the instructions in Sf-900 II SFM medium. 
For further details see section A.2.1 (appendix). 
 
2.3.2.4 Recombinant protein production 
P1 baculoviral stocks were amplified and titres were determined using the plaque assay following 
the manufacturer’s instructions. To produce recombinant Abcb4, nfAbcb4 or ABCB1, 200 ml of Sf9 
cell suspension at a density of 2 · 106 cells/ml were infected with respective baculoviral particles 
(P2 and P3) at a multiplicity of infection (MOI) of 2.5. Cells were incubated for 68 to 72 hours, 
harvested, disrupted using a tight-fitting dounce homogeniser (Germann et al., 1998) or by nitrogen 
2 ESTABLISHMENT OF A PROTOCOL FOR OBTAINING QUALITATIVELY AND QUANTITATIVELY ROBUST DATA FROM ATPASE ASSAYS 
26 
cavitation (Parr instrument company, Moline, USA; 4635 cell disruption vessel; adapted from Volk 
& Schneider et al., 2003), and cell membranes were pelleted by centrifugation and 
ultracentrifugation steps. The pellet containing the membrane fractions was dissolved in ice cold 
TMEP buffer (Germann, 1998, Sarkadi et al., 1992), homogenised using syringes, and total protein 
was determined with the BCA™ Protein Assay Kit (Thermo Scientific). Membrane proteins were 
subjected to western blot analysis using anti P-glycoprotein Mouse mAb C219 (Calbiochem 
Cat.No.517310; 1:500), goat anti mouse igG-HRP (sc-2005, Santa Cruz; 1:2000), and the anti-biotin, 
HRP linked antibody (#7075 P5, Cell Signaling Technology, 1:3333). Only membrane preparations, 
for which a signal was detected in the western blot were used for ATPase assays. 
 
2.3.3 ATPase assays 
ATPase assays were performed in 96-well plates with 20 µg of total membrane protein per well. 
The ATPase activity of ABC transporters is orthovanadate-sensitive and test series were performed 
with and without sodium orthovanadate to determine the Abcb4, nfAbcb4 (mutant), and ABCB1 
ATPase activities within the total ATPase activities of the membrane preparations. Concentrations 
of tested chemicals were arranged in random order and wells at the rim of the 96-well plates were 
preferential used for the phosphate standard. Assay samples with and without sodium 
orthovanadate for a certain concentration were assayed under the same conditions, i.e. in wells 
with the same position on the plate regarding the distance to the plate rim. 
Treatments with verapamil at levels causing close to maximum transporter ATPase stimulation 
(40 µM (ABCB1, Abcb4, nfAbcb4) or 50 µM (Abcb4)) served as positive controls. Liberated 
inorganic phosphate (Pi) was quantified colorimetrically by measuring the absorption at 750 nm 
using a detection reagent with 7.5 % ascorbic acid, 8.75 mM ammonium molybdate tetrahydrate 
and 3.75 mM zinc acetate. The constituents of the assay medium and their concentrations were 
modified from Sarkadi et al. (1992) and Germann (1998). 
 
2.3.3.1 Plate design and handling 
The pipetting scheme for ATPase assays is depicted in Fig. A.1. Various concentrations of the test 
chemicals were arranged in random order and wells at the rim of the wells were preferentially used 
for the phosphate standard or left free. Results from ATPase assays, obtained with a different plate 
design, were re-analysed (see also section A.2.8): Values – to calculate sodium orthovanadate-
sensitive ATPase activities – from wells with different reaction conditions (incubation temperature) 
were excluded, that finally only values from wells were used, which had the same reaction 
conditions.   
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2.3.3.2 Data analysis 
Specific transporter ATPase activities in each test were determined by subtracting the values from 
tests with orthovanadate from those from tests without orthovanadate (Sarkadi et al., 1992). 
Recorded sodium orthovanadate sensitive ATPase activities in nmol Pi/min/mg membrane protein 
from two independent experiments were plotted individually against the tested chemical 
concentrations; when three or more experiments were performed standard errors of the mean 
(SEM) were used to present the data. All concentration response relationships were computed 
using the software GraphPad Prism 5. Non-linear regression to the four parameter logistic equation 
(2.1) was used to obtain concentrations at half-maximal effect (EC50), i.e. ABCB1-like transporter 
ATPase activity modulation (stimulation or inhibition) by chemicals. 
 
 = min + max −min1 + 10 (2.1) 
 
V(c)  is the enzyme activity at a certain concentration of the tested chemical 
min   is the minimal ATPase activity 
max  is the maximal ATPase activity 
logEC50  is the concentration at half-maximal activity 
h                is the Hill slope (also called Hill coefficient, Hill factor) and describes the slope of the  
                  curve at half-maximal concentration 
c   is the concentration of the chemical.  
 
Effect strengths were quantified by relating obtained chemical sensitive ATPase activities from 
stimulation of basal and inhibition of stimulator co-treated ATPase activities to the control ATPase 
activities: values of the minimal (min) and basal ATPase activities (bA), respectively, were 
subtracted from the maximal (max) and control (verapamil) stimulated ATPase activities (sA), 
respectively and ratios were expressed in percent modulation (eq. (2.2)). 
 
Percent	modulation = max	−	minsA	 − 	bA 	 · 100 (2.2) 
 
Effects by chemicals inhibiting basal ATPase activities were related to the basal ATPase activity 
eq. (2.3). 
 
Percent	inhibition	of	basal	ATPase	activity = 100	 −	minbA 	 · 100 (2.3) 
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To test whether two measurements (n ≥ 3) are statistically different, unpaired t-tests were 
performed using the software GraphPad Prism 5. Unpaired t-tests were run for data from ATPase 
assays with and without 2 % DMSO; for ATPase assay data from mutant non-functional Abcb4 and 
from native Sf9 cell membrane preparations. 
For substances which did not stimulate or inhibit the ATPase activity of the recombinant proteins, a 
line was blotted to the data points using linear regression. 
 
To describe the relative variability of basal and verapamil stimulated Abcb4 and ABCB1 ATPase 
activities from different membrane preparations as well as of the mean of all preparations each 
coefficients of variation (CV) were calculated (Everitt, 1998; eq. (2.4)), i.e. the ratio of the standard 
derivation σ to the mean μ. Calculation of standard derivation and mean were performed in 
GraphPad Prism version 5. 
CV = 	./ (2.4) 
 
2.3.3.3 Decision criteria for interaction of chemicals with ABC transporter ATPase 
activities 
Clear and unambiguous interactions of chemicals with the MDR/MXR transporter ATPase activity 
were usually accompanied by unambiguous fits of parameters of the concentration response 
relationships (EC50s) with moderate to good quality of the regressions (r² ≥ 0.4). These chemicals 
usually caused ATPase activity modulation above 30-35 % of control modulation (stimulation) by 
verapamil. Effects by chemicals were considered ambiguous if chemicals caused only weak ATPase 
activity modulation and/or only at the higher concentration range tested, both were often leading 
to ambiguous fits and/or r² ≤ 0.4.  
 
2.4 OPTIMISATION OF ASSAY PARAMETERS 
Concentrations of MgATP, concentrations of sodium orthovanadate, and the duration of the 
reactions were optimised for ATPase assays with recombinant Danio rerio Abcb4. For ATPase 
assays with recombinant Homo sapiens ABCB1 concentrations of MgATP and sodium orthovanadate 
were adapted. Further overall revised parameters of the ATPase assay were the plate design and 
handling. 
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2.4.1 Optimisation of MgATP and sodium orthovanadate concentrations 
A concentration of 22.2 µM verapamil was chosen as this concentration caused a clear but no 
maximal stimulation.  
 
MgATP 
ATPase activities at 22.2 µM verapamil of both recombinant ABCB1-like transporters were rising 
with increasing amounts of MgATP in the assay, reaching the maximum at ≈ 10 mM MgATP (Fig. 2.2 
A). Basal ATPase activities of Abcb4 and ABCB1 were increasing up to ≈ 10 mM and ≈ 5 mM MgATP, 
respectively (Fig. 2.2 A). At higher concentrations (up to 40 mM MgATP) basal and 22.2 µM 
verapamil treated ATPase activities of both proteins decreased (data not shown). 
For recombinant ABCB1 concentrations of MgATP leading to half-maximal activation (EC50s) of 
22.2 µM verapamil stimulated and basal ATPase activities were 0.42 mM (0.15 to 1.19 mM 95 % 
confidence interval , CI) and 0.40 mM (0.08 to 1.88 mM 95 % CI), respectively (Fig. 2.2 A). (See 
Table A.2 for details.) Concentrations of MgATP to achieve half-maximal stimulation of ABCB1 
ATPase are 0.15 to 0.5 mM with and without verapamil stimulation (Hamada & Tsuruo, 1988; 
Sarkadi et al., 1992; Von Richter et al., 2009). MgATP concentrations at half-maximal stimulation of 
Homo sapiens ABCB1 obtained in this study were in the range of previous results from Sarkadi et al. 
(1992) and Von Richter et al. (2009). However, either only values were given (Von Richter et al., 
2009) or MgATP was tested only up to 1 mM and 5 mM (Hamada & Tsuruo, 1988; Sarkadi et al., 
1992).  
For Abcb4 concentrations of MgATP leading to half-maximal activation of 22.2 µM verapamil 
stimulated and basal ATPase activities were 0.63 mM (0.31 to 1.27 mM 95 % CI) and 0.53 mM (0.15 
to 1.91 mM 95 % CI; Fig. 2.2 A), respectively. ATPase assays data for a fish Abcb1 (ABCB1-like) are 
available for a doxorubicin resistant fish hepatoma cell line PLHC-1/dox, derived from clearfin 
livebearer (Poeciliopsis lucida): ATPase assays were performed with 2 mM MgATP and 1.2 mM 
vanadate along with 2 µg membrane protein (Zaja et al., 2011). The calculated Km for stimulation of 
PLHC-1/dox Abcb1 by MgATP was 0.4 mM without and with 30 µM verapamil (Zaja et al., 2011). 
Overall the MgATP concentrations at half-maximal ATPase activity stimulation recorded for Danio 
rerio Abcb4 was slightly higher than for Homo sapiens ABCB1 in this study, and higher than for 
PLHC-1/dox Abcb1 in Zaja et al., 2011. 
 
Sodium orthovanadate 
Different sodium orthovanadate concentrations in the ATPase assay were tested with recombinant 
Abcb4 and ABCB1 and no difference in sodium orthovanadate sensitive ATPase activities was 
detected between 0.2 and 0.38 mM (Fig. 2.2 B). Shapiro & Ling (1994) summarise 50 % inhibition 
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by vanadate at concentrations between 1.5 µM (Doige et al., 1992) to 100 µM (Hamada & Tsuruo, 
1988). As it is the aim to determine the vanadate sensitive ATPase activity of Abcb4 and ABCB1, 
maximal inhibition of ATPase activity needed to be reached, using high orthovanadate 
concentrations. 
 
Fig. 2.2 Abcb4 and ABCB1 ATPase activities with varying MgATP and vanadate concentrations 
ATPase assays were performed for 20 min at 37 °C (ABCB1) and for 40 min at 27 °C (Abcb4). Concentrations 
of MgATP (A) and vanadate (B) were varied as indicated in the graphs. Data were expressed in sodium 
orthovanadate sensitive ATPase activities in nmol Pi/min/mg membrane protein. Concentration response 
relationships in A were from non-linear regression to eq. (2.1). VER, verapamil. Data in nmol Pi and nmol 
Pi/min/mg membrane protein represented as means of triplicate samples X-axes in A was logarithmic with 
antilog scale. 
 
An overview on ATPase assay parameters can be taken from Shapiro & Ling (1994). In more recent 
studies commercial ABCB1 membrane preparations were used (Bircsak et al., 2013, Lacher et al., 
2015) or similar assay parameters (amount of crude membrane preparation: 10-25 µg, 5 mM ATP, 
0.3 mM sodium orthovanadate, incubation at 37 °C for 20 min) to this work were used (Chufan et al. 
(2013), and Chufan et al. (2016)).  
 
2.4.2 Abcb4 ATPase activities determined after different reaction duration 
Amounts of inorganic phosphate were quantified in ATPase assays with recombinant Abcb4 after 
10 to 60 min incubation time. Fig. 2.3 shows amounts of liberated inorganic phosphate expressed 
in nmol Pi (Fig. 2.3 A) and in nmol Pi/min/mg membrane protein (Fig. 2.3 B) from the same 
experiments. At 10 and 60 min values exhibited higher variability. Between 20 and 50 min 
generated Pi per incubation time and amount of protein was quite constant (Fig. 2.3 B). Up to 30 
min the amounts of released inorganic phosphate increased linearly in controls and in all verapamil 
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treatments (Fig. 2.3 A). Signals from Abcb4 ATPase assays performed for 30 and 40 minutes were 
considered as equally valid, with tests for 30 min preferred due to convenience.  
 
 
Fig. 2.3 ATPase activities of recombinant Danio rerio Abcb4 after different reaction durations 
Vanadate-sensitive ATPase activities were determined as a function of time without and with various 
concentrations of verapamil (VER). Data in nmol Pi (A) and nmol Pi/min/mg protein (B) from the same 
experiments, represented as means and SEMs of triplicate samples. Lines originate form linear regressions.  
 
Homo sapiens ABCB1 ATPase activity is linear with time up to 40 min and ATPase assays are 
incubated for 20 min in Germann (1998). Nevertheless, incubation durations for human ABCB1 
ATPase assays were 1 h in Li-Blatter et al. (2009), Litman et al. (1997a), Litman et al. (1997c), Nervi 
et al. (2010).  
In this work an incubation time of 20 min for ATPase assays with recombinant ABCB1 was chosen, 
resembling conditions in Germann (1998), Chufan et al. (2013), and Chufan et al. (2016). 
 
2.4.3 Summary of used ATPase assay conditions 
To optimise signal strength of Abcb4 ATPase assays maximal concentration of MgATP (10 mM) and 
sodium orthovanadate (0.3 mM) were chosen. Assay parameters for ABCB1 and Abcb4 ATPase 
assays are displayed as an overview in Table 2.1. 
Forty and 50 µM verapamil lead to equivalent stimulation of Danio rerio Abcb4 ATPase activities 
(Fig. 2.4 A) and solvent DMSO used in the ATPase assays did not modulate basal Homo sapiens 
ABCB1 ATPase activity (Fig. 2.4 B). 
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Fig. 2.4 Verapamil and DMSO in ATPase assays 
40 µM and 50 µM verapamil lead to equivalent stimulation of Abcb4 ATPase activities. ATPase assays were 
performed with the same membrane preparation but assays were conducted by three different 
experimenters (E1, E2, and E3). Box and whisker plot shows basal (bA) and stimulated (sA) ATPase activities 
of this membrane preparation (A). Basal ABCB1 ATPase activities without and with 2 % DMSO from the same 
membrane preparation each were shown. Means and single values were presented of individual 
experiments (B). 
 
Table 2.1 Overview of ATPase assay conditions for recombinant Abcb4 and ABCB1 in this work 
 
* According to Germann (1998). Solvent (DMSO) did not exceed 2%. 
 
 
2.4.4 Concentration response relationship modelling 
Concentrations of tested chemicals causing half-maximal stimulation or inhibition of basal or 
stimulator co-treated ATPase activities – Km values – were calculated using the Michaelis-Menten10 
equation in various works as in Lespine et al. (2007), Chen et al. (2005), Borgnia et al. (1996), and 
Urbatsch et al. (1994). When using this equation, basal ATPase activities need to be set to zero and 
basal ATPase actvtities were subtracted from all other values. Another characteristic of the 
Michaelis-Menten equation is its fixed slope (which equals one). To describe bell-shaped 
                                                             
10 	0 = 1234	∙67286    where V(S) is the ATPase activity; S is the chemical concentration, Vmax is the maximum     
                                   ATPase activity, and Km is the chemical concentration at half-maximal ATPase acitivity. 
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concentration response relationships, often seen for prototypical ABCB1 ATPase stimulators, a 
modified Michaels-Menten equation was suggested by Litman et al. (1997a), Litman et al (1997c) 
and Km values (called K1, K2) for the ascending and descending part of the curve can be derived. 
In this work (as well as in e.g. Bircsac et al., 2013; Zaja et al., 2011; Aller et al., 2009; and Hohl et al., 
2012) equations using Hill slopes (also called Hill coefficients, Hill factors; e.g. the four parameter 
logistic equation, eq. (2.1)) were used, for which no subtraction of basal ATPase activities is 
necessary and further slopes of the curve are described by the Hill slopes which are calculated and 
not constrained to one. Because ABCB1-like proteins exhibit a basal ATPase activity and it is not yet 
clarified in detail what is its function (see 1.4.2) and as basal ATPase activity depends on the lipid 
environment (reviewed in Sharom, 2014; Loo & Clarke, 2016), it was preferred not to subtract 
basal ATPase activities.  
 
Impact of the used equation to derive kinetic parameters for ATPase assay data 
Available kinetic parameters of the interaction of chemicals with ABC transporters were derived 
with different equations. To study the impact of the use of different equations on concentrations at 
half-maximal ABC transporter stimulation example data were analysed with the Michaelis-Menten 
equation and the four parameter logistic equation. ABCB1 ATPase assays data for verapamil (as a 
standard stimulator) and colchicine (as relatively weak stimulator; data from chapter 4) were 
analysed with regard to how kinetic parameters change depending on the used equation (Table 2.2, 
Fig. A.7).  
If setting constraints11 in the curve fit for max (eq. (2.1))/Vmax (Mich.-Ment.) values and min values 
(not necessary for the Michaelis-Menten equation) quite similar concentrations at half-maximal 
effect were obtained (Table 2.2).  
For colchicine 95 % confidence intervals were smallest using the four parameter logistic equation 
without subtraction of basal ATPase activities. Values for r² were highest if using the four 
parameter logistic equation. For verapamil the 95 % confidence intervals were smallest and r² were 
highest in conditions where basal ATPase activities were subtracted. For both chemicals 
concentrations at half-maximal effect using the Michaelis-Menten equation were slightly lower than 
those calculated with the four parameter logistic equation. With respect to the obtained results the 
four parameter logistic equation and the Michaelis-Menten equation gave very similar results. 
However, the four parameter logistic equation appeared more intuitive as it allows for a variable 
slope and no basal ATPase activities need to be subtracted. 
 
                                                             
11 Values of the controls – verapamil stimulated and basal ATPase activity – were used as max and min values, 
respectively and the respective counterparts – min or max values – were constraint to measured values of the 
treatments.  
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Table 2.2 Kinetic parameters from different equations to describe ABCB1 ATPase activity stimulation 
Number of experiments for colchicine was two, for verapamil twelve. Mich.-Ment., Michaelis-Menten 
equation. 4PL, four parameter logistic equation. Bold characters indicate parameters which were constraint 
individually or by use of the Michaelis-Menten equation. Min and Max values were given in nmol Pi/min/mg 
(membrane protein), 50 % effect concentrations in µM. Dist. indicates the distance of 95 % confidence 
interval (CI) concentrations (of concentrations at half-maximal stimulation) in µM. For fitting 4PL without 
subtracting basal ATPase activities, basal ATPase activity was set as minimum. In fits where basal ATPase 
activities were subtracted minima were set to zero. 
 
 
2.5 ATPASE ACTIVITIES FROM DANIO RERIO WILD-TYPE ABCB4, MUTANT ABCB4 
BACULOVIRUS INFECTED, AND NATIVE SF9 CELL MEMBRANE PREPARATIONS  
Crude membrane preparation protein from native Sf9 cells and baculovirus infected Sf9 cells – 
expressing recombinant (wild-type) Abcb4 or mutant non-functional (nf) Abcb4 – were tested in 
ATPase assays for interaction with verapamil and cyclosporin A (Fig. 2.5), using the same assay 
conditions as for Danio rerio Abcb4 ATPase assays. Verapamil and cyclosporin A stimulated Danio 
rerio basal Abcb4 ATPase activity, as also shown in Fischer et al. (2013). Native Sf9 cell membranes 
(n = 4) were produced in the identical way as membrane preparations of Abcb4 baculovirus 
infected Sf9 cells.  
Non-functional Danio rerio Abcb4 ATPase activity was not stimulated by verapamil. Additionally 
verapamil did not provoke a stimulation of sodium orthovanadate-sensitive ATPase activities of 
membrane preparations from native Sf9 cells. Cyclosporin A had no effect on stimulator co-treated 
nf Abcb4 ATPase activity. EC50 for stimulation of Abcb4 ATPase activity by verapamil was 5.51 µM 
(4.45 to 6.82 µM 95 % CI). The EC50 for inhibition of the verapamil co-treated ATPase activity by 
cyclosporin A was 0.33 µM (0.21 to 0.50 µM 95 % CI; for more details see Table A.3). 
Recorded basal ATPase activities were 4.70 ±0.53 nmol Pi/min/mg membrane protein for native 
Sf9 cell membrane preparations, 3.30 ±1.05 nmol Pi/min/mg membrane protein for non-functional 
Abcb4 and 7.59 ±0.54 nmol Pi/min/mg membrane protein for Abcb4 (from Fig. 2.5 A and B). 
Verapamil stimulated (50 µM) Abcb4 ATPase activities were 17.42 ±0.42 nmol Pi/min/mg 
membrane protein and the fold change was 2.3.  
Basal nf Abcb4 ATPase activities were at the same level as for membrane preparations from native 
Sf9 cells and no stimulation of ATPase activity by verapamil was observed (Fig. 2.5). 
Condition Min Max 50 % effect  (µM)
95 % CI          
(µM) Dist. Slope r²
Colchicine 4PL 11.65 21.95 296.3 238.3 - 368.5 130.2 2.21 0.94
4PL wo/bA 0 10.3 296.2 236.4 - 371.2 134.8 2.21 0.94
Mich.-Ment. 0 10.3 279.3 140.1 - 418.6 278.5 1 0.87
Verapamil 4PL 11.76 37.08 7.98 5.98 - 10.65 4.67 1.22 0.82
4PL wo/bA 0 25.32 7.99 6.39 - 10.0 3.61 1.22 0.88
Mich.-Ment. 0 25.32 7.7 5.80 - 9.60 3.8 1 0.88
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Fig. 2.5 ATPase activities from Danio rerio Abcb4, non-functional Danio rerio Abcb4 and native Sf9 cell 
membrane protein 
Verapamil was tested to stimulate (A) basal (bA) and cyclosporin A was tested to inhibit (B) stimulator 
co-treated ATPase activities of Danio rerio Abcb4 (half-closed triangles, n = 3 for verapamil, n = 2 for 
cyclosporin A) and Danio rerio non-functional Abcb4 (nf Abcb4, grey triangles, n = 3). Native Sf9 cell 
membrane protein (circles) was tested for stimulation by verapamil (n = 4). 40 µM verapamil stimulated 
ATPase activities (sA) served as control. Values are given as means ± SEMs in nmol Pi / min / mg (membrane) 
protein for n ≥ 3 or as single values for n = 2. Danio rerio Abcb4 basal ATPase activities (n = 3) were 
stimulated by verapamil; nf Abcb4 and native Sf9 cell membrane protein ATPase activities were not 
stimulated. Cyclosporin A inhibited 40 µM verapamil co-treated Danio rerio Abcb4 ATPase activities. X-axes in 
A and B were logarithmic with antilog scale. 
 
A statistically significant difference was calculated within an unpaired t-test for recorded basal 
Abcb4 and non-functional Abcb4 ATPase activities as well as for ATPase activities from (wild-type) 
Abcb4 and native Sf9 cell membrane preparations. No statistically significant difference was found 
between basal and verapamil stimulated non-functional Abcb4 ATPase activities. However, basal 
ATPase activities from a few of the 17 Abcb4 membrane preparations were at the level of basal 
nf Abcb4 ATPase activities (see section 2.6.2), which was most likely attributed to Abcb4 data 
variability. Because nf Abcb4 ATPase activity was not stimulated by verapamil, measured ATPase 
activities from ATPase assays with recombinant Danio rerio Abcb4 were specifically caused by 
modulation of the Abcb4 ATPase activity by the tested chemicals (verapamil).  
 
2.6 QUALITY CONTROL 
Western blot analyses (Fig. 2.6) and ATPase assays with verapamil (six concentrations) were 
conducted for each membrane preparation to confirm the presence of recombinant proteins in the 
membrane preparations of infected Sf9 cells. Basal and verapamil stimulated Abcb4 and ABCB1 
ATPase activities were determined in all conducted ATPase assays (Fig. 2.7). 
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Plate design and handling were identified as relevant parameters to obtain consistent ATPase assay 
data. For all reactions in the wells of the 96-well-plate the same conditions with respect to reaction 
time and temperature need to be guaranteed. This was ensured by the pipetting scheme in Fig. A.1. 
 
2.6.1 Immunohistochemical detection of recombinant protein in membrane 
preparations of baculovirus infected Sf9 cells  
Western blot analysis with antibody C219 showed the presence of recombinant Danio rerio Abcb4, 
nf Abcb4 and Homo sapiens ABCB1 in membrane preparations of baculovirus infected Sf9 insect 
cells after 68 to 72 h incubation time after inoculation (Fig. 2.6). Sizes of all proteins were between 
120 and 140 kDa. In membrane preparations of uninfected Sf9 cells no signal was detected (Fig. 
2.6). The appearance of single, strong bands in the Western blots confirmed that virus titre, 
duration of infection, and procedures of crude membrane preparations were suitable to obtain 
large amounts of intact membrane protein. 
 
Fig. 2.6  Western blot of membrane preparations from native Sf9 cells and Sf9 cells expressing recombinant 
ABCB1, Abcb4, and non-functional Abcb4  
Using antibody C219, which is specific to a conserved epitope (VQEALD) present in ABCB1, ABCB4, and 
ABCB11 P-glycoproteins (Georges et al., 1990; Childs et al., 1995; van den Elsen et al., 1999), signals were 
detected in 0.002 mg membrane preparations of Homo sapiens ABCB1 (1), Danio rerio Abcb4 (3) and non-
functional (mutated) Danio rerio Abcb4 (4) expressing Sf9 cells. No signal was detected in native Sf9 cell 
membrane preparations (2). M = marker. 
 
Western blots were routinely performed with each membrane preparation as quality control of the 
obtained recombinant protein to confirm integrity of the expressed recombinant protein and 
absence of degradation products. Respective signals from western blots with a larger number of 
membrane preparations of baculovirus infected Sf9 cells used in this work are given in Fig. A.5. 
Durations of infections were based on previous findings (Fischer et al., 2013; see also Fig. A.6). 
 
2.6.2 Reproducibility of ATPase assay results 
Danio rerio Abcb4 ATPase assays were conducted over three years by different experimenters and 
Homo sapiens ABCB1 ATPase assays over ca. one year by one experimentator. ATPase assay data 
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from earlier plate designs in the beginning of the study were re-analysed as shown in section A.2.8: 
Wells for calculating the sodium orthovanadate-sensitive ATPase activity for a certain value which 
would origin from the middle and from the rim of the well plate were excluded. Finally only rim 
wells or only wells from the middle were passed to account for a certain value.  
Fig. 2.7 shows means and SEM of basal (bA) and verapamil stimulated (sA) ATPase activities from 
all membrane preparations of recombinant transporter proteins used in this work from the left to 
the right in the time course each. Further, overall basal and verapamil stimulated ATPase activities 
(left y-axis) and overall fold change (sA/bA on the right y-axis) were plotted for Abcb4 (Fig. 2.7 A) 
and ABCB1 (Fig. 2.7 B). Means and SEM for bA and sA values originate from 2 to 11 (ABCB1) and 
1 to 18 (Abcb4) ATPase assays per illustrated membrane preparation (7 and 17, respectively). 
Means and SEMs of basal and stimulator treated ATPase activities of Danio rerio Abcb4 (17 
membrane preparations) and Homo sapiens ABCB1 (7 membrane preparations) were 5.28 
± 0.52 SEM and 14.78 ± 0.97 SEM and 10.75 ± 0.54 SEM and 32.12 ± 2.31 nmol Pi/min/mg 
membrane protein, respectively. Fold changes (sA/bA) were 2.97 ± 0.15 SEM for Abcb4 and 2.96 
± 0.13 SEM for ABCB1 (Table 2.3). Smallest and largest fold changes were 2.33 and 3.79 for Abcb4 
and 2.37 and 3.40 for ABCB1, respectively.  
Coefficients of variation of basal (bA) Abcb4 ATPase activity were highest, with 6.62 to 72.62 % for 
all used membrane preparations and 40.72 % for overall basal Abcb4 ATPase activity (Table 2.3). 
For verapamil stimulated (sA) Abcb4 ATPase activity coefficients of variation varied between 7.28 
and 30.20 % and were overall 27 %. Coefficients of variation for bA and sA ABCB1 ATPase activities 
were lower than for Abcb4 and were between 3.40 and 35.67 % and 2.74 and 26.55 %, respectively. 
Overall, i.e. for all ABCB1 membrane preparations coefficients of variation for bA and sA were 
13.30 % and 19.02 %, respectively.  
In Sarkadi et al. (1992) a 5 fold change for verapamil is described with a basal activity of 30 to 
35 nmol Pi/min/mg membrane protein and a stimulated ATPase activity of 150 nmol Pi/min/mg 
membrane protein. Generally, fold changes of stimulated versus basal ATPase activities range from 
2 to 5 fold (Stein & Litman, 2014) and hence obtained fold changes of this work tended to be lower 
but in line with previous findings. Inter-assay and inter-preparation (inter-vesicular) 
reproducibility for ATPase assays with vesicles from actinomycin-D-selected Chinese hamster DC-
3F/ADX lung fibroblast cells (using enzymatic quantification of ATPase activity) were 18.1 % (basal 
ATPase activity), 16.3 % (30 µM verapamil stimulated) and 18.9 % (basal ATPase activity), 26.1 % 
(30 µM verapamil stimulated), respectively, for n = 4 each. Percent variabilities of ABCB1 ATPase 
assay data were similar to those reported in Garrigues et al. (2002).  
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Fig. 2.7  Basal and verapamil stimulated ATPase activities from all used ABCB1 and Abcb4 membrane 
preparations 
From the left to the right in the time course each, Danio rerio Abcb4 (A), Homo sapiens ABCB1 (B): basal (bA) 
and verapamil stimulated (sA) ATPase activities of each membrane preparation with 2 to 11 ATPase assays 
for ABCB1 and 1 to 18 for Abcb4, Means ±SEM of basal (bA) and verapamil stimulated (sA) ATPase activities 
(left y-axis) and overall fold change of sA/bA on the right y-axis as box and whisker (5-95 %) were plotted. 
Dotted lines indicated means of overall Abcb4 (A) and ABCB1 (B) bA (lower) and sA (upper) ATPase 
activities. Single ATPase assays were performed with Abcb4 membrane preparations 17.10.2012, 03.05.2013, 
11.11.2013, and 05.06.2014 (A). 
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Basal and verapamil stimulated ATPase activities of ABCB1 were less variable than those of Abcb4. 
As the same protocol was used (except duration of incubation, concentrations of MgATP, sodium 
orthovanadate), variabilities in Abcb4 data could be due to the bigger sample size, the longer time 
span experiments were performed and more experimentators working on it. In general, lower 
incubation temperature (27 °C) for Danio rerio Abcb4 lead to lower activity, i.e. smaller values. 
Slight changes (e.g. by different velocities of plate handling after the end of incubation time) in 
activity might become more prominent. To improve ATPase assay performance it is suggsted to 
pool membrane preparations. Effect strengths expressed as percent modulation (using eq. (2.2) and 
(2.3)) instead of fold changes were suggested to compare effects across membrane preparation 
batches. 
Verapamil concentrations at half-maximal stimulation of ABCB1 ATPase activity of 0.5, 4.78, 9, and 
11.5 µM (Sarkadi et al., 1992; Von Richter et al., 2009; Feng et al., 2008; and Shirasaka et al., 2006) 
are reported from ATPase assays with recombinant ABCB1 from baculovirus infected Sf9 cells. The 
EC50 for stimulation of ABCB1 by verapamil (EC50 of 7.98 µM with 95 % CI of 5.98 to 10.65 µM; 
Table 2.1) was in the range of previous findings (Von Richter et al., 2009; Feng et al., 2008). 
Verapamil stimulated basal Abcb4 ATPase activity with a similar EC50 (5.51 µM; 4.45 to 6.82 µM 
95 % CI).  
 
2.7 CONCLUSION 
The aim of this chapter was to establish a standardisable and reproducible ATPase assay protocol –
from protein production to data analysis – for Danio rerio Abcb4 and Homo sapiens ABCB1 as 
reference transporter. Results for the reference transporter Homo sapiens ABCB1 – with an EC50 
for MgATP of 0.42 mM at 22.2 µM verapamil, an EC50 of 0.40 mM MgATP at basal ATPase activity, 
an EC50 for verapamil of 7.98 µM and a fold change (stimulated versus basal ATPase activity) of 
about 3 – were in line with previous findings and data were reproducible. This signified that the 
described ATPase assay protocol is standardisable and appropriate to study novel ABC 
transporters, as Danio rerio Abcb4. For Danio rerio Abcb4 the EC50 for MgATP was 0.63 mM at 
22.2 µM verapamil and 0.53 mM MgATP at basal ATPase activity. The EC50 for verapamil was 
5.51 µM and fold changes were also around 3 fold. However, Abcb4 ATPase assay data – using the 
same protocol but obtained over a longer period by different experimenters – were more variable 
than ABCB1 ATPase assay data. Membrane preparations should be pooled and subsequently used 
in the ATPase assay considering all suggested quality control tasks. 
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3 DANIO RERIO ABCB4 AND HOMO SAPIENS ABCB1 ATPASE 
ACTIVITIES AT DIFFERENT TEMPERATURES 
3.1 ABSTRACT 
Danio rerio – found in habitats with temperatures from 16 °C to 38 °C – are usually bred and used 
for ecotoxicological experiments at about 27 °C. Homo sapiens have a constant body temperature of 
about 37 °C. ATPase assays with recombinant Homo sapiens ABCB1 and Danio rerio Abcb4 were 
performed at incubation temperatures reflecting on the species body temperature (37 °C for Homo 
sapiens ABCB1) and on temperatures used in experimental settings (ca. 27 °C for Danio rerio 
Abcb4), respectively.  
The objective of this chapter is to study whether there are differences between Abcb4 and ABCB1 
ATPase activities at these two temperatures each and whether interaction of chemicals with 
recombinant ABCB1 and Abcb4 is influenced by temperature. Concentrations at half-maximal effect 
(using the four parameter logistic equation), minimal/maximal ATPase activities were compared, 
and activation energies were analysed. Abcb4 ATPase activity modulation by verapamil and 
cyclosporin A was very similar – also with respect to kinetic parameters – at both temperatures. 
Activation energies were ca. half as high for Abcb4 than for ABCB1, implying a less temperature-
sensitive protein function, which seems plausible for poikilothermic fish. ATPase assay data from 
recombinant Abcb4, obtained at 27 °C, can be compared to data from ATPase assay with 
recombinant ABCB1 performed at 37 °C.  
 
3.2 INTRODUCTION 
Danio rerio is found in habitats of temperatures from 16 °C to 38 °C (Spence et al., 2006; Engeszer 
et al., 2007). Cultivation of Danio rerio is usually run at around 27 °C with 28.5 °C (Nüsslein-
Vollhard & Dahm, 2002) and 26 ±1 °C (OECD 236 guideline ISO 7346-3) and hereafter a 
temperature of 27 °C was chosen for the ATPase assays with recombinant Danio rerio Abcb4. 
ATPase assays with Homo sapiens ABCB1 were conducted at 37 °C as described previously 
(Germann, 1998; Sarkadi et al. 1992), which is the physiological human body temperature.  
It is of question whether Abcb4 and ABCB1 ATPase assay data – obtained at different temperatures 
– are comparable. Therefore, effects of different incubation temperatures, 27 °C and 37 °C, on 
verapamil and cyclosporin A modulated ABCB1 and Abcb4 ATPase activities were analysed using 
kinetic parameters from concentration response relationships and activation energies Ea.  
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3.3 METHODOLOGY 
All methodological information is content of chapter 2. In chapter 2 (and appendix section A.2) the 
production of baculvirus particles, the production of recombinant membrane proteins, the conduct 
of ATPase assays, data analysis, and interpretation are described in detail. Data for verapamil and 
cyclosporin A interaction with Abcb4 at 27 °C were from Fischer et al. (2013). For Abcb4 and 
cyclosporine A (at 27 °C) one experiment was excluded to obtain data from only one membrane 
preparation. For ATPase assays with verapamil at 27 °C and 37 °C the same batches of membrane 
preparations (Abcb4 and ABCB1) were used each. Tests with cyclosporin A at 27 °C and 37 °C were 
conducted with one batch of membrane preparation each. 
 
3.3.1 Tested chemicals 
Verapamil hydrochloride (CAS 52-53-9) and cyclosporin A (CAS 59865-13-3) were ordered from 
Sigma Aldrich (Deisenhofen, Germany).  
 
3.3.2 Data analysis 
The influence of incubation temperatures of 27 °C and 37 °C on verapamil and cyclosporin A 
interaction with Abcb4 and ABCB1 ATPases were evaluated using kinetic parameters of the four 
parameter logistic equation (eq. (2.1), see chapter 2) and by analysis of activation energies.  
 
Calculation of activation energy 
The Arrhenius equation (eq. (3.1)) describes the relationship of reaction rates (here enzyme 
activity) and temperature (Arrhenius, 1889). 
 
	 9 = −: ∙ ;<3/>?	 (3.1) 
    
The activation energy Ea is the minimum energy required to start a chemical reaction. k is the 
reaction rate (enzyme activity in mol · L-1 · s-1); T is the absolute temperature in K; A is the pre-
exponential factor (number of collisions per second occurring with the proper orientation when all 
concentrations are 1 mol · L-1), and R is the universal gas constant (8.314 J · K-1 · mol -1).  
From this relationship the activation energy Ea can be calculated using eq. (3.2)12 (Mortimer & 
Müller, 2003). 
                                                             
12 For derivations see Mortimer & Müller (2003; p. 261, 262). 
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@A = B ∙ 	 CD ∙ CECE − CD ∙ ln F
9E9DG 
(3.2) 
 
 
T1/2 and k1/2 are the lower/higher absolute temperatures and the respective rate constants of the 
reaction.  
Activation energies were calculated from means of determined basal and verapamil stimulated 
Abcb4 (40 µM, 120 µM) or ABCB1 (40 µM, 200 µM) ATPase activities from one membrane 
preparation for Abcb4 and one membrane preparation for ABCB1. Calculation of activation 
energies of 0.08 µM and 0.74 µM cyclosporin A stimulated Abcb4 ATPase activities based on values 
from ATPase assays with different Abcb4 membrane preparations (see Table 3.1).  
 
3.4 RESULTS 
3.4.1 Abcb4 and ABCB1 ATPase activities at different temperatures 
Danio rerio Abcb4 and Homo sapiens ABCB1 ATPase assay results are shown in Fig. 3.1. ATPase 
activities are given as single data points if n = 2 or as means with SEM for more than two tests per 
chemical and temperature. Kinetic parameters of concentration response relationships (EC50, max, 
and min values), fold changes, % modulation of Abcb4 and ABCB1 ATPase activities, and activation 
energies are shown in Table 3.1.  
Basal Abcb4 ATPase activities (bA) at 27 °C and 37 °C were 7.31 and 11.90 nmol Pi/min/mg 
membrane protein and verapamil stimulated ATPase activities (sA) were 20.51 and 34.30 nmol 
Pi/min/mg membrane protein, respectively. Abcb4 ATPase activities at 37 °C versus 27 °C differed 
by a factor of ≈ 1.6. For ABCB1 basal ATPase activities at 27 °C and 37 °C were 3.47 and 8.58 nmol 
Pi/min/mg membrane protein and verapamil stimulated ATPase activities were 10.94 and 
26.86 nmol Pi/min/mg membrane protein, respectively. Here, the difference was by a factor of 
≈ 2.5. Fold changes of the controls (sA versus bA) for Abcb4 and ABCB1, i.e. the extent of 
stimulation, were about 2.5 to 3.4 fold at 27 °C and 37 °C and no temperature dependency was seen. 
 
Abcb4 and ABCB1 modulation by verapamil and cyclosporin A at 27 °C and 37 °C 
Verapamil stimulated basal Homo sapiens ABCB1 and Danio rerio Abcb4 ATPase activities at 27 °C 
and 37 °C. Stimulation of ATPase activities reached levels above the control stimulation (set to 
100 % modulation) by 40 µM (ABCB1) and 50 µM (Abcb4) verapamil, respectively. Cyclosporin A 
inhibited stimulator co-treated Abcb4 and ABCB1 ATPase activities at both temperatures and 
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ATPase activities at the levels of basal ATPase activities each were reached. The shape and trend of 
the concentration response curves was not affected by the different temperatures.  
Verapamil stimulation of basal Abcb4 (120 µM) and ABCB1 (200 µM) ATPase activities was about 
3.4 and 3.7 fold (27 °C and 37 °C) as well as 4.4 and 3.3 (27 °C and 37 °C) fold, respectively, 
representing 160 % and 106 % as well as ≈ 110 % of verapamil stimulation (Table 3.1). Tested 
concentrations of verapamil were high enough to reach a plateau of maximal stimulation/to 
decrease activity except for Abcb4 at 37 °C (Fig. 3.1).  
 
 
Fig. 3.1 Danio rerio Abcb4 and Homo sapiens ABCB1 ATPase activities at 27 °C and 37 °C 
Results were expressed as means ± SEMs nmol Pi/min/mg membrane protein from two to four individual 
ATPase assays. X-axes were log transformed with antilog number format. Basal activities (bA) were DMSO 
controls (2 %), stimulated ATPase activities (sA) by 40 µM (for ABCB1) and 50 µM (for Abcb4) verapamil 
served as positive controls. Curves were fitted using the four parameter logistic equation (eq. (2.1)) except 
for cyclosporin A and stimulation of ABCB1 (linear regression). The same membrane preparations were used 
for: Stimulation of Abcb4 by verapamil at 27 °C and 37 °C, stimulation of ABCB1 by verapamil at 27 °C and 
37 °C and for modulation of verapamil co-treated ABCB1 ATPase by cyclosporin A at 27 °C.  
 
Abcb4 ATPase activities (bA, sA) were 1.6 fold lower at 27 °C compared to 37 °C, whereas ABCB1 
activities were ≈ 2.4 fold lower (Table 3.1). EC50s for verapamil stimulation of basal Abcb4 and 
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ABCB1 ATPase activities at 27 °C and 37 °C were 5.61 µM and 4.76 µM for Abcb4 and 12.98 µM and 
7.15 µM for ABCB1, respectively. Cyclosporin A decreased verapamil co-treated Abcb4 and ABCB1 
ATPase activities and increased basal Abcb4 ATPase activities at both temperatures. Verapamil 
co-treated Abcb4 ATPase activities were decreased by cyclosporin A 110 % at 27 °C and 104 % fold 
at 37 °C and verapamil co-treated ABCB1 ATPase activities were decreased 122 % at 27 °C and 
96 % at 37 °C (Table 3.1). A decrease of 100 % indicates a decrease from 40 µM verapamil 
stimulated to the basal ATPase activity, a decrease > 100 % signified inhibition below the basal 
ATPase activity. Stimulation of basal Abcb4 ATPase activities by cyclosporin A showed bell-shaped 
concentration response curves reaching 41 % (at 27 °C) and 71 % (at 37 °C) of control stimulation 
(see Table 3.1). Cyclosporin A did not stimulate basal ABCB1 ATPase activity (at 37 °C). EC50s for 
cyclosporin A for stimulation of basal Abcb4 ATPase activity were 0.14 and 0.11 µM at 27 °C and 
37 °C, respectively. Cyclosporin A EC50s for decrease of Abcb4 ATPase activity upon co-treatment 
with verapamil were 0.34 µM and 0.40 µM at 27 °C and 37 °C, respectively. Concentrations of 
cyclosporin A at half-maximal decrease of ABCB1 ATPase activities were very similar, with 0.09 and 
0.10 µM at 37 °C and 27 °C respectively. Cyclosporin A did not increase ABCB1 ATPase activity at 
37 °C and was not tested at 27 °C with ABCB1.  
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3.4.2 Activation energies of basal and verapamil stimulated Abcb4 and ABCB1 
ATPase activities  
Activation energies (Table 3.1) of basal (bA) ATPase activity were 40.75 kJ/mol (Abcb4) and 
81.61 kJ/mol (ABCB1). Ea of 40 µM verapamil and 120 µM verapamil stimulated Abcb4 ATPase 
activities were 49.28 kJ/mol and 48.38 kJ/mol; Ea of 40 µM and 200 µM verapamil stimulated 
ABCB1 ATPase activities were 72.44 kJ/mol and 65.24 kJ/mol. Activation energies of cyclosporin A 
(0.08 µM, 0.74 µM) stimulated Abcb4 ATPase activities were between 48.05 and 53.59 kJ/mol. 
Using means of all basal and stimulated (40 µM verapamil) ATPase activities from Table 3.1 
activation energies of 37.68 and 39.76 kJ/mol (for Abcb4) as well as 69.91 and 69.45 kJ/mol (for 
ABCB1) were calculated.  
 
Activation energies calculated from slopes (m; m = - Ea /R) of Arrhenius plots (Fig. 3.2) gave very 
similar activation energies as using equation (3.2) (Data not shown).  
 
 
Fig. 3.2  Arrhenius plot for ABCB1 and Abcb4 ATPase activities  
Logarithms (ln) of ATPase activities from the concentration response curves for verapamil in Fig. 3.1 were 
plotted against the reciprocal absolute temperature for basal (bA), 40 µM verapamil stimulated, 200 µM (for 
ABCB1), and 120 µM (for Abcb4) verapamil stimulated Abcb4 (A) and ABCB1 (B) ATPase activities at 27 °C 
and 37 °C.  
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3.5 DISCUSSION 
3.5.1 Abcb4 and ABCB1 ATPase activities at different temperatures 
Half-maximal stimulation of Abcb4 ATPase activity was reached at lower verapamil concentrations 
compared to ABCB1 at both temperatures. Further, lower verapamil concentrations for half-
maximal stimulation were needed at higher temperatures for each studied ABC transporter, which 
was in accordance to the observations of Al-Shawi et al. (2003) who reported decreased Km values 
as a function of increasing temperature for ATPase activation by chemicals. EC50s of verapamil 
stimulating ABCB1 ATPase activity at 37 °C were outlined in chapter 2 (2.4.4. and 2.6). Briefly, the 
EC50 of ABCB1 ATPase stimulation by verapamil derived in this study (EC50 of 7.98 µM in chapter 
2; EC50 of 7.15 µM this chapter) was in line with previous findings (4.78 µM in Richter et al., 2009; 
9 µM in Feng et al., 2008). The EC50 of ABCB1 stimulation by verapamil at 27 °C was slightly above 
the 95 % confidence interval of EC50s at 37 °C (4.88 -10.49 µM). For Abcb4 the EC50s of verapamil 
stimulation at 27 °C and 37 °C were very similar. Concentrations of cyclosporin A at half-maximal 
decrease of stimulator co-treated ABCB1 ATPase activity (Table 3.1) were in the range of previous 
findings (Fekete et al., 2015: 0.38 µM; Von Richter et al. 2009: 0.14 µM, Watanabe et al., 1997: 
0.8 µM). The EC50 of cyclosporin A inhibiting the stimulator co-treated Abcb4 ATPase activity of 
0.2 µM (Keiter et al., 2016) is in line with data of this work (0.14 µM). Stimulation of Abcb4 ATPase 
activities by cyclosporin A were previously reported (Fischer et al., 2013).  
Overall, the results suggest that Danio rerio Abcb4 ATPase activity is less influenced by temperature 
than Homo sapiens ABCB1 ATPase activity. 
 
3.5.2 Activation energies of basal and verapamil stimulated Abcb4 and ABCB1 
ATPase activities 
Activation energies of ABCB1 from drug resistant Chinese hamster ovary cells were previously 
studied in Litman et al., (1997c) and an activation energy of 77.2 kJ/mol was calculated for maximal 
verapamil stimulated Chinese hamster ABCB1 ATPase for the temperature range of 22 °C to 40 °C. 
An Ea of 104.2 kJ/mol of basal human ABCB1 ATPase and 99.3 kJ/mol of 130 µM verapamil 
stimulated ATPase was obtained (Al-Shawi et al., 2003). The findings of this work (see Table 3.1) 
were in line with the findings from Litman et al. (1997c) as well as with Al-Shawi et al. (2003) with 
respect to higher Ea for basal than verapamil stimulated Homo sapiens ABCB1 ATPase (purified 
human ABCB1 expressed in the yeast Saccharomyces cerevisiae; Al-Shawi et al., 2003). A decrease in 
activation energies with increasing verapamil concentrations stimulating Homo sapiens ABCB1 
ATPase activity were also reported in Al-Shawi et al. (2003). Nevertheless different chemicals show 
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different effects on activation energies. For example a higher Ea (122.3 kJ/mol) was calculated for 
2 mM colchicine stimulated ABCB1 ATPase activity than for basal ATPase activity (104.2 kJ/mol) 
(Al-Shawi et al., 2003).  
The Ea of basal Abcb4 was about 50 % lower than of basal ABCB1 ATPase activity and further a 
higher Ea of verapamil stimulated Abcb4 ATPase activity (compared to Ea of verapamil stimulated 
ABCB1) was seen. Interpretation of this finding is difficult as there are only few equivalent data 
available. First, a higher Ea for verapamil stimulated than basal Abcb4 ATPase activity could be 
stimulator dependent as seen in Al-Shawi et al. (2003).  
Activation energies calculated from all bA and sA Abcb4 and ABCB1 ATPase activities (using 
different membrane preparations, see Table 3.1) obtained at 27 °C and 37 °C underline and confirm 
the results obtained with only one membrane preparation used at 27° and 37 °C: Activation 
energies of basal Abcb4 ATPase activities were half as high as of basal ABCB1 ATPase activities. 
Obtained activation energies of Abcb4 ATPase modulated by cyclosporin A were similar to those of 
verapamil, i.e. were higher than those of basal ATPase activity. ATPase activities used for 
calculation (Ea of cyclosporin A) originated from different bathes of membrane preparations. 
However, the fold change (sA/bA) of both used membrane preparations was 2.5 fold (Table 3.1). 
Activation energies of Danio rerio enzymes seem higher than Ea of the Abcb4 ATPase activity and 
are 80.5 kJ/mol for a aminopeptidase (30 to 45 °C) reported in Chen et al. (2011) as well as 76.20 
kJ/mol for rhodopsin (5 °C to 24 °C) in Morrow & Chang et al. (2015), respectively. 
In this study it was not tested whether Arrhenius relationships are linear for ABCB1 and Abcb4 
ATPase over a broader range of temperatures. However, Arrhenius relationships for Homo sapiens 
ABCB1 ATP hydrolysis (and transport) are linear between 23 °C and 35 °C (Al-Shawi et al., 2003). 
Activation energies determined in this study may not be definite and were strictly used to compare 
ATPase activities of recombinant ABCB1 and Abcb4. As the membrane environment and not only 
chemical interaction influences ATPase activity and activation energies (Al-Shawi et al., 2003, 
Romsicki & Sharom, 1998) activation energies of Abcb4 and ABCB1 ATPase and their possible 
physiological implementations should be studied in the species’ specific membrane environment.  
Further, Al-Shawi et al. (2003) argue that larger activation energies are linked to larger 
conformational rearrangements. Translated to the lower Ea for Abcb4 this could imply that in Abcb4 
smaller conformational changes take place than in ABCB1. 
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3.6 CONCLUSION 
Interaction of chemicals with Danio rerio Abcb4 and Homo sapiens ABCB1 were analysed with 
ATPase assays performed at 27 °C and 37 °C, respectively, resembling temperatures the species 
were kept at (26-28 °C; Nüsslein-Vollhard & Dahm, 2002; OECD 236 guideline ISO 7346-3) and live 
at, respectively. However, zebrafish are found in habitats of 16 to 38 °C (Spence et al., 2006; 
Engeszer et al., 2007). As chemicals were compared for their interaction with Abcb4 and ABCB1 
ATPase activities, the question of this section was to determine whether the different incubation 
temperatures are influencing ABCB1 and Abcb4 ATPase activities. 
Verapamil and cyclosporin A were tested to modulate recombinant Abcb4 and ABCB1 ATPase 
activities at 27 and 37 °C. The effect strengths (percent modulation in relation to control 
stimulation), EC50s, and shape of concentration response curves were similar at the two 
temperatures for Abcb4 and less similar with respect to the EC50 for verapamil stimulation for 
ABCB1.  
From the observations was drawn the conclusion that results from ATPase assays with 
recombinant Danio rerio Abcb4 at 27°C can be compared to Homo sapiens ABCB1 ATPase assay data 
at 37 °C to investigate to which extend chemicals interact similar or dissimilar with the two 
P-glycoproteins. Abcb4 ATPase activities seem less temperature-sensitive than ABCB1 ATPase 
activities and activation energies were lower for Abcb4. Al-Shawi et al. (2003) interpret larger 
activation energies as an indication for larger conformational rearrangements and hence smaller 
conformational rearrangements might take place in Abcb4 than in ABCB1. 
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4 COMPARISON OF FUNCTIONAL PROPERTIES OF THE 
MULTIDRUG TRANSPORTER ABCB4 FROM DANIO RERIO WITH 
HOMO SAPIENS ABCB1 BASED ON ATPASE ACTIVITIES OF 
RECOMBINANT PROTEIN 
4.1 ABSTRACT 
Various transporter proteins of the ABC transporter family control the transition of chemicals 
across tissue compartments. Homo sapiens ABCB1 translocates structurally diverse chemicals and 
can mediate multidrug resistance (MDR), whereas Homo sapiens ABCB4 is a phosphatidylcholine 
translocator in the liver. The term multixenobiotic resistance (MXR) was coined as ABCB1-like 
transporters and evidence for their respective function are found in all studied species. In the 
model organism Danio rerio the transporter protein Abcb4 is functional homologous to 
Homo sapiens ABCB1. Both transporters are poly-specific MDR/MXR transporters and it is of 
interest whether their ATPase activities are modulated by the same chemicals as stimulators and 
inhibitors. 
ATPase assays with membrane preparations containing recombinant Homo sapiens ABCB1 and 
Danio rerio Abcb4 were used to compare interactions of chemicals with the proteins’ ATPase 
activities. Recombinant transporter proteins were obtained with the baculovirus expression system 
in Sf9 cells. ATPase assay data inform about affinity of chemicals for and interaction of chemicals 
with the ABC transporters at the molecular level. Stimulators increase basal ATPase activity. 
Inhibition can concern basal and/or stimulator co-treated ATPase activity. Inhibition of (ABCB1) 
ATPase activity is not contradicting transport of a chemical. However, inhibitors of basal and 
stimulator co-treated ATPase activity can mitigate substrate translocation (in a co-exposure 
scenario). The selection of chemicals aimed at expanding knowledge on interaction of chemicals 
with ABCB1 and Abcb4 ATPase activities – including commonly studied ABCB1-like modulators and 
chemicals known to interact with Abcb4  – using the same methodology.  
Sixteen of the 17 tested chemicals interacted with the ATPase activity of both studied transporters 
and only one interacted not at all. Thirteen chemicals exhibited EC50s below 100 µM, ten below 
50 µM, and four below 10 µM for both transporters, implying that interactions were specific also for 
Abcb4. Inhibition of basal and/or stimulator co-treated ATPase activities by ivermectin, tonalide, 
and galaxolide may be an ecotoxicological relevant result as it implied chemosensitising potential of 
these chemicals. Information on interaction or not seem transferable from Homo sapiens ABCB1 
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ATPase assay data to Danio rerio Abcb4 ATPase assay data. A severe difference in interaction would 
mean that a chemical interacts with the ATPase activity of only one of the transporters. No definite 
conclusion on transport of a chemical can be drawn from ATPase assay data, e.g. there are 
inhibitors of basal ABCB1-like transporter ATPase activity that are transported (while others 
inhibitors are not). However, non-transported inhibitors of ABCB1-like transporter ATPase 
activities would be ecotoxicological relevant category of chemicals: Organisms would not benefit 
from ABCB1-like transporter mediated multixenobiotic resistance but would be threatened by 
chemosensitisation (i.e. increased sensitivity of an organism towards a potentially harmful 
substrate chemical).  
Alignment of Danio rerio Abcb4, Homo sapiens ABCB1, and Mus musculus ABCB1a and comparison 
of residues known to bind chemicals or being involved in function implied that the transporters are 
largely conserved with respect to sites, several chemicals bind to. Dissimilar residues in Abcb4 
compared to their mammalian counterparts were preferentially seen at positions only one of the 
four surveyed chemicals bind to. 
 
4.2 INTRODUCTION 
The transition of chemicals across tissue compartment interfaces in organisms is commonly 
controlled by numerous different cellular transporter proteins mediating uptake, efflux, and ion 
exchange processes (Dobson & Kell, 2008; Leslie et al., 2005). In all members of the ATP binding 
cassette (ABC) transporter superfamily biological processes, e.g. translocation of their substrates, is 
linked to ATP hydrolysis (Bouige et al., 2002). Homo sapiens ABCB1 (ABCB1) was identified to be 
responsible for pleiotropic cross-resistance of cancer cells against a variety of anti-cancer drugs 
(Juliano & Ling, 1976). However, there are also ABC transporters which are not linked to MDR, as 
e.g. mammalian ABCB4 which is a phosphatidylcholine translocase in the liver (Smith et al., 2000; 
Rosmorduc et al., 2001, Smith et al., 1994; Ruetz & Gros, 1994). The term multixenobiotic 
resistance (MXR), in analogy to multidrug resistance (MDR) (Juliano & Ling, 1976), was coined as 
there is evidence for ABCB1-like proteins and function in the so far studied aquatic species (Kurelec 
et al., 1992).  
Danio rerio Abcb4 is a co-orthologue to Homo sapiens ABCB1 and ABCB4 with 64 % amino acid 
similarity to both and a phylogenetic analysis reveals that Abcb1 is absent in Danio rerio (Fischer 
et al., 2013, supplemental information, Luckenbach et al., 2014). Nevertheless, Danio rerio Abcb4 
(Abcb4) is a functional homolog to Homo sapiens ABCB1 (Fischer et al., 2013) as it prevents 
standard ABCB1-like substrates as calcein-AM and rhodamine B to accumulate inside Danio rerio 
embryos and leads to reduced toxicity of microcystin-LR to Abcb4 expressing Danio rerio embryos 
(Lu et al., 2015).  
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Limited data, especially quantitative information, is available on interaction of chemicals with 
Danio rerio Abcb4 ATPase activity as stimulators or inhibitors. So far the perception is that Abcb4 is 
functionally homologous to ABCB1 acting as MDR transporter implying that both transporters 
similarly interact with a wide variety of compounds. Hence it is of interest whether and to what 
extent functional profiles of ABCB1 and Abcb4 correspond. Such data would be informative 
regarding the question how conserved the multidrug resistance related functional profiles are 
across these transporters and to what extent ATPase assay data on interaction of a chemical with 
Abcb4 ATPase activity could be extrapolated from already existing ABCB1 (ATPase assay) data. 
Additionally amino acid sequences of ABCB1 and Abcb4 were aligned and mammalian ABCB1 
amino acid positions to which chemicals bind to or which are involved in protein function were 
compared to Abcb4 amino acid positions. 
Available data on chemical-transporter-interactions may be ambiguous, as results may depend on 
the applied test system (ATPase assays, transport/transport inhibition studies) and study designs 
(Stein & Litman, 2014; Bentz et al., 2013; Sjöstedt et al., 2014), described in detail in 1.5.1. In this 
study the same methodology, ATPase assays with recombinant protein, was applied to study 
whether and how chemicals interact with ABCB1 and Abcb4 ATPase activities. Recombinant 
Danio rerio Abcb4 and Homo sapiens ABCB1 were produced in Sf9 cells using the baculovirus 
expression system. ATPase assays with the recombinant protein were conducted as described in 
chapter 2 studying the interaction of chemicals with the transporter ATPase activity in two test 
modes: interaction with the basal and with the stimulator co-treated ATPase activity. Compounds 
which stimulate the basal ATPase activity of the protein – which leads to increasing amounts of 
liberated inorganic phosphate – act as stimulators; chemicals which decrease basal ATPase activity 
act as inhibitors (of basal ATPase activity). A decrease in stimulator co-treated ATPase activity 
leads to reduced amounts of liberated inorganic phosphate and is seen for chemicals competing 
with verapamil to stimulate ATPase activity or chemicals interacting in a non-competitive manner. 
Generally, inhibition of basal and/or verapamil co-treated ATPase activity indicate 
chemosensitisation potential of a chemical. Inhibition of stimulator co-treated ATPase activity 
indicates competitive substrate properties (or non-competitive inhibition; Glavinas et al., 2008; Von 
Richter et al., 2009; Litman et al., 1997b). This situation is described e.g. for cyclosporin A and 
ABCB1 with no stimulation of basal ATPase, inhibition of co-treated ATPase, and transport by 
ABCB1 (Goldberg et al., 1988, Polli et al., 2001). However, no definite conclusion on net transport or 
transport inhibition can be drawn from ATPase assay data (Stein & Litman, 2014).  
Tested chemicals were selected considering existing data on interaction with either ABCB1 or 
Abcb4 and aiming at the expansion of knowledge on the interaction of chemicals with both 
ABCB1-like transporter ATPase activities.  
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Cyclosporin A, verapamil, vinblastine, doxorubicin, galaxolide, tonalide, and phenanthrene were 
recently shown to interact with Danio rerio Abcb4 ATPase activity (Fischer et al., 2013). These data 
were re-analysed (section A.2.8) and compared to ABCB1 data of this work. Amprenavir, 
dipyridamole, colchicine, dexamethasone, etoposide, and trospium are transported Homo Sapiens 
ABCB1 substrates (Polli et al., 2001, Callegari et al., 2011) and either ATPase assay data were 
variable (e.g. for colchicine), missing (trospium) or limited to single concentrations (ATPase assay 
data in Polli et al., 2001). Carbamazepine, phenytoin, and testosterone were chosen because no 
interaction with Homo sapiens ABCB1 ATPase is described (Feng et al., 2008; Polli et al., 2001). 
Ivermectin was chosen because it is one of the first discovered in vivo ABCB1/ ABCB1a substrate 
(Pouliot et al., 1997; Schinkel et al., 1994; Schinkel et al., 1996) (see section 4.3.2).  
 
4.3 METHODOLOGY 
The methodology used in this chapter – production of recombinant transporter proteins, their 
usage in ATPase assays, and subsequent data analysis – was described in chapter 2. Danio rerio 
Abcb4 ATPase assay data obtained with the described method are published in Fischer et al., 
(2013) and Keiter et al., (2016), Cunha et al. (2017). Detailed protocols for the complete procedure 
are given in section A.2.  
 
4.3.1 Chemicals 
All chemicals were ordered as followed and were stored according to the supplier’s instructions. 
Tris (hydroxymethyl) aminomethane (Tris Base), ethylene glycol tetraacetic acid (EGTA), 
tetracycline, and ascorbic acid were ordered from Applichem (Darmstadt, Germany). Grace Insect 
media unsupplemented, 4 % agarose gel (low melting, Cat.-no. 18300-012), and Sf 900 1.3x, Sf9 
Cells (Cat No. 11496-015; Lot No 644282) were ordered from Gibco life technology (Thermo 
Fischer Scientific, Waltham, USA). IPTG and Bluo-gal and Sf-900 II SFM medium were ordered from 
Invitrogen (Thermo Fischer Scientific, Waltham, USA). Potassium chloride, potassium dihydrogen 
phosphate (KH2PO4), and 2-Mercaptoethanol were ordered from Merck Chemicals GmbH 
(Darmstadt, Germany). Penicillin/Streptomycin 100x in 0.9 % NaCl, Dulbecco’s PBS (1x) with 
calcium/ magnesium were from PAA (GE Healthcare, Little Chalfont, UK). Magnesium chloride and 
D-Mannitol were from Riedel-de Haën (Honeywell Specialty Chemicals Seelze GmbH). 3-
morpholinopropane-1-sulfonic acid (MOPS), sodium hydroxide, gentamycin, and kanamycin 
sulphate were from Roth (Karlsruhe, Germany). Sodium dodecyl sulphate (SDS, 20765; used for 
ATPase assays) was ordered from Serva (Heidelberg, Germany). Sodium azide, Dithiothreitol 
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(DTT), sodium orthovanadate, adenosine triphosphate (ATP), verapamil hydrochloride, cyclosporin 
A, zinc acetate, ammonium molybdate, Trypan blue Solution (0.4 %), fetal bovine serum (FBS, 
F7524), 0.3 g/l Neutral red Solution, and protease inhibitor (P8340) were ordered from Sigma 
Aldrich (Deisenhofen, Germany).  
Tested chemicals: Aprenavir (CAS 161814-49-9), and trospium chloride (CAS 10405-02-4) were 
ordered from Selleckchem (Boston, USA); Carbamazepine from Acros (Thermo Fischer Scientific, 
Waltham, USA); colchicine (CAS 64-86-8 )from Merck (Darmstadt, Germany); dexamethasone (CAS 
50-02-2) from Applichem (Darmstadt, Germany). Cyclosporin A (CAS 64-86-8), dipyridamole (CAS 
58-32-2), doxorubicin hydrochloride (23214-92-8), etoposide (CAS 33419-42-0) , ivermectin (CAS 
70288-86-7), phenanthrene (CAS 85-01-8), phenytoin (CAS 57-41-0), testosterone (CAS 58-22-0), 
verapamil hydrochloride (CAS 52-53-9), and vinblastine sulfate (CAS 143-67-9) were ordered from 
Sigma-Aldrich (Schnelldorf, Germany). Galaxolide (CAS 1222-05-5; 73 % of the total are 
diasterimeric isomers of 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-[2]-
benzopyran) was a kind gift from International Flavors & Fragrances Inc. (IFF; Union Beach,USA) 
and tonalide (CAS 21145-77-7; 7-acetyl-1,1,3,4,4,6-hexamethyl-1,2,3,4-tetrahydronaphthalene; 
purity: 98 %) was obtained from Bush Boake Allen Inc. (Jacksonville, USA). Stock solutions of the 
tested chemicals were prepared in dimethyl sulfoxide (DMSO); concentrations used in the tests did 
not exceed 2 % DMSO. 
Usage, CAS numbers, molecular weight, logP (logKow), water solubilities (experimental, predicted by 
ALOGpS and EpiSiute) and highest concentrations of the test chemicals used in the ATPase assays 
are given in Table 4.1. 
 
4.3.2 Chemical selection – additional information 
Abcb4 ATPase raw data for cyclosporin A, verapamil, vinblastine, doxorubicin, galaxolide, tonalide, 
and phenanthrene were from Fischer et al. (2013) and were re-analysed in this study (see A.2.8). 
Briefly, values to calculate sodium orthovanadate sensitive ATPase activities which were from 
replicate wells located with dissimilar distance to the rim of the 96-well-plate were excluded. For 
cyclosporin A and verapamil data for Abcb4 see also chapter 3. One experiment (one ATPase assay) 
with Abcb4 and vinblastine was excluded, as effects from the rim of the plate were too severe. 
Another ATPase assay (recombinant Abcb4 and vinblastine) was performed instead. One of four 
tonalide experiments from Fischer et al. (2013) was excluded due to low quality. 
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4.3.3 Chemical concentrations used in ATPase assays 
Maximal concentrations used in the ATPase assays were according to the respective water 
solubility, with exceptions (see below). Values for water solubility were from respective suppliers 
of the compound or determined using the ALOGPS 2.1 program (Tetko et al., 2005) 
(http://www.vcclab.org/lab/alogps/) or EpiSuite (US EPA, from the logP). Water solubilities of 
chemicals differed up to orders of magnitude (trospium chloride, carbamazepine, and colchicine). 
Experimental solubilities may be preferred but uncertainties could be different from chemical to 
chemical, whereas for predicted chemicals the same method was used. Predicted water solubilities 
were often not of good accuracy for high molecular weight chemicals and ionic substances 
(EpiSuite, estimated from logP). Classical ABCB1 modulators as verapamil, vinblastine, 
cyclosporine A, doxorubicin, and ivermectin as well as tonalide, galaxolide and phenanthrene were 
tested in concentrations which were used in previous works (Fischer et al., 2013) and were above 
their water solubilities. Concentrations of doxorubicin were below its water solubility limit. 
 
4.3.4 ATPase assay conditions  
ATPase assays with recombinant Danio rerio Abcb4 were performed with 10 mM MgATP in absence 
and presence of 0.3 mM sodium orthovanadate at 27 °C for 30 min (amprenavir, carbamazepine, 
dexamethasone, dipyridamole, colchicine, etoposide, phenytoin, testosterone) and for 40 min 
(doxorubicin, galaxolide, phenanthrene, tonalide, trospium, vinblastine, ivermectin). ATPase assays 
with recombinant Homo sapiens ABCB1 were performed with 5 mM MgATP in absence and 
presence of 0.25 sodium orthovanadate for 20 min at 37 °C. Concentrations of verapamil used to 
study stimulator co-treated ATPase activities were 40 µM (ABCB1, some test with Abcb4) or 50 µM 
(Abcb4), both leading to an unambiguous stimulated ATPase. For details see chapter 2. 
 
4.3.5 Analysis of amino acid sequences 
Amino acid sequences of Danio rerio Abcb4 (UniProt- K9M7F0), Homo sapiens ABCB1 (P08183), 
and Mus musculus ABCB1a (UniProt-P21447) were aligned (multiple sequence alignment) using the 
Clustal O webservice (https://www.ebi.ac.uk/Tools/msa/clustalo/). Sequences of Mus musculus 
ABCB1a were added because findings from Aller et al., (2009) and Nicklisch et al. (2016) refer to it.  
Amino acid positions, which were previously described to bind to chemicals (Loo & Clarke, 1997; 
Loo et al., 2006; Aller et al., 2009, Nicklisch et al., 2016) or to be involved in ATPase activity 
inhibition (Chufan et al., 2016), were marked. Inhibition of Homo sapiens ABCB1 ATPase activity by 
zosuquidar, elacridar (also known as GF120918), and tariquidar, involves certain phenylalanine 
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and tyrosine pairs (F978, F728, Y953, Y310), whose interaction lead to hydrogen-bond contacts 
between the inhibitor and the tyrosines. Upon mutation of these residues to alanine, the used 
inhibitors provoked stimulation instead of inhibition of basal ATPase activity (Chufan et al., 2016). 
 
4.4 RESULTS 
4.4.1 Interaction of chemicals with recombinant Abcb4 and ABCB1 ATPase  
Chemicals were compared for their abilities to modulate ATPase activities of recombinant Danio 
rerio Abcb4 and Homo sapiens ABCB1. Fifteen chemicals were tested individually (versus basal 
ATPase activity, bA) or in combination with verapamil (versus co-treated ATPase activity, co-tr.) to 
increase and/or decrease ABCB1 and Abcb4 ATPase activities. Two chemicals (amprenavir, 
dipyridamole) were tested to modulate basal ATPase activity. Molecular weights of tested 
chemicals ranged from 178 g/mol (phenanthrene) to 1200 g/mol (cyclosporin A), logP values from 
0.53 (doxorubicin) to 5.16 (tonalide). 
Basal and verapamil stimulated ATPase activities were 10.80 (± 0.41 SEM) and 31.92 (± 1.21 
SEM) nmol Pi/min/mg membrane protein for ABCB1 and 5.49 (± 0.99 SEM) and 15.12 
(± 0.69) nmol Pi/mim/mg membrane protein for Abcb4 (from ATPase assays used in this chapter). 
Fold changes of verapamil stimulated versus basal ATPase activities were 2.95 and 2.75 for ABCB1 
and Abcb4, respectively.  
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4.4.1.1 Kinetic parameters of Abcb4 and ABCB1 ATPase assay data 
Chemicals were compared for their interaction with Danio rerio Abcb4 and Homo sapiens ABCB1 
ATPase activity with respect to interaction – no interaction or type of interaction   ̶  and further with 
regard to derived kinetic parameters from concentration-response relationships. Kinetic 
parameters from ambiguous fits were indicated (≈ and ~ in Table 4.2 [GraphPad Prism 5 output 
format].) 
 
Stimulation of basal Abcb4 and ABCB1 ATPase activities by chemicals 
Strong Homo sapiens ABCB1 ATPase stimulators as dipyridamole, verapamil, and amprenavir 
stimulated also Danio rerio Abcb4 ATPase activity (Fig. 4.1). Kinetic parameters and effect levels 
given in percent modulation are presented in Table 4.2. Dexamethasone as relatively weak 
stimulator of ABCB1 ATPase was also only a weak Abcb4 ATPase stimulator but with a comparably 
low EC50. Highest affinity, i.e. lowest EC50, to Abcb4 had dipyridamole (0.43 µM) < verapamil 
(5.61 µM) < amprenavir (32.75 µM) < dexamethasone (38.25 µM) and for ABCB1 dipyridamole 
(1.81 µM) < amprenavir (2.49 µM) <verapamil (7.15 µM) and dexamethasone (188.4 µM). Strongest 
stimulation compared to control stimulation by verapamil was seen for Abcb4 by amprenavir 
(117 %), verapamil (110 %), dipyridamole (70 %) and dexamethasone (35 %) and for ABCB1 by 
dipyridamole (134 %), verapamil (106 %), amprenavir (91 %) and dexamethasone (43 %). For 
these chemicals r² for non-linear regressions were ≥ 0.45. Amprenavir, verapamil, and 
dipyridamole were not tested to decrease verapamil co-treated ATPase activities; dexamethasone 
decreased both co-treated ATPase activities to a minor extent. The order with respect to effect 
strengths was more similar for both proteins than the order with respect to EC50s.  
Vinblastine (53 %) and trospium (53 %) clearly stimulated basal ABCB1 ATPase activities whereas 
for Abcb4 interaction was very weak (12% and 22 %; Table 4.2). Vinblastine concentrations at half-
maximal ATPase stimulation were similar for Abcb4 (0.75 µM) and ABCB1 (0.5 µM). Concentrations 
of trospium at half-maximal stimulation of basal Abcb4 and ABCB1 ATPase activities were also 
similar with 170.7 and 110.4 µM, respectively. However, r² for non-linear regressions from 
concentration response relationships of trospium and vinblastine were around 0.22 to 0.29 for 
Abcb4. 
  
Inhibition of basal and/or stimulator co-treated ABCB1 and Abcb4 ATPase activities by chemicals 
Concentration response curves of ivermectin, galaxolide, and tonalide showed inhibition of basal 
and verapamil co-treated Abcb4 and ABCB1 ATPase activities (Fig. 4.1). Highest affinities (lowest 
EC50s) to basal and co-treated Abcb4 ATPase activities were determined for ivermectin (7.39 µM 
and 7.91 µM) < galaxolide (24.85 and 28.71 µM) < tonalide (≈ 40 µM and 24.79 µM) and to ABCB1 
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ivermectin (0.30 and 0.87 µM) < galaxolide (32.25 and ≈35.81 µM) < and tonalide (42.31 and 
21.66 µM), given in Table 4.2. Percent inhibition of basal ATPase activities (eq. (2.3)) reached up to 
64 % (basal ABCB1 ATPase activity inhibition by galaxolide). Strongest effects for both ABC 
transporters were seen for ivermectin (56 % and 45 % inhibition of bA of ABCB1 and Abcb4, 
respectively). Effects by tonalide were smallest for ABCB1 and Abcb4 with 50 % and 13 % 
inhibition of ATPase activities, respectively. Non-linear regressions gave ambiguous parameters 
(EC50) for galaxolide (inhibition of co-treated ABCB1 ATPase activity) and tonalide (inhibition of 
basal Abcb4 ATPase activity). Inhibition of basal and co-treated Abcb4 ATPase by ivermectin, 
inhibition of co-treated ABCB1 ATPase activity by ivermectin, and inhibition of co-treated Abcb4, 
basal ABCB1 ATPase activities by galaxolide and tonalide were considered unambiguous effects 
(see also Table 4.3). 
 
Inhibition of stimulator co-treated ABCB1 and Abcb4 ATPase activities by chemicals 
Stimulator co-treated Danio rerio Abcb4 and Homo sapiens ABCB1 ATPase activities were clearly 
decreased by cyclosporin A (110 % and 96 %), etoposide (56 % and 93%), and vinblastine (115 % 
and 91 %) (Table 4.2). Concentrations at half-maximal decrease of stimulator co-treated Abcb4 
ATPase activities were lowest for cyclosporin A (0.34 µM) < vinblastine (4.83 µM), and < etoposide 
(94.22 µM). For half-maximal inhibition of stimulator co-treated ABCB1 ATPase activities 
concentrations were lowest for cyclosporin A (0.09 µM), followed by etoposide (25.67 µM) and 
vinblastine (28.52 µM). The order of effect strength was similar for both proteins: vinblastine 
> cyclosporin A > etoposide. Dexamethasone had stronger inhibiting effect on stimulator co-treated 
Abcb4 than stimulator co-treated ABCB1 ATPase activities with 69 % and 35 % modulation, 
respectively and half-maximal decrease of stimulator co-treated ATPase activities were obtained at 
0.56 µM (Abcb4) and 139.9 µM (ABCB1) dexamethasone. 
Trospium decreased stimulator co-treated Abcb4 and ABCB1 ATPase activities but to a lesser 
extent (33 % and 23 % inhibition) and/or less certainty (r² were 0.20 and 0.35) and with EC50s of 
0.05 µM (Abcb4) and 14.27 µM (ABCB1). Doxorubicin clearly decreased stimulator co-treated 
ABCB1 ATPase activity about 57 % with an EC50 of 33.74 µM, whereas only a weak decrease of co-
treated Abcb4 ATPase activity was determined (18 %; EC50 of 13.48 µM). 
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Dissimilar interaction of chemicals with ABCB1 and Abcb4 ATPase activities 
Three of the 17 tested chemicals exhibited different effects on Homo sapiens ABCB1 and Danio rerio 
Abcb4 ATPase activities: Cyclosporin A, colchicine, and testosterone. Cyclosporin A was increasing 
basal Abcb4 ATPase activities at lower concentrations (< 2µM) up to 41 % with an EC50 of 0.14 µM, 
followed by a decrease at concentrations above 2 µM resulting in a bell-shaped concentration 
response curve (Fig. 4.1). Stimulator co-treated Abcb4 and ABCB1 ATPase activities were decreased 
by cyclosporin A about 110 % and 96 %. EC50 values for cyclosporin A were very similar for both 
proteins and test modes (≈ 0.1 to 0.3 µM).  
Colchicine stimulated basal ABCB1 ATPase activity about 35 % (EC50 of 296.3 µM) and stimulator 
co-treated Abcb4 ATPase activity was decreased 63 % (EC50 of 28.16 µM) by colchicine. The same 
pattern was seen for testosterone with a 50 % increase of ABCB1 (EC50 of 40.47 µM) and a 
decrease of 71 % of verapamil co-treated Abcb4 (EC50 of 51.08 µM) ATPase activity. 
For further three chemicals, etoposide, phenytoin and phenanthrene, interaction with Danio rerio 
Abcb4 and/or Homo sapiens ABCB1 was ambiguous, with respect to effect strength or goodness of 
fit (Table 4.2). Etoposide decreased stimulator co-treated Abcb4 and ABCB1 ATPase activities, 
described above, and only increased basal ABCB1 ATPase activities about 14 % with an EC50 of 
≈ 67.72 µM obtained in an ambiguous fit (r² = 0.25). Phenytoin decreased stimulator co-treated 
Abcb4 ATPase activity about 51 % with an EC50 of 8.71 µM. Concentration response relationships 
for phenytoin could not be fit for the other test modes (with ABCB1, Abcb4) but however suggested 
stimulation of basal and stimulator co-treated ABCB1 ATPase activity. Phenanthrene inhibited 
basal Abcb4 (36 %) and slightly increased basal ABCB1 (26 %) ATPase activities. Concentrations of 
half-maximal decrease of basal Abcb4 and of half-maximal stimulation of basal ABCB1 ATPase 
activities of 10.49 µM and 51.16 µM were determined, respectively, and had low r² (0.17 to 0.37) 
values.  
 
No interaction with Abcb4 and ABCB1 ATPase activities 
Carbamazepine neither modulated Danio rerio Abcb4 ATPase activity nor Homo sapiens ABCB1 
ATPase activity. 
 
4.4.1.2 Overview on interaction of chemicals with Abcb4 and ABCB1 ATPase activities 
Effects of chemicals on Homo sapiens ABCB1 and Danio rerio Abcb4 ATPase activities were 
summarised in Table 4.3. Unambiguous interaction of chemicals with ABC transporter ATPase 
activities was indicated by bold letters; different and similar interaction was indicated by a dark 
and light grey background, respectively. Interactions were not indicated as unambiguous where 
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either concentration response relationships gave ambiguous fits or goodness of fits was low 
(letters b and c in Table 4.3).  
Overall, more chemicals increased basal for ABCB1 than Abcb4 ATPase activity: Eight chemicals 
clearly increased basal ABCB1, five chemicals clearly increased basal Abcb4 ATPase activities. The 
number of chemicals which clearly decreased stimulator co-treated Abcb4 and ABCB1 ATPase 
activities was similar. All chemicals which stimulated basal as well as those who additionally 
decreased stimulator co-treated ATPase activities were in the group stimulators for both proteins: 
dexamethasone, amprenavir, dipyridamole, and verapamil for both P-glycoproteins. Further 
stimulators were cyclosporin A for Abcb4 and colchicine, vinblastine, testosterone, and trospium 
for ABCB1. Inhibition of (only) stimulator co-treated ATPase activity was clearly seen for Abcb4 for 
colchicine, testosterone, and vinblastine and for ABCB1 for doxorubicin and cyclosporin A. Three of 
the 17 tested chemicals exhibited a different pattern of interaction with on Homo sapiens ABCB1 
and Danio rerio Abcb4 ATPase activities: Cyclosporin A inhibited Abcb4 and ABCB1 stimulator 
co-treated ATPase activities but only stimulated basal Abcb4 ATPase activity; colchicine and 
testosterone inhibited stimulator co-treated Abcb4 ATPase activity and stimulated basal ABCB1 
ATPase activity. Three chemicals decreased stimulator co-treated and basal ATPase activities of 
Abcb4 and ABCB1 to minor or larger extent: ivermectin, galaxolide, and tonalide. One chemical, 
carbamazepine, did neither interact with Abcb4 nor ABCB1. 
 
Table 4.3 Overview on interaction of chemicals with ABCB1 and Abcb4 ATPase activities 
Chemicals were tested to modulate basal (bA) and stimulator co-treated ATPase activities (cA) of 
recombinant ABCB1 and Abcb4. a Effect on stimulator co-treated ATPase activities was not tested. 
b Ambiguous fit. c r² of the fit was ≤ 0.4. d Concentration response curve suggested interaction. Unambiguous 
interaction indicated in bold letters. Light/dark grey background indicated unambiguous similar/dissimilar 
interaction of chemicals with Abcb4 and ABCB1 ATPase activities. See Table 4.2 for details. 
     
Chemical Dr  Abcb4 Hs ABCB1
Amprenavir stimulationa stimulationa 
Carbamazepine none none
Colchicine inhibition cA stimulation
Cyclosporin A stimulation, inhibition cA inhibition cA
Dexamethasone stimulation, inhibition cAc stimulation, inhibition cAc
Dipyridamole stimulationa stimulationa 
Doxorubicin inhibition cAc inhibition cA
Etoposide inhibition cAc stimulationb,c, inhibition cA
Galaxolide inhibition bAc, cA inhibition bA, cAb
Ivermectin inhibition bA, cA inhibition bAc, cA
Phenanthrene inhibition bAc stimulationc
Phenytoin inhibition cA stimulation cAd
Testosterone inhibition cA stimulation
Tonalide inhibition bAb,cA inhibition bA,cAc
Trospium stimulationc, inhibition cAc stimulation, inhibition cAc
Verapamil stimulationa stimulationa 
Vinblastine stimulationc, inhibition cA stimulation, inhibition cA 
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4.4.2 Drug binding sites of Homo sapiens ABCB1 and Mus musculus ABCB1a 
compared to Danio rerio Abcb4 amino acid sequence  
Amino acid sequences of Danio rerio Abcb4, Homo sapiens ABCB1, and Mus musculus ABCB1a were 
aligned and available information on binding of verapamil (to ABCB1; Loo & Clarke, 1997; Loo et al., 
2006), cyclic peptide inhibitors cyclic-tris-(S)-valineselenazole (QZ59-SSS), cyclic-tris-(R)-
valineselenazole (QZ59-RRR) (to ABCB1a; Aller et al., 2009), and polybrominated diphenyl ether 
(PBDE)-100 (to ABCB1a; Nicklisch et al., 2016) to amino acid residues was added (Fig. 4.2). Clustal 
O multiple sequence alignment gave amino acid identities (using clustal2.1) of 64 % of Abcb4 to 
ABCB1, 87 % identity of Abcb4 to ABCB1a and 64 % identity of ABCB1a to ABCB1. 
Forty-three amino acid positions were marked. Sixteen amino acid residues are known to bind to 
verapamil, 15 to PBDE-100, 13 to QR59-RRR, and 17 to QR59-SSS. Twelve residues of Danio rerio 
Abcb4, four residues of ABCB1a, and two residues of ABCB1 were different among the 43 surveyed 
positions (Table 4.4)13. (Amino positions chemicals bind to were given for the species in the 
respective study.) Two of the surveyed residues were different for all three ABC transporters: 
Position G64 of Homo sapiens ABCB1 (verapamil binding to; Loo & Clarke, 1997; Loo et al., 2006) is 
aligned to A63 of Mus musculus ABCB1a and V69 of Danio rerio Abcb4. Position F833 in ABCB1a 
(QZ59-SSS binding) is aligned to A835 in Abcb4 and T837 in ABCB1. Different amino acids among 
the surveyed transporters were predominantly found at positions to which only one of the four 
chemicals bind (Table 4.4). Fourteen of the 43 residues bind to more than one chemical (QR59-RRR 
and QR59-SSS were count as two) and these residues were only different at two positions in Danio 
rerio Abcb4. 
ABCB1a and ABCB1 residues differed only at four positions and seem more similar with regard to 
residues chemicals bind to. However, two amino acids which PBDE-100 binds to were identical for 
Abcb4 and ABCB1 (A728 [S], I734 [V]) and different for Mus musculus ABCB1a. Residues which 
three or even four chemicals bind to were Mus musclus ABCB1a V987, Q721, and F724 (Table 4.4).  
Amino acid residues involved in Homo sapiens ABCB1 function (F978, F728 [= mouse ABCB1 F724], 
Y953, Y310), i.e. whose interaction lead to hydrogen-bond contacts between the inhibitor and the 
tyrosines and whose mutations lead to stimulation instead of inhibition of basal ATPase activity 
(Chufan et al., 2016), were similar among the surveyed amino acid sequences except of one 
position: F978 matched F974 in Mus musculus ABCB1a whereas I976 was aligned in Danio rerio 
Abcb4. Position F728 and its conserved equivalents Danio rerio Abcb4 F727 and Mus musculus 
ABCB1a F724 were also described to bind verapamil (Loo & Clarke, 1997; Loo et al., 2006; to 
ABCB1), PBDE-100 (Niklisch et al., 2016; to Abcb4), QZ59-SSS, and QZ59-RRR (Aller et al., 2009) 
                                                             
13 Except for four positions (Abcb4 V69, N67, I760, A835) amino acids belonged to at least strong groups of 
very similar properties or were conserved (indicated by clustal O) and two of these four positions presented 
different amino acids in all three ABC transporters. 
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(see Fig. 4.2, Table 4.4). Positions Y310 and Y953 (Homo sapiens ABCB1) were conserved in Danio 
rerio Abcb4 (Y315; Y949) and Mus musculus ABCB1a (Y306; Y951).  
 
Table 4.4 Overview on amino acid sequence comparison of Abcb4, ABCB1, and ABCB1a 
Residues which were different among the surveyed transporters, to which bind more than one chemical, or 
which were also known to be involved in ABC transporter function were listed. Amino acid positions which 
were different were indicated in bold. Grey background indicated ABC transporters literature refers to. 
Verapamil, cyclic-tris-(R)-valineselenazole (QZ59-RRR), cyclic-tris-(S)-valineselenazole (QZ59-SSS), and 
PBDE-100 bind to more than to the listed amino acid positions, see Fig. 4.2, Aller et al. (2009), Nicklisch et al., 
(2016).  
 
a Binding of QZ59-RRR, QZ59-SSS, b Binding of QZ59-RRR, QZ59-SSS, PBDE-100, verapamil,   
c Binding of PBDE-100, d Loo & Clarke (1997), Loo et al. (2006), e Aller et al. (2009), f Nicklisch et al. 
(2016), g Chufan et al. (2016)  
D.r._Abcb4       60 LIMSMANGAVLPLMVIVFGDMTDSFVDDTLLDNLKNITLPPNFTFPETSNITLGEKMTTH  119 
Danio rerio Mus musculus Homo sapiens
Abcb4 ABCB1a ABCB1
Binding of chemical
ver V69 A63 G64 d
ver N67 H60 H61 d
ver M866 I864 I868 d
ver S943 T941 T945 d
ver F973 L971 L975 d
PBDE-100 Y981 F979 F983 f
PBDE-100 A728 S725 A729 f
PBDE-100 I734 V731 I735 f
QZ59-SSS F309 L300 L304 e
QZ59-SSS I760 L758 L762 e
QZ59-SSS A835 F833 T837 e
QZ59-SSS E988 Q986 Q990 e
QZ59-RRR, ver. L344 L335 L339 d,e
QZ59-RRR, PBDE-100 S977 S975 S979 e,f
QZ59-RRR, PBDE-100 F731 F728 F732 e,f
QZ59-RRR, PBDE-100 Y312 Y303 Y307 e,f
QZ59-SSS, ver. A983 A981 A985 d,e
QZ59-SSS, QZ59-RRR, ver V980 V978 V982 d,e
QZ59-SSS, QZ59-RRR, PBDE-100 Q724 Q721 Q725 e,f
QZ59-SSS, QZ59-RRR, PBDE-100, ver F727 F724 b F728 d,e,f
QZ59-SSS, QZ59-RRR V74 M68 M69 e
QZ59-SSS, QZ59-RRR F341 F332 F336 e
QZ59-SSS, QZ59-RRR I345 I336 I340 e
QZ59-SSS, QZ59-RRR F348 F339 F343 e
QZ59-SSS, QZ59-RRR Y951 Y949 Y953 e
QZ59-SSS, QZ59-RRR I976 F974 F978 e
Function
Inhibition of ATPase I976 F974 a F978 g
Inhibition of ATPase F727 F724 b F728 g
Inhibition of ATPase Y951 Y949 a Y953 g
Inhibition of ATPase Y315 Y306 c Y310 g
Characteristic Reference
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H.s._ABCB1       55 TLAAIIHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRY  114 
M.m._ABCB1a      54 TLAAIIHGVALPLMMLIFGDMTDSFASVGNVSKN---STNMSEADKRAMFAKLEEEMTTY  110 
                     : :: :*. ****:::**:*** *..   :..        .         .* *.** : 
                              
 
D.r._Abcb4       180 LTDDVYKINEGIGDKLGMLIQNLTTFIVGIIIGFAKGWKLTLVILAVSPLLGISAAVIGK  239 
H.s._ABCB1       175 LTDDVSKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAK  234 
M.m._ABCB1a      171 LTDDVSKINEGIGDKIGMFFQAMATFFGGFIIGFTRGWKLTLVILAISPVLGLSAGIWAK  230 
                     ***** *********:**::* ::**: *:*:**::**********:**:**:**.: .* 
           
 
D.r._Abcb4       300 VNIAMGFTFFMIYMSYALAFWYGSTLILGGEYTIGMLLTIFFAVLIGAFGLGQTSPNIQT  359 
H.s._ABCB1       295 ANISIGAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEA  354 
M.m._ABCB1a      291 ANISMGAAFLLIYASYALAFWYGTSLVISKEYSIGQVLTVFFSVLIGAFSVGQASPNIEA  350 
                     .**::* :*::** *********::*::. **:** :**:**:******.:**:**.*:: 
 
 
D.r._Abcb4       420 LKVMSGQTIALVGSSGCGKSTTIQLLQRFYDPQEGSVSIDGHDIRSLNVRGLRELIGVVS  479 
H.s._ABCB1       415 LKVQSGQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVS  474 
M.m._ABCB1a      411 LKVKSGQTVALVGNSGCGKSTTVQLMQRLYDPLDGMVSIDGQDIRTINVRYLREIIGVVS  470 
                     *** ****:****.********:**:**:*** :* **:**:***::*** ***:***** 
 
D.r._Abcb4       714 ILCATINGGMQPAFAVIFSKIIAVFAEPDQ-NLVRQRCDLYSLLFAGIGVLSFFTLFLQG  772 
H.s._ABCB1       715 VFCAIINGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQG  774 
M.m._ABCB1a      711 IFCAIINGGLQPAFSVIFSKVVGVFTNGGPPETQRQNSNLFSLLFLILGIISFITFFLQG  770 
                     ::**  ****:****::****::.**:. .  :  **..:*:**** :*::**:*:**** 
 
 
D.r._Abcb4       833 TLAQNVANLGTAIVISFVYGWQLTLLILSIVPIMAVAGAIQMKLLAGHALKDKKELEQAG  892 
H.s._ABCB1       835 VITQNIANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSG  894 
M.m._ABCB1a      831 VIFQNIANLGTGIIISLIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSG  890 
                     .: **:*****.*:**::********:*:****:*:**.::**:*:*:********* :* 
 
D.r._Abcb4       893 KIATEAIENVRTVVSLTRESKFESLYEENLIVPYKNAKKKAHVFGLTFSFSQAMIYFAYA  952 
H.s._ABCB1       895 KIATEAIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYA  954 
M.m._ABCB1a      891 KIATEAIENFRTVVSLTREQKFETMYAQSLQIPYRNAMKKAHVFGITFSFTQAMMYFSYA  950 
                     *********.*******:*.*** :* :.* :**:*: :***:**:****:***:**:** 
 
D.r._Abcb4       953 GCFKFGSWLIEQKLMTFEGVFLVISAVVYGAMAVGEANSFTPNYAKAKMSASHVLMLINR  1012 
H.s._ABCB1       955 GCFRFGAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEK  1014 
M.m._ABCB1a      951 ACFRFGAYLVTQQLMTFENVLLVFSAIVFGAMAVGQVSSFAPDYAKATVSASHIIRIIEK  1010 
                     .**:**::*: ::**:**.*:**:**:*:******:..**:*:****.:**:*:: :*:: 
 
 
  
 Verapamil                    QR59-SSS                    QZ59-RRR& QZ59-SSS 
  PBDE-100                   QZ59-RRR                    QZ59-RRR& QZ59-SSS, verapamil, PBDE-100 
 
Fig. 4.2 Multiple amino acid sequence alignment of Abcb4, ABCB1, and ABCB1a  
Danio rerio (D.r.) Abcb4, Homo sapiens (H.s.) ABCB1, and Mus musculus (M.m.) ABCB1a multiple sequence 
alignment was performed using CLUSTAL O (version 1.2.3). Residues to which chemicals bind were labelled. 
Same/different amino acids were given in blue/red colour. M.m. ABCB1a M68, L300, F332, I336, F339, Q721, 
L758, F833, M982, G985, Q986, S989, Y949, F974, F724, V978, A981 bind cyclic peptide inhibitor cyclic-tris-
(S)-valineselenazole (QZ59-SSS;); M.m. ABCB1a M68, F728, Y303, F332, I336, F339, Q721, Y949, F974, S975, 
F724, V978, L335 bind and cyclic-tris-(R)-valineselenazole (QZ59-RRR) (Aller et al., 2009). Verapamil binding 
protected H.s. ABCB1 from MTS (methanethiosulfonate) labelling by MTS-verapamil (Loo & Clarke, 1997; Loo 
et al., 2006), data were used for comparison in Aller et al. (2009, fig. 3B), these M.m. ABCB1a residues are 
H60, A63, L64, S218, I302, A338, I864, G868, F938, T941, L971, G980, L335, A981, F724, V976. M.m. ABCB1a 
Y303, Y306, A307, F310, F331, Q721, F724, S725, I727, F728, V731, S752, F755, S975, and F979 bind to 
PBDE-100 (Nicklisch et al., 2016). Positions involved in inhibition of H.s. ABCB1 ATPase activity, F978, F728, 
Y953, Y310 (Chufan et al., 2016), were labelled by grey background.  
 
 
 
4.5 DISCUSSION 
In this work the ATPase assay with recombinant Homo sapiens ABCB1 and Danio rerio Abcb4 was 
used to quantitatively study interaction of chemicals with the ATPase activity of the two ABC 
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transporters. Interactions of chemicals with Danio rerio Abcb4 ATPase were previously described 
in Fischer et al. (2013), Keiter et al. (2016), and Cunha et al. (2017) using the protocol of this work. 
Besides kinetic parameters for PFOS interacting with the Abcb4 ATPase activity in Keiter et al. 
(2016), this is the first time EC50s for the interaction of chemicals with Danio rerio Abcb4 ATPase 
are presented. Therefore, in most cases it was only possible to relate quantitative findings to 
previous data for ABCB1 of mammals or of other aquatic species than zebrafish. Chemicals were 
selected with regard to expand existing knowledge on interaction of chemicals with the ATPase 
activity of both ABCB1-like transporters. ATPase assay data were analysed with regard to EC50s 
and percent modulation (see 2.3.3.2). The Danio rerio Abcb4 amino acid sequence was aligned to 
those of Homo sapiens ABCB1 and Mus musculus ABCB1a and amino acid positions which are 
known to bind to chemicals (verapamil [Loo & Clarke, 1997; Loo et al., 2006], QZ59-RRR, QZ59-SSS 
[Aller et al., 2009], PBDE-100 [Nicklisch et al., 2016) or to be involved in transporter function 
(inhibition of ATPase activity [Chufan et al., 2016]) were analysed for their counterparts in Abcb4. 
 
4.5.1 Concentration response relationships and kinetic parameters of chemicals 
interacting with ABCB1 and Abcb4 ATPase activities   
Carbamazepine was neither interacting with Abcb4 nor ABCB1 ATPase activities, which was in line 
with previous results for ABCB1 (Owen et al., 2001; Feng et a., 2008, and Fortuna et al., 2012). 
 
4.5.1.1 Stimulation of basal ABCB1 and Abcb4 ATPase activities 
Stimulation of basal ABCB1 ATPase activity by amprenavir, dipyridamole, verapamil, and 
vinblastine obtained in this work was in line with previous findings for these chemicals 
(amprenavir [Bachmeier et al., 2005]; dipyridamole [Litman et al., 1997c]; verapamil [Richter et al., 
2009; Feng et al., 2008; see also section 3.4.1 and 2.6.2]; vinblastine [Sarkadi et al., 1992; Aänismaa 
and Seelig, 2007]). However, concentrations at half-maximal stimulation differed for some 
chemicals: EC50s for human ABCB1 of this work were lower for amprenavir by a factor of 18 (Km of 
46.9 µM for Homo sapiens ABCB1 ATPase stimulation [Bachmeier et al., 2005]) and higher for 
dipyridamole by a factor of 3.7 (K1 [≈ Km ≈ EC50] of 0.4 µM for stimulation of ATPase activity of 
microsomal membrane fraction of CR1R12 cells [Litman et al., 1997c]). 
Comparison of kinetic parameters from the Michaelis-Menten equation and the four parameter 
logistic equation in section 2.4.4 in chapter 2 suggested that both equations gave quite similar 
concentrations at half-maximal stimulation with values from Michaelis-Menten equations being 
slightly lower. The modified Michealis-Menten equation used in Litman et al. (1997c) seems only 
appropriate to describe complete bell-shaped concentration response relationships. (Bell-shaped 
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concentration response curves are proposed for chemicals which occupy stimulating high affinity 
binding sites at lower and inhibiting low affinity binding sites at higher concentrations (Litman 
et al., 1997c).) As its slope is constrained to one it probably gives similar K1 values as Michaelis-
Menten equations Km. However, obtained concentrations at half-maximal stimulation probably 
depend on the tested concentration range of the respective chemical. 
Effects of amprenavir, dipyridamole, and verapamil on basal Abcb4 ATPase activity were similar to 
effects on basal Homo sapiens ABCB1 ATPase activity (see Fig. 4.1, Table 4.2) with very similar 
EC50s for verapamil and both ABC transporters and EC50s for amprenavir and dipyridamole which 
were different by a factor of about 13 for amprenavir and of 4.2 for dipyridamole. Stimulation of 
basal Abcb4 ATPase activity by vinblastine was not unambiguous due to low r² (0.3) and low 
percent modulation (12 % of control stimulation by verapamil). However, vinblastine inhibited 
stimulator co-treated Abcb4 (and ABCB1) ATPase activity (discussed under 4.5.1.3). 
Dexamethasone and trospium were previously described as transported substrates of mammalian 
ABCB1 but effects on ATPase activity were either negative (dexamethasone) or not tested yet 
(trospium): Dexamethasone is a transported ABCB1 substrate (Polli et al., 2001; Ueda et al., 1992; 
Schinkel et al., 1996), but no effect of dexamethasone on Homo sapiens ABCB1 ATPase activity or on 
calcein-AM efflux in MDR1-MDCKII (MDR1=ABCB1) cells was reported (Polli et al., 2001) which is 
in conflict with stimulation of basal ABCB1 ATPase activity by dexamethasone in this work. These 
findings may be contradicting due to the tested concentrations (20 µM in Polli et al., 2001 versus up 
to 500 µM in this work with an EC50 of 188.4 µM for ABCB1) and the decision criteria (two-fold 
increase compared to basal ATPase activity, used in Polli et al., 2001). Taken together, 
dexamethasone is most likely a transported ABCB1 substrate and a stimulator (this work) of 
ABCB1 and of Abcb4 ATPase activity (EC50 for Abcb4 by factor of five lower than for ABCB1). 
Trospium was previously described as transported Homo sapiens ABCB1 and Mus musculus ABCB1a 
(also known as Mdr3, Mdr1a14) substrate (Callegari et al., 2011; Geyer et al., 2009) which seem 
consistent with ABCB1 ATPase activity stimulation of this work. EC50s for stimulation of ABCB1 
and Abcb4 by trospium were similar (Table 4.2) but the percent increase was only 22 % for Abcb4. 
Furthermore, r² values, as an indicator for the goodness of fit, was below 0.3 each. However, the 
concentration-response relationship for trospium interaction with ABCB1 and Abcb4 were quite 
similar.  
Chemicals stimulating basal or inhibiting stimulator co-treated ABCB1 and Abcb4 ATPase activity 
which were further shown to be transported ABCB1 substrates are also potential transported 
Abcb4 substrates. 
 
                                                             
14 http://www.uniprot.org/uniprot/P21447 
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4.5.1.2 Inhibition of basal and stimulator co-treated ABCB1 and Abcb4 ATPase 
activities 
EC50s of tonalide and galaxolide for the inhibition of basal Abcb4 and co-treated ABCB1 ATPase 
activities were ambiguous and of low accuracy (low r² values; Fig. 4.1, Table 4.2). Both chemicals 
inhibited co-treated Abcb4 and basal ABCB1 ATPase activities with EC50s between 22 µM and 
≈ 40 µM, which were higher than the water solubilities of these chemicals (galaxolide 6.7 µM, 
tonalide 1 µM to 4.8 µM, see Table 4.1). However, there are arguments that galaxolide and tonalide 
interaction with Abcb4 and ABCB1 ATPase were no artefacts. Actual tonalide and galaxolide 
concentrations in the ATPase assays could be higher than the available water solubilities due to 
higher temperatures (27 °C or 37 °C) and/or due to the buffer environment including 2 % DMSO. 
Previous studies demonstrated galaxolide (IC50 of 2.43 µM) and tonalide (IC50 of 2.05 µM) to 
inhibit MXR transport activity in gills of Mytilus californianus suggesting ABCB1-like transporter 
inhibiting properties of these compounds (Luckenbach & Epel, 2005). Galaxolide and tonalide are 
described to stimulate basal and inhibit stimulator co-treated Danio rerio Abcb4 ATPase activities 
in Fischer et al. (2013). As for the majority of chemicals Abcb4 ATPase activities are even at lowest 
tested concentrations above the level of basal ATPase activities (in Fischer et al., 2013), procedures 
were reviewed. The used plate design was identified as disadvantageous and values – to calculate 
sodium orthovanadate-sensitive ATPase activities – from wells with different reaction conditions 
(incubation temperature or duration) were excluded, that finally only values from wells were used 
which had the same reaction conditions (section A.2.8). 
Inhibition of Abcb4 and ABCB1 ATPase activities by ivermectin were seen in the range of its water 
solubility (0.8 to 10 µM, Table 4.1) and inhibition of stimulator co-treated ATPase activities was 
seen also at lower concentrations (< 1 µM). Unambiguous inhibition was seen for the stimulator 
co-treated ABCB1 and Abcb4 ATPase activities and for inhibition of basal Danio rerio Abcb4 ATPase 
activity. (The concentration-response relationship fit for the inhibition of basal ABCB1 ATPase 
activity had a low r² (0.37).) In general, results for ivermectin of this work are in line with previous 
ABCB1 ATPase assay data for ivermectin (Lespine et al., 2006 [IC50 of 2.5 µM for inhibition of 
stimulated ATPase activity], Lespine et al., 2007 [EC50 of 2 µM for inhibition of basal ATPase 
activity], Lacher et al., 2015 [figure 1B]), which show inhibition of basal and/or stimulator co-
treated ATPase activity. The EC50s of ivermectin for Abcb4 were higher (and close to the limit of its 
water solubility) than for Homo sapiens ABCB1 (EC50s of 0.3 and 0.87 µM) implying lower affinity 
of ivermectin to Danio rerio Abcb4 than to ABCB1. Ivermectin is described as transported substrate 
(Pouliot et al., 1997; Schinkel et al., 1994, Schinkel et al., 1996; Didier & Loor, 1996) and as inhibitor 
(Pouliot et al., 1997, Bain & LeBlanc, 1996 [human ABCB1]; Didier & Loor, 1996 [mouse ABCB1a]). 
Furthermore, transport studies using proximal kidney tubules from the teleost fish Fundulus 
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heteroclitus suggest ivermectin as transported substrate and inhibitor of ABCB1-like protein in this 
fish species (Fricker et al., 1999).  
Ivermectin, tonalide, and galaxolide may act as inhibitors of ABCB1/Abcb4 mediated substrate 
translocation and may have chemosensitising potential, due to inhibition of basal and/or stimulator 
co-treated Abcb4 and ABCB1 ATPase activities.  
A survey of literature revealed that there are also inhibitors of basal (human ABCB1) ATPase 
activity, tariquidar15 and elacridar (also known as GF120918), which are not transported by human 
ABCB1 (Chufan et al., 2016; Kannan et al., 2011; Loo et al., 2012; Polli et al., 200116). Whether 
inhibitors of basal Abcb4 ATPase activities are transported (as seen for ivermectin) by Abcb4 
should be assessed in future studies. Non-transported inhibitors of ABCB1-like transporter ATPase 
activity would be of ecotoxicological relevance, as they mitigate translocation of (potential harmful) 
ABCB1-like substrates (which can lead to chemosensitisation) but would not be translocated 
themselves. Screening for chemicals inhibiting basal ATPase activity with high affinities is 
suggested a promising tool to identify high affinity modulators of ABCB1-like proteins, i.e. transport 
inhibitors (Chufan et al., 2016). 
 
4.5.1.3 Inhibition of stimulator co-treated Abcb4 and ABCB1 ATPase activities 
Cyclosporin A was previously described to inhibit (verapamil co-treated) ABCB1 ATPase activity in 
Von Richter et al (2009), Fekete et al. (2015), Watanabe et al. (1997) with EC50s of 0.138 µM, 
0.38 µM, and ≈ 0.8 µM, respectively, which are similar to the EC50s obtained in this work (Table 
4.2). Inhibitory effects of vinblastine on (CR1R12 Chinese hamster ovary cell) Abcb1 ATPase were 
previously described in Litman et al. (1997c), if interpretation of bell-shaped concentration 
response curves/relationships are considered; and a K2 (equals concentration at half-maximal 
inhibition) of 17.3 µM is described. EC50s of this work for vinblastine (4.83 µM and 28.52 µM) were 
in the range of this previous finding. Etoposide was so far not tested to modulate stimulator 
co-treated (ABCB1) ATPase activity. Interaction of etoposide with ABCB1 ATPase activity as 
stimulator was described in Müller et al. (1996), which is in accordance with results of this work 
and will be discussed later (section 4.5.1.4). 
Doxorubicin, trospium, and dexamethasone decreased ATPase activities to a lesser extent than the 
previously mentioned chemicals (Table 4.2, Fig. 4.1). Von Richter et al. (2009) reported doxorubicin 
being an ABCB1 ATPase stimulator with a K1 (half-maximal stimulation of ATPase activity) of above 
250 µM and furthermore being effluxed (Caco-2 cell monolayer). Shen et al. (2007) demonstrated 
                                                             
15 Tariquidar was stimulating basal ABCB1 ATPase activity in Loo et al., 2012. 
16 Elacridar (GF120918) was reported to accumulate in MDCKII-MDR1 (expressing human ABCB1) cells (Polli 
et al., 2001) but no transport was demonstrated so far. 
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decreased accumulation of doxorubicin in MDR-transduced human cancer cells (MDA-MB-435mdr) 
compared to the wild-type cells (MDA-MB-435wt) and increased accumulation of doxorubicin in in 
the MDR-transduced cells when ABCB1 function was inhibited by e.g. cyclosporin A. Doxorubicin is 
not stimulating ABCB1 ATPase activity, not leading to calcein-AM accumulation and was not 
effluxed in MDCK II MDR1 efflux assays (Polli et al., 2001), which could be due to the tested 
concentrations (10 or 20 µM for efflux ratios, 20 µM in ATPase assays) and usage of effect criteria 
with a ratio > 2 (for ATPase activity and efflux ratios from MDR1-MDCKII monolayer transport 
studies). 
Studies investigating disposition/bioavailability of trospium (Geyer et al., 2009) did not focus on 
ATPase activity or transport decreasing properties. Studies investigating interaction of 
dexamethasone with stimulator co-treated ATPase activity of ABCB1-like transporters were not 
available. Therefore, the here provided data for ABCB1 and Abcb4 fill gaps of knowledge. 
Chemicals, which decrease stimulator co-treated ATPase activity could be transported substrates – 
as demonstrated for cyclosporin A (Goldberg et al., 1988; Polli et al., 2001) or doxorubicin (Shen 
et al., 2008; Von Richter et al., 2009) for ABCB1 – likely also for Danio rerio Abcb4. Furthermore, 
chemicals inhibiting stimulator co-treated ATPase activity can also act as chemosensitisers if there 
is a potentially harmful transported substrate present. 
 
4.5.1.4 Chemicals with different effects on ABCB1 and Abcb4 ATPase activities 
Three among the 17 tested chemicals exhibited noticeably dissimilar effects on Homo sapiens 
ABCB1 and Danio rerio Abcb4 ATPase activities: cyclosporin A, colchicine, and testosterone. 
Cyclosporin A inhibited stimulator co-treated ABCB1 and Abcb4 ATPase activities (Fig. 4.1, Table 
4.2) and stimulated basal Abcb4 ATPase activity with a bell-shaped concentration response curve 
(Fig. 4.1 and further Fischer et al., 2013) as seen e.g. for vinblastine and did not stimulate ABCB1 
ATPase (Fig. 4.1). However, cyclosporin A also stimulates basal rhesus monkey ABCB1-like 
transporter protein with a bell-shaped concentrations response curve similar to those in Fig. 4.1 for 
Abcb4, shown in a study on species differences in rhesus monkey, beagle dog and human ABCB1 
(Xia et al., 2005). 
Colchicine inhibited the stimulator co-treated Abcb4 ATPase activities and stimulated Homo sapiens 
ABCB1 ATPase activity (Table 4.2). Homo sapiens ABCB1 ATPase stimulating properties of 
colchicine were also reported in Müller et al. (1996, ABCB1 expressing Sf9 cells), Aänismaa & Seelig, 
(2007, ABCB1 (MDR1) transfected mouse embryo fibroblast cells NIH-MDR1-G185), and Sarkadi 
et al. (1992, ABCB1 expressing Sf9 cells). Concentrations of colchicine at half-maximal stimulation 
of ABCB1 ATPase from previous studies are quite variable, with 20 µM (Sarkadi et al., 1992) 
227.6 µM (Aänismaa and Seelig, 2007), and 321 µM (Fekete et al. 2015). ABCB1 ATPase assay data 
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for colchicine were analysed in chapter 2 (section 2.4.4) and equations (four parameter logistic 
equation, Michaelis-Menten equation) to derive EC50s were not identified to cause the above 
mentioned variable EC50s. Findings from Aänismaa and Seelig (2007) and Fekete et al. (2015) are 
in agreement with this study. Testosterone also inhibited stimulator co-treated Abcb4 and 
stimulated basal ABCB1 ATPase activities. In line with the finding for ABCB1 and testosterone in 
this study, Von Richter et al. (2009) also reported stimulation of ABCB1 ATPase, but with a Km value 
above 250 µM, probably due to a larger concentration range tested in Von Richter et al., 2009. In 
this study testosterone was tested up to 100 µM. 
For etoposide, phenytoin, and phenanthrene effects on Abcb4 and/or ABCB1 ATPase activities 
were smaller and therefore less clear. Etoposide inhibited stimulator co-treated Abcb4 and ABCB1 
ATPase activities as described above and slightly stimulated basal ABCB1 ATPase activity (Table 
4.2, Fig. 4.1). Stimulation of ABCB1 ATPase activity by etoposide is in accordance with Müller et al 
(1996), whereas Polli et al. (2001) report neither ATPase stimulation nor calcein-AM efflux 
inhibition by etoposide. The latter would point to inhibitory effect. As discussed above, it its 
noteworthy that in Polli et al. (2001) single concentrations were tested and effects were defined 
above a treated to control ratio of two. 
Stimulator co-treated Abcb4 ATPase activity was clearly decreased by phenytoin, whereas 
concentration response relationships (using the four parameter logistic equation) for phenytoin 
and ABCB1 could not be fit. In a previous study, phenytoin was tested negative in ATPase assays 
(commercial Sf9 membranes containing human ABCB1; 1.25 to 150 µM; in Feng et al., 2008) which 
is in line with the finding of this work. However, an IC50 > 100 µM for phenytoin inhibiting 
calcein-AM efflux (MDR1-MDCK cells) is described in the same study (Feng et al., 2008), pointing to 
interaction of phenytoin and ABCB1.  
The results for phenytoin and ABCB1 from this work (Fig. 4.1) suggested slight stimulation of 
stimulator co-treated ATPase activity. An increase of stimulator co-treated ATPase activity could 
indicate cooperative stimulation (see Litman et al., 1997b). Forty-one chemicals were tested at 
different concentrations to interact with basal as well as verapamil, vinblastine, and progesterone 
co-treated ATPase activities (at a fixed concentration) in Garrigues et al. (2002). For e.g. the pairs 
dipyridamole and vinblastine as well as dipyridamole and progesterone combined effects, i.e. 
ATPase stimulation, increased with increasing concentrations while for most of the tested 
chemicals ATPase activity decreased if tested along with verapamil, vinblastine or progesterone 
(Garrigues et al., 2002).  
For Phenanthrene – inhibiting basal Abcb4 ATPase activity and slightly stimulating basal ABCB1 
ATPase activity (Fig. 4.1, Table 4.2) – four of the tested concentrations were above its water 
solubility (4.6 µM, Table 4.1). Nevertheless, effects of phenanthrene on Abcb4 ATPase activity were 
already seen at low concentrations which were in the range of its water solubility and again, it is 
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not known whether water solubilities are transferable to ATPase assay conditions (higher 
temperature, buffer environment including 2 % DMSO) and should be assessed in this condition. 
Phenanthrene is described to stimulate basal and inhibit stimulator co-treated Danio rerio Abcb4 
ATPase activities (Fischer et al., 2013). But solely looking at the trend of the concentration response 
curves, an inhibition of basal and stimulator co-treated ATPase activities are also seen in Fischer 
et al. (2013). Furthermore, phenanthrene toxicity was increased (37 %) upon co-exposure to (the 
Abcb4 ATPase activity inhibiting) cyclosporin A in Danio rerio embryos, indicating substrate 
properties of phenanthrene. As ABCB1 ATPase activity stimulation by phenanthrene reached only 
26 % and r² were maximal 0.37 effects were not categorised as unambiguous. Effects of 
phenanthrene on basal Abcb4 ATPase activity reached 36 % inhibition, but as the concentrations 
response relationship fit was of low quality effects were not considered unambiguous. Even in the 
case that phenanthrene clearly stimulated basal ABCB1 (implying substrate properties) and clearly 
inhibited basal Abcb4 ATPase activity, phenanthrene could be transported by both transport 
proteins (suggested for Abcb4 in Fischer et al., 2013) and therefor interaction of ABCB1 and Abcb4 
with phenanthrene is not considered severely different. 
ABCB1 and Abcb4 interactions with cyclosporin A, colchicine, and testosterone do not appear 
strictly different as stimulation of basal and inhibition of co-treated ATPase activities can both be 
indicative for ABCB1-like substrates (Glavinas et al., 2008)17. EC50s for these chemicals were very 
similar except for colchicine (difference by a factor of 10), indicating similar affinity to ABCB1 and 
Abcb4. 
Inhibition of stimulator co-treated ATPase activity – likely caused by competitive stimulation or 
non-competitive inhibition (Glavinas et al., 2008; Von Richter et al., 2009; Litman et al., 1997b) – 
was seen for all chemicals tested to modulate stimulator co-treated Abcb4 ATPase activity. None18 
of the chemicals tested for modulation of basal and stimulator co-treated Abcb4 ATPase activity, 
only stimulated basal Abcb4 ATPase activity (but basal ABCB1, e.g. colchicine and testosterone).  
Overall, concentrations at half-maximal stimulation (of basal) or inhibition (of basal or stimulator 
co-treated) of Abcb4 ATPase activities were below 100 µM except for trospium and were similar to 
those for ABCB1, indicating specific interaction with the ATPase activity of the transporter proteins 
and moderate affinities to the ABC transporters.  
Severely different interacting chemicals would modulate the ATPase activity of one transporter 
protein (e.g. ABCB1) but not at all of the other studied transporter protein (e.g. Abcb4) – which was 
not clearly seen for any of the tested chemicals.  
                                                             
17 Stimulation of basal ATPase activity is often seen for high turnover substrates, inhibition of stimulator co-
treated ATPase activity for slow turnover substrates or inhibitors (Glavinas et al., 2008).  
18 Verapamil, dipyridamole, and amprenavir were not tested to inhibit stimulator co-treated ATPase 
activities. 
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No definite conclusion on transport of a chemical can be drawn from ATPase assay data (Stein & 
Litman, 2014). Hence, (preferably quantitative) information on ABCB1-like transporter mediated 
transport of chemicals is needed to compare or categorise consequences of chemical-ABCB1-like-
transporter interactions. (In the case that a chemical is a basal ATPase activity inhibitor of both 
compared transporter proteins and is only transported by one of those, the consequence of the 
initial modulation of ATPase activity would be different for this chemical.) Non-transported 
inhibitors of ABCB1-like transporter ATPase activities would be an ecotoxicological relevant 
category of chemicals: Organisms would not benefit from ABCB1-like transporter mediated 
multixenobiotic resistance but would be threatened by chemosensitisation. 
Nonetheless, screening of chemicals using ATPase assays serve as first hint whether a chemical is a 
potential transported substrate or acting as inhibitor (of ABCB1-like transporter ATPase activity 
and most likely of ABCB1-like transporter mediated transport of a substrate chemical). 
From the presented data and at the current state of knowledge can be drawn the conclusion, that 
with regard to modulation of ATPase activity Abcb4 is interacting with the same (herein tested) 
chemicals as ABCB1. ABCB1 ATPase assay data can probably be used as first guess for Abcb4 
ATPase activity interaction or not. A remaining open question is to what extent ATPase stimulators 
and inhibitors are transported by Abcb4.  
 
4.5.2 Drug binding sites of Homo sapiens ABCB1 and Mus musculus ABCB1a 
compared to amino acid sequence of Danio rerio Abcb4 
Danio rerio Abcb4, Homo sapiens ABCB1, and Mus musculus ABCB1a (due to results obtained for this 
transporter) amino acid sequences were aligned and residues known to bind to certain chemicals 
or are involved in ABC transporter function were labelled and compared among the three 
MDR/MXR transporters. 
The number of amino acids (13 to 17) involved in chemical binding was similar for all four 
chemicals (retrieved from Aller et al., 2009, Nicklisch et al., 2016). However, molecular weight19 and 
logP20 values of the studied chemicals were also quite similar. Phenylalanine (F, hydrophobic 
functional group) seemed to be important for binding of (hydrophobic) chemicals as it is involved 
five times each in QZ59-RRR, QR59-SSS, and six times in PBDE-100 binding, and three times in 
verapamil binding (in ABCB1a). It appears intuitive that hydrophobic chemicals bind to 
hydrophobic residues. Abcb4, ABCB1a, and ABCB1 residues chemicals bind to could be different to 
those discussed here for chemicals with other properties (lower or higher molecular weight, lower 
                                                             
19 491 g/mol for verapamil (table 4.1), 565 g/mol for PBDE-100 (Nicklisch et al., 2016); QZ59-RRR and QZ59-
SSS 860 g/mol (http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0JZ) 
20 LogP of PBDE-100, QZ59 (-RRR/-SSS), and verapamil were 7.66 (EpiSuite KOWWIN v. 1.68 estimate; 
experimental 6.84 [Geyer et al., 2000]), 5.57 (EpiSuite KOWWIN v. 1.68 estimate), and 4.66 (see Table 4.1) 
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or higher logP, and others). (It would be interesting to analyse Abcb4 or ABCB1 binding sites for 
more hydrophilic chemicals.) 
With respect to total numbers of dissimilar positions (among the surveyed, Fig. 4.2) Danio rerio 
Abcb4 differed more (twelve of 43 surveyed positions were different, ≈ 27 %) from Homo sapiens 
ABCB1 (two positions) or Mus musculus ABCB1a (four positions) than ABCB1 and ABCB1a among 
each other, which seemed plausible with regard to the overall amino acid identity of 64 % of Abcb4 
compared to ABCB1 and 87 % to ABCB1a. 
It is known that when Homo sapiens ABCB1 residues Y307/Q725/V982 chemicals bind to were 
mutated, ATPase activity is not abolished and secondary sites are used and these secondary sites 
are capable of chemical transport (Chufan et al., 2013). These residues were conserved in Danio 
rerio Abcb4, Mus musculus ABCB1a (see Table 4.4). Nevertheless, there are amino acid positions 
whose mutation to alanine (see Table 4.4) lead to stimulation instead of inhibition of basal ATPase 
activity (Chufan et al., 2016). Residues involved in function (ABCB1 Y307/Q725/V982 from Chufan 
et al., 2013; ABCB1 F978, F728, Y953, Y310 in Chufan et al., 2016) were found relatively close to 
each other (distance of one or two amino acid positions) and were surrounded by residues to which 
chemicals bind to. This observation may signify that possibly more than one amino acid position is 
important for a specific function and the consequence of a dissimilar amino acid residue at a certain 
position may also depend on neighbouring residues.  
Abcb4 amino acid positions which were different to their mammalian ABC transporter 
counterparts predominantly concerned residues which bind to only one of the four surveyed 
chemicals. Amino acid residues (of ABCB1 or ABCB1a) to which more than one (of the four) 
chemical bind were predominantly identical in Danio rerio Abcb4 (and Mus musculus ABCB1a, and 
Homo sapiens ABCB1): only two Abcb4 residues were different to mammalian ABCB1/ABCB1a 
residues. One of those is I976 (aligned to position ABCB1 F978/ABCB1a F974) whose human 
counterpart is involved in ATPase activity inhibition (Chufan et al., 2016). This position (Danio rerio 
I976) could be interpreted as a difference worth to mention.  
Dissimilar amino acids chemicals bind to among the studied ABCB1-like transporters could indicate 
different interaction with or binding to chemicals. Alternatively, dissimilar amino acids (chemicals 
bind to) could compensate differences at other positions of the ABC transporters or differences 
related to other features of the ABC transporters to maintain ABC transporter function. For 
example, Abcb4 exhibited a lower activation energy for the basal ATPase activity (by a factor of 2) 
and also a lower activation energy for the verapamil stimulated ATPase activity (by a factor of 1.5) 
compared to Homo sapiens ABCB1 (see chapter 3), which probably is also manifested genetically 
and in the amino acid sequence. From the comparison of amino acid positions (Table 4.4, Fig. 4.2) 
and ATPase assay data for ABCB1 and Abcb4 can be concluded that chemical binding to Abcb4 is 
probably similar to ABCB1. 
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4.6 SIGNIFICANCE OF FINDINGS AND OUTLOOK 
The model organism Danio rerio is gaining more and more importance and attention in 
pharmacology and (eco-) toxicology (e.g. Scholz et al., 2008, Sipes et al., 2011, Kari et al., 2007; Dai 
et al., 2014). Phylogenetic analysis from Fischer et al. (2013) and Luckenbach (2014) revealed that 
the Danio rerio P-glycoprotein Abcb4 is a co-orthologue to Homo sapiens ABCB4 and no Abcb1 
protein is found in Danio rerio. Hence it is important to know about possible species differences 
with regard to ABCB1-like ABC transporters and their role in toxicokinetics. 
Available ATPase assay data for Homo sapiens ABCB1 can probably be used as a first guess for 
qualitative interaction of chemicals with Danio rerio Abcb4 ATPase activity. Overall, Abcb4 amino 
acid position aligned to mammalian ABCB1/ABCB1a positions involved in chemical binding and/or 
function appeared similar. Amino acid positions to which all of the four studies chemicals bind were 
mainly similar and could represent generally needed ABC transporter-chemical contacts. As 
dissimilar amino acid positions were mainly found at positions only one of the surveyed four 
chemicals bind to, they may be only used by some chemicals and hence may be less crucial for 
overall chemical binding.  
None of the tested 17 chemicals clearly interacted only with the ATPase activity of one of the two 
ABC transporters. The majority of chemicals interacted in a similar way – i.e. stimulated basal 
and/or inhibited stimulator co-treated Abcb4 and ABCB1 ATPase activity, or inhibited basal and 
also stimulator co-treated Abcb4 and ABCB1 ATPase activity. Nevertheless, whether and which 
inhibitors of basal Abcb4 ATPase activity are transported should be the objective of future studies. 
In addition, (quantitative) transport and transport inhibition studies with ATPase stimulators and 
inhibitors, respectively, should be run to study to what extent Abcb4 facilitated active transport of 
chemicals is modulating Danio rerio toxicokinetics.  
Inhibitors of Abcb4 ATPase activity that are not transported by Abcb4 would be of ecotoxicological 
importance, as organisms (here Danio rerio) exposed to these chemicals would not be protected by 
Abcb4 mediated multixenobiotic resistance and were moreover threatened by chemosensitisation 
by these chemicals. 
The next chapter of this work was dedicated to investigate whether and how environmental 
pollutants interact with Danio rerio Abcb4 ATPase activity using the ATPase assay with 
recombinant Abcb4 expressed in Sf9 cell membranes.  
 81 
5 DANIO RERIO ABCB4 ATPASE ACTIVITY MODULATION BY 
POTENTIAL ENVIRONMENTAL POLLUTANTS COMPARED TO 
STANDARD MODULATORS 
5.1 ABSTRACT 
Organisms have developed detoxification mechanisms to cope with (natural) toxins occurring in 
their diets and environment. Members of the ABC transporter family contribute to the 
detoxification by ATP hydrolysis coupled translocation of chemicals out of the cell membrane. The 
so far most prominent efflux transporter ABCB1 (MDR1, P-gp) translocates a variety of different 
chemicals and contributes to their bioavailability. Hence, the terms multidrug resistance (MDR) and 
multixenobiotic resistance (MXR) were coined, pointing to the function of these transporters as 
they prevent their potentially harmful substrates to accumulate inside cells. This ABCB1-like 
transporter function is inhibited by certain chemicals which can lead to chemosensitisation: 
enhanced toxicity of or increased sensitivity towards potentially harmful substrate chemicals. 
ABCB1-like transporters are present in all studied organisms, including the model species zebrafish 
(Danio rerio). 
Nowadays, thousands of anthropogenic chemicals are in use in consumer and industry products 
and several chemicals were found to leak to the environment. Wildlife organisms are potentially 
exposed to a cocktail of pollutants. It is of question whether and how these anthropogenic 
chemicals interact with ABCB1-like transporter proteins as Danio rerio Abcb4. In this study Danio 
rerio Abcb4 ATPase assay data for 33 environmental chemicals (n = 15 from this work and n = 18 
from previous works using the identical protocol) were surveyed. When possible, chemical 
selection aimed at diversity of chemicals with regard to physicochemical properties. Recombinant 
Danio rerio Abcb4 protein used in the ATPase assays was obtained with the baculovirus expression 
system in Sf9 cells. Chemicals were tested up to their water solubility to modulate basal and 
stimulator co-treated Abcb4 ATPase activity.  
EC50s and effect strengths of environmental chemicals interacting with the Abcb4 ATPase activity 
from this works’ data and those generated from literature were compared to those of 13 well 
known modulators of ABCB1 and Abcb4 ATPase activities from chapter 4. 
Generally, a couple of environmental chemicals clearly interacted – like standard modulators – as 
stimulators of basal and/or inhibitors of stimulator co-treated Abcb4 ATPase activity. Bisphenol A, 
pentachloropyridine, thiacloprid, thiram, diclofenac, fluoxetine, and isoeugenol clearly inhibited 
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stimulator co-treated Abcb4 ATPase activity. Inhibition of stimulator co-treated ATPase activity 
indicates slow turnover competitive substrates or inhibitors. Further, several chemicals clearly 
acted as inhibitors of basal and stimulator co-treated Abcb4 ATPase activity: sertraline and 
perfluorooctane sulfonate. Non-transported inhibitors could be of ecotoxicological relevance as 
organisms would not benefit from ABCB1-like transporter (e.g. Abcb4) mediated multixenobiotic 
resistance, but could be threatened by chemosensitisation by this chemical. Azinphosmethyl, 
thiacloprid, and hydroxycitronellal clearly stimulated basal Abcb4 ATPase activities and could be 
transported substrates. (Whether apparently net transport is observed probably depends on how 
lipophilic the chemicals are.)  
EC50s, which can be interpreted as affinities to Abcb4, of the studied environmental chemicals 
reached from below 10µM to ca. 357 µM and tended to be higher than for standard modulators 
(highest EC50 of 171 µM). Effect strengths (percent modulation) of environmental chemicals were 
similar to standard modulators for inhibition of stimulator co-treated ATPase activity and lower for 
stimulation of basal ATPase activity. Low EC50s can be seen as an indicator for specific interactions, 
whereas high EC50s and effects only at high concentrations could point to rather unspecific 
interaction with Abcb4 ATPase activity. Future research should focus on apparent (and 
quantitative) transport of the herein revealed Abcb4 ATPase activity modulators, possibly 
associated multidrug/multixenobiotic resistance as well as chemosensitisation in real world 
scenarios and mixtures. 
 
5.2 INTRODUCTION 
Evidence for ABCB1-like transporter protein and function was confirmed in all studied species and 
the term multixenobiotic resistance (MXR) was coined (Kurelec et al., 1992), in analogy to 
multidrug resistance (MDR) (Juliano & Ling, 1976). For zebrafish (Danio rerio), a popular model 
organism in ecotoxicology, developmental biology, and pharmacology (Scholz et al., 2008; Hölttä-
Vuori et al., 2010; Stewart et al., 2012; McGrath, 2012), it was previously shown that Abcb4 is able 
to confer MXR in Danio rerio embryos (Fischer et al., 2013, Lu et al., 2015). In the previous chapter 
prototypical modulators were tested to interact with Danio rerio Abcb4 ATPase activity in 
comparison to the well-known Homo sapiens ABCB1 (ATPase activity). Considering this exceptional 
versatility of ABCB1-like transporters the question arises whether and to what extent Danio rerio 
Abcb4 ATPase is modulated by environmental pollutants of anthropogenic origin as stimulators or 
whether these chemicals could act as chemosensitisers. Mammalian ABCB1 related function seem 
especially important in the context of permeability of drugs to sanctuary sites of the body as across 
the blood-brain barrier (as well as for cancer therapy). Similar observations could be expectable 
with respect to wildlife organisms as Danio rerio. Concentrations of blood-brain barrier non-
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permeable chemicals (e.g. translocated Abcb4 substrates) could be increased in the Danio rerio 
brain when inhibitors mitigate Abcb4 function (for Danio rerio blood-brain barrier see Fleming 
et al., 2013).  
Environmental chemicals were tested to modulate basal and stimulator (verapamil) co-treated 
Abcb4 ATPase activity using recombinant Danio rerio Abcb4 from baculovirus infected Sf9 cell 
membrane preparations. The methodology for recombinant protein production and the ATPase 
assays is described in chapter 2 and in more detail in the appendix, section A.2. 
Chemicals stimulating basal ATPase activity could be transported substrates of the ABC 
transporter. However, if these stimulators are very lipophilic they partition to the membrane 
quickly and no or only poor net transport may be expected (see also section 1.5.1.3). Inhibition of 
stimulator co-treated ATPase activity indicated slow turnover competitive substrates or inhibitors 
(Glavinas et al., 2008; Von Richter et al., 2009; Litman et al., 1997b). Hence, inhibitors of co-treated 
ATPase activity could also be transported substrates as seen for cyclosporin A (Goldberg et al., 
1988; Polli et al., 2001) and doxorubicin (Shen et al., 2008; Von Richter et al., 2009). Chemicals 
inhibiting basal ATPase activity with high affinity are likely also high affinity transport inhibitors 
(Chufan et al., 2016). Inhibitors of basal and stimulator co-treated ATPase activity may act as 
chemosensitisers in a mixture scenario. See also section 1.5 in chapter 1. 
The selection of the here assayed chemicals aimed at diversity, including insecticides, herbicides, 
ingredients of personal care products, and pharmaceuticals (amongst others). Tested 
environmental chemicals had molecular weights between 172.3 to 406.9 g/mol and LogP values 
from 0.96 to 4.18. The concentration range was chosen with regard to the water solubility of the 
chemicals and at least half of the tested concentrations were below the lowest water solubility 
value. Organophosphate insecticides (azinphosmethyl, malathion), an organochlorine insecticide 
(endosulfan), a neonicotinoid insecticide (thiacloprid), fungicides (thiram, propiconazole), 
herbicides (acetochlor, metazachlor, terbuthylazine), an intermediate for agrochemicals 
(pentachloropyridin), the environmentally occurring anticancer drug ifosfamid (of 0.5 to 1.2 µg/L 
in effluents of a sewage treatment plant; Kümmerer &, Al-Ahmad, 2010) and ingredients of 
consumer products (benzophenone, perfluorooctane sulfonate, bisphenol A, hydroxycitronellal, 
butyl benzoate) were tested to modulate Danio rerio Abcb4 ATPase activity. EC50s of and percent 
modulation by the tested chemical in relation to control stimulation were analysed. 
Furthermore, literature data on chemical interaction with Danio rerio Abcb4 ATPase activity were 
analysed analogously for the fluorosurfactant perfluorooctane sulfonate (PFOS; Keiter et al., 2016); 
the pharmaceuticals diclofenac, simvastatin, fluoxetine, and sertraline; the synthetic musk 
fragrances celestolide, musk xylene, and musk ketone; the essential oils nerol, citronellol, 
isoeugenol, camphene, α-amylcinnamaldehyde, and α-hexylcinnamaldehyde; and the preservative 
propylparaben (Cunha et al., 2017). 
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EC50s and percent modulation of Abcb4 ATPase activity by environmental pollutants (from this 
work, Keiter et al., 2016, Cunha et al., 2017) were compared to effects by 13 prototypical 
modulators from chapter 4 (see  5.3.3). 
5.3 METHODOLOGY 
5.3.1 Tested chemicals 
Acetochlor, azinphosmethyl, benzophenone, bisphenol A, butyl benzoate, endosulfan, 
hydroxycitronellal, metazachlor, pentachloropyridine, thiacloprid, and thiaram were from Sigma-
Aldrich (Deisenhofen, Germany; incl. Fluka, SAFC). Malathion and terbuthylazine were from Riedel-
de Haën (Honeywell Specialty Chemicals Seelze GmbH) and ifosfamide from LKT (Minneapolis, 
United States of America).  
Usage, CAS numbers, suppliers per chemical, molecular weight, partition coefficient for 
octanol/water (logP), water solubilities (experimental, predicted by ALOGpS and EpiSiute) and 
highest chemical concentrations used in the ATPase assays were given in Table 5.1. Water 
solubilities were retrieved using the software EpiSuite (WSKOW v.1.41) 21  and ECOSAR 22 
(WSKOWWIN v1.43), as well as the webpage ALOGPS23 (ALOGpS). Further experimental data were 
taken from the literature, as indicated in Table 5.1. Water solubility values usually varied around 
one order of magnitude and were indicated in Table 5.1. Stock solutions of the tested chemicals 
were prepared in dimethyl sulfoxide (DMSO); concentrations used in the ATPase assays did not 
exceed 2 % DMSO. At least six concentrations per chemical were assayed and concentrations were 
chosen to reach up to the chemicals’ water solubility, except for endosulfan, ifosfamid, 
hydroxycitronellal, and metazachlor. For endosulfan three concentrations were above and for the 
other three chemicals all concentrations were below the according water solubility. 
 
 
 
 
 
 
 
 
                                                             
21 http://www2.epa.gov/tsca-screening-tools/epi-suitetm-estimation-program-interface 
22  http://www2.epa.gov/tsca-screening-tools/ecological-structure-activity-relationships-ecosar-predictive-
model 
23 www.vcclab.org/lab/alogps/ 
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5.3.2 Production of recombinant protein and use in ATPase assays 
Specific interactions of tested chemicals with the Danio rerio Abcb4 ATPase were determined in 
ATPase assays using membrane preparations containing recombinant Abcb4. Recombinant 
membrane proteins were generated in Sf9 cells with the baculovirus expression system. The 
methodology for generation of baculovirus molecules, recombinant membrane protein production, 
conduction of ATPase assay, and data analysis was described in chapter 2. Detailed protocols for 
the complete procedure are given in the appendix (section A.2).  
 
5.3.3 Comparison of effects from standard modulators and environmental chemicals 
EC50s (eq. (2.1), chapter 2) and effect strengths (percent modulation, eq. (2.2) and (2.3), chapter 2) 
for interaction of chemicals with basal and stimulator co-treated Abcb4 ATPase activities were 
calculated for all chemicals and were visualised using a correlation matrix within GraphPad prism 
(including also EC50s from ambiguous fits). Concentration ranges of chemicals were chosen with 
regard to the chemicals’ water solubilities (Table 5.1); for chemicals from Cunha et al. 2017 see 
table 1 in Cunha et al., 2017). 
Standard modulators tested in chapter 4 were amprenavir, colchicine, cyclosporin A, 
dexamethasone, dipyridamole, doxorubicin, etoposide, ivermectin, phenytoin, testosterone, 
trospium, verapamil, and vinblastine.  
Environmental chemicals were  
• those tested in this chapter (acetochlor, azinphosmethyl, benzophenone, bisphenol 
A, butyl benzoate, endosulfan, hydroxycitronellal, ifosfamide, malathion, 
metazachlor, pentachlorpyridine, propiconazole, terbuthylazine, thiacloprid, and 
thiram),  
• tonalide, galaxolide, and phenanthrene tested in chapter 4, 
• perfluorooctane sulfonate (PFOS) from Keiter et al. (2016), 
• α-amylcinnamaldehyde, α-hexylcinnamaldehyde, camphene, celestolide, citronellol, 
diclofenac, fluoxetine, isoeugenol, musk ketone, musk xylene, nerol, propylparaben, 
sertraline, and simvastatin from Cunha et al. (2017). 
 
Abcb4 ATPase assay data from Keiter et al. (2016) and Cunha et al. (2017) were obtained with 
methodology described in chapter 2. EC50s and effect strengths of chemicals tested in Abcb4 
ATPase assays in Cunha et al. (2017) were calculated as for data from this work and were 
interpreted accordingly. 
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5.4 RESULTS  
5.4.1 Modulation of Abcb4 ATPase activity by environmental chemicals 
At least six concentrations of the test chemicals were tested to modulate basal (bA) and 50 µM 
stimulator (verapamil) co-treated Abcb4 ATPase activities (cA). As controls served basal (bA) and 
50 µM verapamil stimulated (sA) Abcb4 ATPase activities. Concentration response relationships for 
modulation of Danio rerio Abcb4 ATPase activity by environmental chemicals were computed in 
GraphPad Prism 5 using non-linear regression to the four parameter logistic equation (Fig. 5.1). For 
non-interacting chemicals a line was fitted using linear regression. 
EC50s, 95 % confidence interval of the EC50s, Hill slopes, max and min values, r² as well as percent 
modulation as a measure of the effect strength were listed in Table 5.2.  
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Fig. 5.1 Concentration response relationships of environmental chemicals modulating the Abcb4 ATPase   
Abcb4 ATPase activities in nmol Pi/min/mg membrane protein were plotted versus chemical concentrations. 
Data points were represented as means ± SEM for n ≥ 3 and all data points were plotted for n = 2. Chemicals 
were tested to modulate basal (bA) /stimulator co-treated (cA) ATPase activity (closed/open symbols). 
Control (verapamil) stimulated (sA) and basal ATPase activities (bA) from the respective tests and means of 
the used membrane preparations (bA/sA prep) were plotted additionally. Lowest (pointed) and highest 
(dashed) water solubilities (Table 5.1) were indicated by vertical lines. 
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5.4.1.1 Stimulation of basal Abcb4 ATPase activity by tested chemicals 
Amongst the chemicals tested in this chapter the herbicides acetochlor, terbuthylazine, and 
metazachlor, the organophosphate malathion, the anti-cancer drug ifosfamide, the 
organophosphate azinphosmethyl, the neonicotinoid insecticide thiacloprid, and the musk 
hydroxycitronellal stimulated basal Abcb4 ATPase activity, with strongest effects for the latter 
three chemicals. Further, the essential oil nerol and slightly the synthetic musk fragrance musk 
xylene stimulated basal Abcb4 ATPase activity (Cunha et al., 2017) and according data were 
analysed to derive kinetic parameters.  
Azinphosmethyl, hydroxycitronellal, and thiacloprid clearly stimulated basal Abcb4 ATPase activity 
(Fig. 5.1) with EC50s of 90.3 µM, 10.1 µM, and 241.5 µM (Table 5.2). However, effects by 
azinphosmethyl and thiacloprid were only observed in the higher concentration range (Table 5.1, 
Table 5.2). Percent modulation reached from 38 % (thiacloprid) to 43 % (azinphosmethyl).  
Malathion reached 24 % of control stimulation by verapamil with an EC50 of 9.3 µM, though the r² 
of the regression was low (0.16) and the 95 % confidence interval of the EC50 reached to higher 
concentrations than tested (0.1 to 918.4 µM). 
Acetochlor, metazachlor, ifosfamide, and terbuthylazine stimulated basal Abcb4 ATPase activity to 
a minor extent, i.e. effect strengths were lower than for the before mentioned chemicals with 25 %, 
16%, 20 %, and 26 %, respectively (Table 5.2). EC50s were 329.3 µM (acetochlor), ≈ 81.6 µM 
(metazachlor), 1 µM (ifosfamide), 7.2 µM (terbuthylazine). Stimulation of basal Abcb4 ATPase 
activity by acetochlor was seen in the higher concentration range. The EC50 fit for metazachlor was 
ambiguous. Basal Abcb4 ATPase stimulation by terbuthylazine reached only 26 % of control 
stimulation but concentration response relationship fit was of considerably quality (r² of 0.48; 
EC50 of 7.2 µM).  
Further, nerol and musk xylene slightly stimulated basal Abcb4 ATPase activity (Cunha et al., 2017) 
with percent modulation of 39 % and 19 % and EC50s of 125.1 µM (but with large 95 % confidence 
interval and low r²) and ≈ 73.6 µM (ambiguous fit), respectively (Table 5.2).  
With regard to EC50s (of basal Abcb4 ATPase stimulation) analysed environmental chemicals were 
ranked as follows: ifosfamid (1 µM) >  terbuthylazine (7.2 µM) >  malathion (9.3 µM) 
>  hydroxycitronellal (10.1 µM) >  musk xylene (≈ 73.6 µM) >  metazachlor (81.6 µM) 
azinphosmethyl (90.3 µM) >  nerol (125.1 µM) >  thiacloprid (241.5 µM) >  acetochlor (329.3 µM) 
(see also Table 5.2, Table 5.3). Effect strengths (percent modulation) of these anaylsed 
environmental chemicals were ranked as follows: azinphosmethyl (43 %) > hydroxycitronellal 
(41 %) > thiacloprid (38 %) >  nerol (39 %) >  terbuthylazine (26 %) > acetochlor (25 %) > 
malathion (24 %) > ifosfamide (20 %) > musk xylene (19 %) > metazachlor (16 %).  
5 DANIO RERIO ABCB4 ATPASE ACTIVITY MODULATION BY POTENTIAL ENVIRONMENTAL POLLUTANTS COMPARED TO STANDARD MODULATORS 
 
90 
Concentrations at half-maximal effect and percent modulation of Abcb4 ATPase activity by 
standard stimulators tested in chapter 4 were illustrated in relation to the environmental chemicals 
analysed in this chapter (Fig. 5.2). 
Generally, the tested environmental chemicals stimulated the Abcb4 ATPase activity to a lesser 
extent than the standard modulators tested in chapter 4 (Table 4.2, Fig. 5.2 A, B) and EC50s reached 
up to ≈ 330 µM. EC50s of basal Abcb4 ATPase stimulating standard modulators (see Fig. 5.2 A) 
were below 50 µM except for trospium (≈ 171 µM) and percent modulation reached up to 117 % 
(amprenavir). However among standard modulators and environmental chemicals were chemicals 
provoking moderate stimulation with low EC50s, e.g. hydroxycitronellal and cyclosporin A, on the 
one hand and on the other hand chemicals with high EC50s (> 100 µM), e.g. thiacloprid and 
trospium. 
 
5.4.1.2 Inhibition of basal Abcb4 ATPase activity by chemicals 
Basal Abcb4 ATPase activity was inhibited by the industrial chemical bisphenol A, the preservative 
butyl benzoate, the organochlorine insecticide endosulfan, and the fungicide thiram, but with 
effects only at the limit (bisphenol A) or above (endosulfan) their water solubilities or to minor 
extent (thiram, butyl benzoate) (Fig. 5.1). Inhibitors of basal Abcb4 ATPase activity were further 
galaxolide, tonalide, phenanthrene (chapter 4), PFOS (Keiter et al., 2016), diclofenac, fluoxetine, 
sertraline, and simvastatin (Cunha et al., 2017). Overall, 13 of 47 tested chemicals (this chapter; 
chapter 4; Cunha et al., 2017; Keiter et al., 2016) inhibited basal Abcb4 ATPase activity to minor or 
greater extent. 
Effects by bisphenol A on basal and stimulator co-treated Abcb4 ATPase activities lead to almost 
total inhibition of basal ATPase activity (95 % inhibition of basal ATPase activity, eq. (2.3), Table 
5.2) and inhibition below basal ATPase activity (130 % inhibition related to control stimulated 
ATPase activity, eq. (2.2)) when tested to modulate stimulator co-treated ATPase activity (Fig. 5.1). 
However, this strong inhibition was seen at the highest concentration tested which was at the limit 
of its water solubility (500 µM). EC50 fit for bisphenol A was ambiguous with ≈ 175.4 µM. Inhibition 
of basal Abcb4 ATPase activity by endosulfan was not seen at concentrations below its reported 
water solubilities (Table 5.1). The EC50 for inhibition of basal Abcb4 ATPase activity by endosulfan 
(25.5 µM) was above its water solubility (factor 2 to 20,Table 5.1, Table 5.2) . Modest basal ATPase 
activity inhibiting effects were seen for thiram (14 %) and butyl benzoate (1 %) with EC50s of 
3.8 µM, and 9.6 µM, respectively (Table 5.2). 
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Environmental chemicals clearly inhibiting basal Abcb4 ATPase activity were the fluorosurfactant 
PFOS (Keiter et al., 2016) and the antidepressant sertraline (Cunha et al., 2017) with EC50s of 
236.8 µM and 76.4 µM, respectively and effect strengths of 51 % and 92 %, respectively.  
The antidepressant fluoxetine (24 %), the non-steroidal anti-inflammatory drug diclofenac (33%), 
and the lipid lowering drug simvastatin (24 %) inhibited basal Abcb4 ATPase activity to a minor 
extent (Cunha et al., 2017) and exhibited EC50s of ≈ 268.6 µM (ambiguous fit, fluoxetine), 145.8 µM 
(diclofenac), and 0.37 µM (simvastatin) (Table 5.2).  
Environmental chemicals from chapter 4 inhibiting basal Abcb4 ATPase activity were 
phenanthrene, galaxolide, and tonalide.  
Strongest inhibition of basal Abcb4 ATPase activity was seen for bisphenol A (95 %) > sertraline 
(92 %) > PFOS (51 %) > galaxolide (37 %) > phenanthrene (36 %) > diclofenac (33 %) > fluoxetine, 
endosulfan, simvastatin (24 %) > thiram (14 %) > tonalide (13 %) > butyl benzoate (1 %). EC50s 
were lowest for simvastatin (0.4 µM) < thiram (3.8 µM) < butyl benzoate (9.6 µM) < phenanthrene 
(10.5 µM) < endosulfan (25.5 µM) < galaxolide (28.7 µM) < tonalide (≈ 40.1 µM) < sertraline 
(76.4 µM) < diclofenac (145.8 µM) < bisphenol A (≈ 175 µM) < PFOS (236.8 µM) < fluoxetine 
(≈ 268.6 µM). The standard modulator ivermectin inhibited basal Abcb4 ATPase activity to 45 % 
with an EC50 of 7.4 µM. 
In Fig. 5.2 C percent modulation and EC50s from inhibitors of basal Abcb4 ATPase activity are 
visualised. Inhibitors of basal Abcb4 ATPase activity exhibited EC50s from 0.4 to ≈ 268.6 µM and 
percent inhibition reached up to 95 %, i.e. to almost total inhibition of basal ATP activity. Strongest 
inhibiting effects were seen by chemicals exhibiting rather high EC50s or EC50s above their water 
solubility. 
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Fig. 5.2 Comparison of Danio rerio Abcb4 ATPase activity modulation by standard modulators and 
environmental chemicals 
EC50s and percent modulation (effect strengths) are given for standard modulators (triangles) from 
chapter 4 (see Table 4.2) and for environmental chemicals (circles, values from Table 5.2) stimulating basal 
(A,B) and/or inhibiting stimulator co-treated (D,E) Abcb4 ATPase activities. Percent modulation was the 
maximum chemical specific modulation of ATPase activities related to control modulation by verapamil when 
subtracting min and bA (eq. (2.2)) or percent inhibition of bA (eq. (2.3)) for inhibition of basal ATPase 
activity. All chemicals exhibiting (minor to strong) effects were included. (See also Table 5.3) Chemicals 
inhibiting basal Abcb4 ATPase activity: galaxolide, phenanthrene, tonalide, ivermectin (standard modulator) 
(chapter 4), bisphenol A, butyl benzoate, endosulfan, thiram (this chapter), PFOS (Keiter et al., 2016), 
diclofenac, fluoxetine, sertraline, simvastatin (Cunha et al., 2017) are summarised (C).  
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5.4.1.3 Inhibition of stimulator co-treated Abcb4 ATPase activity  
Acetochlor, bisphenol A, butyl benzoate, endosulfan, hydroxycitronellal, ifosfamid, malathion, 
pentachloropyridine, propiconazole, thiacloprid, and thiram inhibited the stimulator co-treated 
Danio rerio Abcb4 ATPase activity.  
Further environmental chemicals which inhibited the stimulator co-treated Abcb4 ATPase activity 
were the fluorosurfactant PFOS (Keiter et al., 2016), the anti-inflammatory drug diclofenac, the 
antidepressants fluoxetine and sertraline, and the essential oil isoeugenol (Cunha et al., 2017) as 
well as galaxolide and tonalide (chapter 4). Clear and unambiguous inhibition of the stimulator co-
treated Abcb4 ATPase activity (Fig. 5.1) was registered for bisphenol A, pentachloropyridine, 
thiacloprid, and thiram with EC50s of 108 µM, 5.5 µM, 92.2 µM, and 26.6 µM, respectively (Table 
5.2). Percent modulation reached 130 % (bisphenol A), 79 % (pentachloropyridine), 79 % 
(thiacloprid), and 35 % (thiram) of 50 µM verapamil stimulation. Also hydroxycitronellal (64%) 
and ifosfamid (54 %) inhibited stimulator co-treated Abcb4 ATPase activity at low concentrations 
with EC50s of 5 µM and 4.3 µM, respectively, but r² of the concentration response relationships 
were below 0.4 (Table 5.2). Effects by acetochlor (65 % [of 50 µM verapamil stimulation], EC50 of 
≈ 329 µM), butyl benzoate (67 %, EC50 of 232.4 µM), endosulfan (46 %, EC50 of 21.9 µM), 
malathion (59 %, EC50 of ≈ 169.7 µM) and propiconazole (77 %, EC50 of ≈ 74.6 µM) were only seen 
at concentrations in the range of the chemicals’ water solubilities (Table 5.1, Fig. 5.1) and 
parameter fitting of concentration response relationships was in part ambiguous. 
Effect strengths and EC50s for further environmental chemicals inhibiting stimulator co-treated 
Abcb4 ATPase activity were 146 % and 68.5 µM (PFOS, Keiter et al., 2016), 90 % and 118.9 µM 
(diclofenac), 84 % and 174.4 µM (fluoxetine), 94 % and 140.8 µM (isoeugenol), and 117 % and 
111.1 µM (sertraline, Cunha et al., 2017), see Table 5.2.  
Lowest EC50s were determined for ifosfamide (4.3 µM) < hydroxycitronellal (5 µM) < 
pentachloropyridine (5.5 µM) < endosulfan (21.9 µM) < tonalide (24.79 µM) < thiram (26.6 µM) < 
galaxolide (28.71 µM) < PFOS (68.5 µM) < propiconazole (≈ 74.6 µM) < thiacloprid (92.2 µM) < 
bisphenol A (108 µM) < sertraline (111.1 µM) < diclofenac (118.9 µM) < isoeugenol (140.8 µM) < 
malathion (≈ 169.7 µM) < fluoxetine (174.4 µM) < butyl benzoate (232.4 µM) < acetochlor 
(≈ 375 µM). Strongest effects (percent modulation) were seen for galaxolide (194 %) > PFOS 
(146 %) > bisphenol A (130 %) > sertraline (117 %) > tonalide (104 %) > isoeugenol (94 %) 
> diclofenac (90 %) > fluoxetine (84 %) pentachloropyridine (79 %) > thiacloprid (79 %) 
> propiconazole (77 %) > butyl benzoate (67 %) > hydroxycitronellal (64 %) > acetochlor (65 %) 
> ifosfamide (54 %) > malathion (59 %) > endosulfan (46 %) > thiram (35 %).  
In relation to standard modulators from chapter 4, environmental chemicals caused similarly 
strong inhibition of stimulator co-treated Abcb4 ATPase activity, with percent modulation mainly 
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above 35 % and up to > 100 % modulation, i.e. below the level of basal Abcb4 ATPase activity. 
However, standard modulators tested in chapter 4 exhibited lower EC50s (≈ 0.1 to ≈ 94 µM) than 
the tested environmental chemicals (EC50s of ≈ 5 µM to ≈ 375 µM).  
Six of ten standard modulators from chapter 4, inhibiting stimulator co-treated Abcb4 ATPase 
activity, had EC50s below 10 µM, two were between 10 µM and 50 µM, and two were between 
50 µM and 100 µM. About half of the 18 inhibitors (of stimulator co-treated ATPase activity) among 
the tested and surveyed environmental chemicals exhibited EC50s above 100 µM and reached up to 
357 µM (Fig. 5.2). 
 
5.4.2 Overview of results 
An overview of interaction of environmental chemicals from this work, Keiter et al. (2016) and 
Cunha et al. (2017) with Danio rerio Abcb4 ATPase activity is given in Table 5.3. Clear and 
unambiguous stimulation of basal, inhibition of basal and/or stimulator co-treated Abcb4 ATPase 
activity by chemicals was usually accompanied by unambiguous fits of parameters of the 
concentration response relationships with moderate to good quality of the regressions (e.g. 
r² ≥ 0.4), indicated in bold letters. These chemicals usually caused ATPase activity modulation 
above 30-35 % of control modulation (stimulation) by verapamil. Effects by chemicals were not 
considered unambiguous if only weak ATPase activity modulation was seen and/or only at the 
highest concentration range tested – both often leading to ambiguous fits and/or low r².  
Inhibition of stimulator co-treated Abcb4 ATPase activity was seen for acetochlor, bisphenol A, 
butyl benzoate, endosulfan, hydroxycitronellal, ifosfamide, malathion, pentachloropyridine, 
propiconazole, thiacloprid, thiram, PFOS, diclofenac, fluoxetine, isoeugenol, and sertraline. Effects 
were not unambiguous for acetochlor, butyl benzoate, endosulfan, malathion, propiconazole. The 
chemicals musk xylene, nerol, acetochlor, bisphenol A, metazachlor, ifosfamid, terbuthylazine, 
azinphosmethyl, hydroxycitronellal, and thiacloprid stimulated basal Abcb4 ATPase activities with 
strongest unambiguous effects seen for the latter three. For galaxolide, phenanthrene, tonalide, 
bisphenol A, butyl benzoate, endosulfan, thiram, diclofenac, fluoxetine, simvastatin, sertraline, and 
PFOS inhibition of basal Abcb4 ATPase activity was seen, with strongest unambiguous effects for 
the latter two. 
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Table 5.3 Overview of environmental chemicals tested for interaction with the Danio rerio Abcb4 ATPase 
activity 
Chemicals were tested to stimulate or inhibit basal (bA) and stimulator co-treated (cA) Abcb4 ATPase 
activity. Bold letters indicated unambiguous interactions. Grey backgrounds indicated effects only at or above 
the limit of water solubility, with light grey for effects only above lower water solubility values and dark grey 
for effects only at or above the highest water solubility values (Table 5.1). Data from chapter 4 a, Keiter et al. 
(2016) b, and Cunha et al. (2017) c were indicated by indices.  
 
 
 
 
 
 
 
 
Usage modulation of bA modulation of cA
Acetochlor Herbicide stimulation inhibition
Azinphosmethyl Organophosphate insecticide stimulation -
Benzophenone UV-blocker - -
Bisphenol A Industrial chemical inhibition inhibition
Butyl benzoate Preservative inhibition inhibition
Endosulfan Organochlorine insecticide inhibition inhibition
Hydroxycitronellal Musk stimulation inhibition
Ifosfamide Anti-cancer drug stimulation inhibition
Malathion Organophosphate insecticide stimulation inhibition
Metazachlor Herbicide stimulation -
Pentachloropyridine Intermediate of agrochemicals - inhibition
Propiconazole Fungicide - inhibition
Terbuthylazine Herbicide stimulation -
Thiacloprid Neonicotinoid insecticide stimulation inhibition
Thiram Fungicide inhibition inhibition
Galaxolide a Fragrance inhibition inhibition
Tonalide a Fragrance inhibition inhibition
Phenanthrene a Industrial chemical inhibition -
Perfluorooctane sulfonate b Fluorosurfactant inhibition inhibition
α-amylcinnamaldehyde c Essential oil - -
α-hexylcinnamaldehyde c Essential oil - -
Camphene c Essential oil - -
Celestolide c Synthetic musk fragrances - -
Citronellol c Essential oil - -
Diclofenac c Nonsteroidal anti-inflammatory drug inhibition inhibition
Fluoxetine c Antidepressant inhibition inhibition
Isoeugenol c Essential oil - inhibition
Musk ketone c Synthetic musk fragrances - -
Musk xylene c Synthetic musk fragrances stimulation -
Nerol c Essential oil stimulation -
Propylparaben c Preservative - -
Sertaline c Anti-depressant inhibition inhibition
Simvastatin c Lipid-lowering drug inhibition -
 Danio rerio  Abcb4 ATPase activity
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5.5 DISCUSSION 
Danio rerio Abcb4 is a multidrug/multixenobiotic resistance transporter (Fischer et al., 2013, Lu 
et al., 2015) for which interaction with various pharmaceuticals and natural toxins was 
demonstrated. ABCB1-like transporters are known for their low specificity with regard to their 
substrates and inhibitors (Ambudkar et al., 1992; Ambudkar & Gottesman, 1998; Aller et al., 2009; 
see section 1.1.1). Aim of this chapter was to study whether and to what extent environmental 
chemicals interact with Danio rerio Abcb4 ATPase activity as stimulators and/or inhibitors. Using 
ATPase assays environmental chemicals were studied for their modulation of basal and stimulator 
(here verapamil) co-treated Danio rerio Abcb4 ATPase activity. Recombinant membrane protein for 
the ATPase assays was produced using the baculovirus expression system. Tested chemical 
concentrations were chosen with regard to the water solubility of the chemicals reaching up to 
1 mM and do not reflect on concentrations found in the environment. Environmental 
concentrations are often in nM range (see supplemental material from Kurth et al., 2015; Cunha 
et al., 2017, table 1). Percent modulation and EC50s of environmental chemicals interacting with 
Danio rerio Abcb4 ATPase activity were compared to those of standard modulators tested to 
interact with the Abcb4 ATPase activity in chapter 4. 
 
5.5.1 Stimulation of Abcb4 ATPase activity  
Unambiguous stimulators of Danio rerio Abcb4 ATPase activity were hydroxycitronellal, 
azinphosmethyl, and thiacloprid. Basal Abcb4 ATPase activity stimulation by acetochlor, 
metazachlor, terbuthylazine, ifosfamide, and malathion were not considered unambiguous, i.e. was 
minor, as either EC50s were in the range of water solubility (acetochlor, malathion), fits were 
ambiguous (metazachlor) or percent modulation in relation to verapamil stimulation was below 
30 % (for terbuthylazine, ifosfamide, acetochlor, malathion, metazachlor; see Table 5.2).  
Following, available knowledge on interaction or involvement of the studied chemicals with 
ABCB1-like function is summarised. 
Increased mortality after co-exposure to the neonicotinoid insecticide thiacloprid and verapamil is 
reported in honey bees and involvement of ABCB1-like transporters is suggested (Hawthorne & 
Dively, 2011). Acetochlor, metazachlor, and further chloroacetanilide herbicides interact with 
Homo sapiens ABCB1 ATPase activity and acetochlor and metazachlor reach about 40 % and 30 % 
of (40 µM) verapamil stimulated ABCB1 ATPase activity, respectively (Oosterhuis et al., 2008). 
Additionally, calcein-AM (a substrate of ABCB1 and ABCC transporters [Homolya et al., 1993; Holló 
et al., 1994; Essodaïgui et al., 1998]) efflux is decreased in acetochlor or metazachlor co-exposed in 
K562-MDR cells, indicating that these herbicides act transport inhibitors (Oosterhuis et al., 2008). 
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Literature results for thiacloprid, acetochlor, and metazachlor suggesting interaction with ABCB1-
like function, in line with the finding of this work for Danio rerio Abcb4.  
Ifosfamide is described to induce MDR transporters in LS180 cells (human colon adenocarcinoma-
derived) but ifosfamide pre-exposed LS180 cells do not show increased accumulation of rhodamine 
123 if co-exposed to the ABCB1 inhibitor zosuquidar (Harmsen et al., 2010). Anyways, no explicit 
study investigating the interaction of ifosfamide with MDR/MXR transporter ATPase activity is 
available yet. Malathion does not show interaction with Poeciliopsis lucida Abcb1 ATPase activity 
(Zaja et al., 2011), whereas exposure to malathion lead to increased rhodamine B accumulation in 
gills of the zebra mussel Dreissena polymorpha (Smital et al., 2004), indicating either species 
differences with regard to interference of malathion with ABC transporter function or different 
assay systems lead to different results, as previously reported in Polli et al. (2001). 
For the first time, (slight to moderate) stimulation of basal Abcb4 ATPase was demonstrated for the 
environmental chemicals terbuthylazine, hydroxycitronellal, ifosfamide, and azinphosmethyl 
activity. Because ABCB1 and Abcb4 ATPase activity modulation by the standard ABCB1-like ATPase 
stimulators and inhibitors (tested in chapter 4) was quite similar, it is likely that the here identified 
Abcb4 ATPase modulating/stimulating environmental chemicals may interact with ABCB1 ATPase 
activity as well.  
The essential oil nerol and the synthetic fragrance musk xylene slightly stimulated basal Abcb4 
ATPase activity (Cunha et al., 2017), underlined by according concentration response relationship 
fits with low r² or small percent modulation derived in this chapter.  
Stimulation of basal Abcb4 ATPase activity by environmental chemicals – in total ten identified in 
this chapter; Keiter et al., 2016; and Cunha et al., 2017 – reached maximal 43 % of control 
stimulation by verapamil and overall appeared weaker compared to standard modulators (seven 
stimulators from chapter 4, with maximal 115 %). EC50s for environmental chemicals were higher 
– four of ten chemicals with EC50s below 50 µM and up to 329 µM compared to four of seven 
chemicals with EC50s below 50 µM with maximum EC50 of 171 µM for the standard modulators 
from chapter 4. However, among the environmental chemicals and the standard modulators were 
chemicals provoking moderate Abcb4 ATPase activity stimulation at low concentrations, e.g. 
hydroxycitronellal and cyclosporin A on the one hand and on the other hand causing minor effects 
at relatively high concentrations, e.g. thiacloprid and trospium.  
Low EC50s can be interpreted as high affinity of the chemicals to Abcb4 and hence chemicals 
exhibiting low EC50s may specifically interact with Abcb4 ATPase activity. Hence, besides only 
slight stimulation of basal Abcb4 ATPase activity, EC50s below 10 µM for terbuthylazine and 
ifosfamid (Table 5.2) could indicate a specific interaction. Chemicals for which effects were only 
seen at highest concentrations tested (e.g. at the limit of their water solubilities) could also interact 
with Abcb4 by secondary mechanisms as alteration of membrane properties. 
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Hydroxycitronellal, ifosfamide, malathion, thiacloprid, and acetochlor additionally inhibited 
stimulator co-treated Abcb4 ATPase activity, indicating that these chemicals could act as transport 
inhibitors when there is a transported substrate present. 
Stimulation of basal ATPase activity must not be seen in line with ABCB1-like mediated transport of 
the stimulator (see Polli et al., 2001, section 1.5.1.3) as very lipophilic chemicals like verapamil 
quickly partition to the membrane and apparent net transport may be not or hardly seen (Stein & 
Litman, 2014; Polli et al., 2001). However, basal Abcb4 ATPase activity simulators with relatively 
low logP (e.g. < 2.5) as hydroxycitronellal, ifosfamid, malathion, thiacloprid (Table 5.1) could be 
apparently transported substrates of Abcb4. Bioavailability of Abcb4 ATPase activity stimulators 
could be influenced by Abcb4 function in Danio rerio. In case organophosphate insecticides 
(azinphosmethyl, malathion) are metabolised by P450 enzymes to the respective -oxon forms also 
in the Danio rerio brain (as the organophosphate-oxon is neurotoxic [Buratti et al., 2003]) 
neuroactive effects by e.g. azinphosmethyl (Klüver et al., 2015) could be enhanced when Abcb4 
mediated translocation of e.g. azinphosmethyl is inhibited. As neonicotinoid insecticides are 
suggested to exhibit effects also in vertebrate species (Gibbons et al, 2015), e.g. reduced swimming 
activity of Danio rerio larvae exposed to the neonicotinoid insecticide imidacloprid (Crosby et al., 
2015), a similar neuroactive effect is expectable for the here tested neonicotinoid thiacloprid. 
Accordingly, in case the Abcb4 ATPase activity stimulator thiacloprid is an apparently net 
transported Abcb4 substrate, neuroactive effects could be enhanced when co-exposed to an Abcb4 
inhibitor. 
 
5.5.2 Inhibition of Abcb4 ATPase activity  
Inhibition of basal and stimulator co-treated Danio rerio Abcb4 ATPase activity was seen for 
bisphenol A, butyl benzoate, endosulfan, thiram, (this work), galaxolide, tonalide (discussed in 
chapter 4); and is further described for diclofenac, fluoxetine, sertraline (Cunha et al., 2017), and 
PFOS (Keiter et al., 2016). ATPase assay data thereof were analysed for the comparison to standard 
modulators. Clear and unambiguous effects were seen for the latter two chemicals, sertraline and 
PFOS (Table 5.2, for discussion see Cunha et al., 2017; Keiter et al., 2016). Modulation of basal 
Abcb4 ATPase activity by simvastatin (data from Cunha et al., 2017) and phenanthrene (chapter 4) 
was minor and effects were not considered unambiguous as data interpretation of this work 
suggests stimulation whereas previous studies (Fischer et al., 2013; Cunha et al., 2017) describe 
stimulating effects for phenanthrene and simvastatin. 
The softener bisphenol A decreased Abcb4 basal ATPase activity with strongest effects at its 
(lower) limit of water solubility and only an ambiguous fit was possible. ABCB1-like transporter 
modulating properties of bisphenol A are previously described for sea urchin Abcb1 and human 
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ABCB1 (Anselmo et al., 2012; Bošnjak et al., 2014; Jin & Audus, 2005). Co-exposure to bisphenol A 
lead to increased accumulation of calcein-AM in sea urchin (Paracentrotus lividus) embryos of 
different ages (Anselmo et al., 2012; Bošnjak et al., 2014). Verapamil (used as Abcb1 inhibitor) 
increased bisphenol A accumulation in sea urchin embryos (2-cell stadium and pluteus) up to 
2.5-fold for 100 nM bisphenol A (Bošnjak et al., 2014), suggesting bisphenol A being a transported 
substrate of sea urchin MDR/MXR transporters. Bisphenol A increases also calcein-AM 
accumulation in human trophoblast cells pre-exposed to bisphenol A, indicating also modulation of 
Homo sapiens ABCB1 by the chemical (Jin & Audus, 2005). Summarising, bisphenol A interacts with 
Danio rerio Abcb4, Homo sapiens ABCB1, and Paracentrotus lividus Abcb1 and displays properties 
as ATPase inhibitor (zebrafish Abcb4), ABCB1-like mediated transport inhibitor (human ABCB1, 
sea urchin Abcb1), and ABCB1-like substrate (sea urchin Abcb1).   
Danio rerio Abcb4 ATPase assay data for endosulfan (Fig. 5.1) showed inhibition of basal ATPase 
activity, but effects were only seen at concentrations higher than the reported water solubilities 
(1.11 to 9.85 µM, see Table 5.2, Table 5.1). The effects of endosulfan on stimulator co-treated 
ATPase activity appeared not concentration dependent. However, clouds of dots can be explained 
by one replicate with low and one with higher Abcb4 ATPase activity of the membrane 
preparations used and for both replicates a decrease in ATPase activity was visible (Fig. A.8). 
Endosulfan was previously shown to interact with ABCB1-like proteins: Inhibition of Homo sapiens 
ABCB1 mediated doxorubicin efflux by endosulfan (Bain & LeBlanc, 1996), stimulation of Chinese 
hamster (Cricetulus griseus) ABCB1 ATPase above 10 µM (Sreeramulu et al., 2007), inhibition of 
Homo sapiens ABCB1 ATPase activity (Bircsak et al., 2013; Lacher et al.,2015), and increased 
rhodamine B accumulation in zebra mussel Dreissena polymorpha gill tissue (Smital et al., 2004). It 
is noteworthy, that in Sreeramulu et al. (2007), Bircsak et al. (2013), and Lacher et al. (2015) 
concentrations of endosulfan achieving an effect were higher than ≈ 10 µM (i.e. its water solubility). 
In Smital et al. (2004) concentration dependent effects of endosulfan on rhodamine B accumulation 
were seen up to ≈ 30 nM (0.03 µM), followed by slight attenuation of the effect at 100 nM. The 
observed modulatory effects of endosulfan on Danio rerio Abcb4 ATPase activity of this work were 
in line with Lacher et al. (2015) with regard to inhibition of (Danio rerio Abcb4 and Homo sapiens 
ABCB1) ATPase activities and with Bircsak et al. (2013) as they obtained a similar EC50 (33.6 µM). 
Still, concentrations at half-maximal effect of this work as well as of previous works were above the 
reported water solubilties (Table 5.1). Nevertheless, solubilities of chemicals in ATPase assay 
conditions (2 % DMSO, at least 27 °C for Danio rerio Abcb4, 37 °C for Homo sapiens ABCB1) are not 
known and might be higher than water solubilities. Summarised, endosulfan exhibited inhibitor 
properties, including inhibition of Abcb4 and human ABCB1 ATPase activities in most studies (this 
study, Bircsak et al., 2013; Lacher et al.,2015) but stimulated Chinese hamster ABCB1 ATPase 
activity (Sreeramulu et al., 2007).  
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ATPase assay data of this work firstly demonstrated basal and stimulator co-treated Abcb4 ATPase 
activity inhibition by butyl benzoate and thiram. 
Whether bisphenol A, endosulfan, and other chemicals inhibiting basal Abcb4 ATPase activity are 
also transported by Abcb4 cannot be concluded from the presented data. Some inhibitors of basal 
ABCB1-like ATPase activity are transported (ivermectin [Pouliot et al., 1997; Schinkel et al., 1994; 
Schinkel et al., 1996]); others are not (tariquidar [Chufan et al., 2016; Kannan et al., 2011; Loo et al., 
2012]). Non-transported inhibitors could be a threat to organisms as they would not be 
transported, but would inhibit the translocation of substrate chemicals by ABCB1-like transporters. 
EC50s for basal ABCB1 ATPase activity inhibition by tariquidar, elacridar, and zosuquidar were 
between 0.01 and 0.03 µM (Chufan et al., 2016) and were lower than those of ivermectin (ABCB1: 
0.3 µM, Abcb4 7.4 µM, this work). Most of the analysed chemicals exhibited EC50s above 10 µM for 
inhibition of basal Abcb4 ATPase activity (see also Fig. 5.2), i.e. were less potent than ivermectin 
(for Abcb4), and less potent than elacridar, zosuquidar, and tariquidar (referring to data for human 
ABCB1).  
Inhibition of ABCB1-like transporter function by propiconazole were previously described 
(Pivcevic & Zaja, 2006) with propiconazole inhibiting calcein-AM efflux in NIH 3T3 mouse 
fibroblast cells stably transfected with Homo sapiens ABCB1 gene (EC50 of 3.5 µM). Furthermore, 
propiconazole inhibits the transport of the ABCB1 substrate N-methyl quinidine (NMQ) in 
commercially available Homo sapiens ABCB1 membrane vesicles with an IC50 of 122.9 µM (Mazur 
et al., 2015). Concentrations at half-maximal inhibition seem to vary (3.5 µM in Pivcevic & Zaja, 
2006; 122.9 µM in Mazur et al., 2015) between test systems and inhibiting effects possibly also 
depend on the chemical used as stimulator, as seen in Garrigues et al. (2002). The EC50 for 
propiconazole of this study (≈ 74.6 µM) for inhibition of co-treated Abcb4 ATPase activity was 
between the previously reported EC50s for Homo sapiens ABCB1 interaction. Inhibition of 
stimulator co-treated ATPase activity is also indicative for slowly transported substrates (Glavinas 
et al., 2008, Von Richter et al., 2009). However, as pentachloropyridine and propiconazole are quite 
lipophilic (Table 5.1) apparent net transport may be unlikely. 
Proven Abcb4 transport inhibitors among environmental chemicals are PFOS, phenanthrene, 
galaxolide, and tonalide which enhance accumulation of rhodamine B in Danio rerio embryos 
(Fischer et al., 2013, Keiter et al., 2016). Furthermore, chemosensitisation is observed in Danio rerio 
embryos as vinblastine toxicity increased upon co-exposure to PFOS (Keiter et al., 2016). However, 
it is argued that effects by PFOS (modulation of ATPase activity and enhanced accumulation of 
rhodamine B) may not be explained solely by a specific ABC transporter interaction and the authors 
assume effects of PFOS also on the membrane properties (Keiter et al., 2016). 
Inhibitors of stimulator co-treated Abcb4 ATPase activity among the standard modulators tested in 
chapter 4 mainly exhibited EC50s below 50 µM (eight of ten). Environmental chemicals (a total 
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number of 18 chemicals, tested in this chapter, chapter 4, Keiter et al., 2016; and Cunha et al., 2017) 
inhibiting stimulator co-treated Abcb4 ATPase activity displayed EC50s up to 375 µM and only ca. 
half of these chemicals had EC50s below 50 µM (Fig. 5.2).  
In general, one could question whether effects by environmental chemicals – often modulating 
Abcb4 ATPase activity with rather high EC50s (> 100 µM) and/or at rather high concentrations (see 
Fig. 5.2) – were specific to Abcb4 interaction. Chemicals exhibiting high EC50s and/or effects only 
at the highest tested concentrations may also display rather unspecific effects. Although Keiter et al. 
(2016) clearly show that PFOS is a potent inhibitor of the MXR-related zebrafish Abcb4 transporter 
at high concentrations, they summarise that inhibition of Abcb4 function is most likely not the only 
cause for increased accumulation of Abcb4 substrates in the presence of PFOS. Rather, both 
transporter protein inhibition and enhanced accumulation of substrate compounds in zebrafish 
embryos are assumed to be associated with intercalation of PFOS into cellular membranes leading 
to modifications of membrane properties (for details see Keiter et al., 2016). However, it is known 
that membrane constituents and chemicals similar to those interact with ABCB1 and influence 
ABCB1 ATPase activity (Romsicki & Sharom, 1998; Sharom, 2014). 
Recently, the environmental chemical PBDE-100 was demonstrated to bind to the ABCB1-like 
conserved region in Mus musculus ABCB1a and is inhibiting the (verapamil-stimulated) ABCB1a 
ATPase activity (IC50 of 23.2 µM in Nicklisch et al., 2016). This finding underlines specific 
interactions of at least the environmental chemical PBDE-100 with the MDR/MXR transporter Mus 
musculus ABCB1a.  
 
5.6 SUMMARY AND OUTLOOK 
Twenty-five of overall so far tested 33 environmental chemicals (this work, Keiter et al., 2015, 
Cunha et al., 2017) modulated Danio rerio Abcb4 ATPase activity. Generally, environmental 
chemicals interacted as stimulators of basal and inhibitors of stimulator co-treated Abcb4 ATPase 
activity, and, moreover, some of them acted as inhibitors of basal ATPase activity (twelve, and 
ivermectin as a representative of the standard modulators). Unambiguous inhibition of basal Abcb4 
ATPase activity was seen for sertraline and PFOS. Some of the screened chemicals provoked effects 
at rather low concentrations exhibiting also low EC50s (similar to standard ABCB1-like ATPase 
modulators), though other chemicals modulated Abcb4 ATPase activity only at the highest 
concentrations tested which were in the range of the chemicals water solubilities. 
Among the herein surveyed environmental chemicals bisphenol A, pentachloropyridine, 
thiacloprid, thiram (this chapter), galaxolide, tonalide, (chapter 4) as well as PFOS (Keiter et al., 
2016), diclofenac, isoeugenol, and fluoxetine (Cunha et al., 2017) clearly inhibited verapamil 
co-treated Danio rerio Abcb4 ATPase activity. Inhibition of stimulator co-treated (Abcb4) ATPase 
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activity indicates competitive stimulation or non-competitive inhibition (Glavinas et al., 2008; Von 
Richter et al, 2009). Basal ATPase activity inhibition indicates properties as transport inhibitors 
(Chufan et al., 2016). Whether inhibitors of basal ATPase activity are transported by ABCB1-like 
proteins seems to depend on the chemical (ivermectin is transported [Pouliot et al., 1997; Schinkel 
et al., 1994; Schinkel et al., 1996] – tariquidar is not [Chufan et al., 2016; Kannan et al., 2011; Loo 
et al., 2012]) and should be assessed, also for Abcb4, in future studies. Inhibitors of (basal and/or 
stimulator co-treated) ATPase activity – especially when exhibiting low EC50s/high affinities –
likely act as transport inhibitors and are of ecotoxicological relevance if there are transported 
harmful ABCB1-like (as Abcb4) transporter substrates present in a mixture.  
Azinphosmethyl, hydroxycitronellal, and thiacloprid clearly stimulated basal Abcb4 ATPase activity 
and could be net transported substrates as their logPs are moderate with 1.89 to 2.27. EC50s tend 
to be higher and effect strengths were around 50 % for environmental chemicals stimulating basal 
ATPase activity compared to the standard stimulators tested in the previous chapter (chapter 4). 
With respect to effects on stimulator co-treated ATPase activities environmental chemicals and 
standard modulators seemed more similar, but also here EC50s of environmental chemicals were 
higher. Overall, EC50s of the herein studied environmental chemicals reached up to about 357 µM 
and EC50s of standard modulators up to 171 µM. EC50s above 100 µM and effects only seen at high 
concentrations (e.g. close to the chemicals water solubility) may indicate also indirect effects on 
Abcb4 ATPase modulation. However, low EC50s (around 10 µM) – which can be interpreted as 
specific interactions and as an indicator for high affinity to Abcb4 – were seen for standard 
modulators and environmental chemicals.  
Further research is needed to answer the question whether environmental chemicals and with 
what physicochemical properties are apparently net transported by Danio rerio Abcb4 in vivo and 
from what Abcb4 expression on Abcb4 modulates toxicokinetics of chemicals. As most organisms, 
including Homo sapiens, are exposed to various chemicals, multidrug/ multixenobiotic resistance 
and MDR/MXR transporter-related chemosensitisation should be assessed in mixtures. 
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6 SUMMARY AND IMPLICATIONS OF MAIN OUTCOMES OF THE 
THESIS  
This thesis was conducted to increase knowledge on Danio rerio Abcb4 characteristics and presents 
a compilation of data for standard mammalian ABCB1-like transporter stimulators or inhibitors as 
well as for environmental chemicals modulating Danio rerio Abcb4 ATPase activity. The transporter 
protein Danio rerio Abcb4 was chosen because this species (Danio rerio) and its embryos, 
respectively, are used as model organism (Scholz et al., 2008; Hölttä-Vuori et al., 2010; Stewart 
et al., 2012; McGrath, 2012). Obtained data may contribute to an understanding to what extent 
ABCB1-like mediated multixenobiotic resistance and/or chemosensitisation are of ecotoxicological 
relevance.  
Available information on chemical interaction with ABCB1-like transporters (including ATPase 
assay data) does not appear congruent in all cases leading also to a lack of appropriate reference 
data. Therefore a test system, the ATPase assay, was established to obtain data on interaction of 
chemicals with recombinant Danio rerio Abcb4 ATPase activity – which was also adapted to study 
interaction with Homo sapiens ABCB1 (ATPase activity) as reference transporter – comprising the 
complete protocol for recombinant protein production, ATPase assay conduct, and data analysis. 
The ATPase assay with recombinant transporter protein (here Danio rerio Abcb4 and Homo sapiens 
ABCB1) is a suitable screening tool as reproducible quantitative data can be obtained. ATPase 
assays with recombinant protein of interest reveal ABCB1-like transporter interaction on the 
molecular level. As from ATPase assay data no definite conclusion on ABCB1-like transporter 
mediated transport of a chemical can be drawn (Stein & Litman, 2014), future studies should 
promote mechanistic understanding on how modulation of catalytic activity (seen in ATPase 
assays) is translated to the transport of a chemical. Subsequently, quantitative ATPase assay data 
for chemical ABCB1-like transporter (e.g. Abcb4) interaction might be used for QSAR (Quantitative 
structure–activity relationship) analyses to refine in silico methods as PBTK (physiologically based 
pharmacokinetic) models to predict absorption/uptake and fate of chemicals. 
The described methodology was applied to answer subsequent questions. Most important 
outcomes are reflected on in the light of ecotoxicological implications and future research 
questions. 
Since the teleost fish Danio rerio and the mammal Homo sapiens have different and further non-
constant and constant body temperatures, respectively, – are Abcb4 and ABCB1 ATPase assay data 
suitable for a comparison? Furthermore, how do ATPase activities of Abcb4 and ABCB1 change 
with different temperatures? (Chapter 3) 
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Presented data show that ATPase assays with recombinant Abcb4 (at 27 °C) are comparable to 
ABCB1 ATPase assay data obtained at 37 °C and that Danio rerio Abcb4 seems less 
temperature-sensitive than ABCB1. Calculated activation energies – energy which is needed to 
provoke ATP hydrolysis by the ABC transporter inherent catalytic domain – of basal Abcb4 ATPase 
activity was half as high as those of basal ABCB1 ATPase activity and similarly, lower activation 
energies were registered for Abcb4 than for ABCB1 verapamil stimulated ATPase activities. Larger 
activation energies are proposed to be indicative for larger conformational rearrangements 
(Al-Shawi et al., 2003), and hence possibly smaller rearrangements take place in Abcb4 compared 
to ABCB1. An interesting future question is whether and/or how this differences in activation 
energies for basal and verapamil stimulated Abcb4 and ABCB1 ATPase activities is translated to 
possible differences with regard to the translocation of substrate chemicals.  
Danio rerio Abcb4 was demonstrated to be an MDR/MXR transporter functional homologous to 
Homo sapiens ABCB1 (Fischer et al., 2013; Lu et al., 2015). Nonetheless, limited information on 
stimulators and inhibitors of Abcb4 is available. Are stimulators and inhibitors of Homo sapiens 
ABCB1 also stimulators of Danio rerio Abcb4? To what extent are ABCB1 ATPase assay data 
transferable to Abcb4? How similar/dissimilar are amino acid positions of Abcb4 compared to 
ABCB1 amino acid positions known to bind to chemicals? (Chapter 4) 
Qualitative information on interaction of chemicals with Homo sapiens ABCB1 ATPase activity was 
transferable to Danio rerio Abcb4 ATPase activity: Of all the 17 tested chemicals, one chemical did 
neither interact with Abcb4 nor ABCB1 (Carbamazepine). No chemical clearly interacted severely 
different, i.e. interacted only with the ABCB1 or the Abcb4 ATPase activity.  
Available ATPase assay data, transport studies, and a linking understanding of ABCB1-like 
transporter function is not sufficient yet to draw a definite conclusion on the transport of chemicals 
from ATPase assay data. Consecutively, findings of this work are linked to the existing knowledge. 
Ivermectin clearly inhibited basal and stimulator co-treated Abcb4 ATPase activity and 
unambiguously inhibited stimulator co-treated (and slightly basal) ABCB1 ATPase activity. In case 
that ivermectin is not transported by Abcb4 – which is not known yet and cannot be concluded 
from ATPase assay data – ivermectin would interact differently with Abcb4 compared to ABCB1, as 
transport of ivermectin by Homo sapiens ABCB1 was demonstrated (Pouliot et al., 1997). However, 
there are inhibitors of basal Homo sapiens ABCB1 ATPase activity (e.g. tariquidar [Chufan et al., 
2016; Kannan et al., 2011; Loo et al., 2012]) that are not transported by human ABCB1. The latter 
category of chemicals would be of ecotoxicological relevance and future works should assess which 
inhibitors of basal ATPase activity are transported and which not. Organisms would not benefit 
from MDR/MXR to these non-transported inhibitors but could be threatened by chemosensitisation 
caused by these chemicals. The difference in the type of interaction as seen for cyclosporin A, 
colchicine, and testosterone – which were stimulators for one transporter and inhibitors of co-
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treated ATPase activity of the other – could lead to different effects in transport studies and in 
situations where cells or organism are exposed to mixtures of chemicals. Colchicine and 
cyclosporine A are known transported ABCB1 substrates (Polli et al., 2001). 
Affinities of chemicals to Abcb4 and ABCB1 (EC50s) were mostly similar. The majority of chemicals 
exhibited EC50s below 100 µM, ten chemicals with EC50s below 50 µM and four below 10 µM for 
Danio rerio Abcb4 and Homo sapiens ABCB1. Due to comparable EC50s for modulation of Abcb4 and 
ABCB1 ATPase activities by the herein studied chemicals also Abcb4 is specifically interacting with 
these chemicals.  
Alignment of amino acid sequences from Danio rerio Abcb4, Homo sapiens ABCB1, and Mus 
musculus ABCB1 revealed that dissimilar amino acids were preferably found at residue positions to 
which only one of the four tested chemicals (data from Aller et al., 2009; Nicklisch et al., 2016; Loo 
& Clarke, 1997; Loo et al., 2006) bind. Positions to which more than one chemical binds were 
largely similar. No obvious hints have been found suggesting that chemical binding to Abcb4 is 
certainly different from ABCB1. Chemicals interacting with ABCB1 ATPase activity likely also 
interact with Abcb4 ATPase activity. With regard to the results of the previous chapter (ca. half as 
low activation energies for Abcb4 than for ABCB1), subsequent studies should focus on whether 
and how Abcb4 substrates and inhibitors are (quantitatively) transported by Danio rerio Abcb4.  
Environmental chemicals are omnipresent in the aquatic environment and it is of ecotoxicological 
relevance whether and to what extent these chemicals interact with ABCB1-like transporter 
function. Do environmental chemicals interact with Abcb4 and do they modulate ATPase activity 
comparably to standard ABCB1 stimulators and inhibitors? (Chapter 5) 
The presented data imply that environmental pollutants interacted in a similar way with Abcb4 
ATPase activity as standard modulators, i.e. as stimulators and/or inhibitors. Azinphosmethyl, 
thiacloprid, and hydroxycitronellal stimulated basal Abcb4 ATPase activities and could be 
transported substrates. MDR/MXR transporter function has impact on the permeability of 
substrate chemicals to sanctuary tissues of the body as the blood-brain barrier; e.g. ABCB1a 
prevents ivermectin to accumulate in mouse brains (Schinkel et al., 1994). Danio rerio 
brain/nervous system bioavailability of the herein identified Abcb4 ATPase activity stimulators 
(and possibly transported substrates) azinphosmethyl and neonicotinoid insecticide thiacloprid 
might as well depend on Abcb4 mediated efflux of these chemicals. In case azinphosmethyl is 
metabolised by P450 enzymes to azinphosmethyl-oxon also in the Danio rerio brain (as the 
organophosphate-oxon is neurotoxic [Buratti et al., 2003]), neuroactive effects (Klüver et al., 2015) 
could be enhanced when Abcb4 mediated efflux of azinphosmethyl is inhibited. Recent studies 
suggest that neonicotinoid insecticides exhibit effects also in vertebrate species (Gibbons et al, 
2015), e.g. reduced swimming activity of Danio rerio larvae exposed to the neonicotinoid insecticide 
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imidacloprid (Crosby et al., 2015), implying similar neuroactive effects for the here identified 
Abcb4 ATPase stimulator thiacloprid. 
Chemicals inhibiting stimulator co-treated Abcb4 ATPase activities, as hydroxycitronellal, 
acetochlor, malathion, thiacloprid, pentachloropyridine, and propiconazole, could also be 
transported substrates. (However, apparent net transport of very lipophilic substrates is prone to 
be missed in transport studies, due to fast partition of lipophilic chemicals back to the membrane 
(Stein & Litman, 2014; Polli et al., 2001).) Nevertheless, in a mixture scenario and in wildlife, 
inhibitors of stimulator co-treated ATPase activity could act as chemosensitisers where they could 
also enhance toxicity of e.g. the naturally occurring toxicant Microcystin-LR (Lu et al., 2015). 
Several chemicals acted as inhibitors of basal and/or verapamil co-treated ATPase activity with 
strongest effects seen for sertraline and perfluorooctane sulfonate. Inhibitors of basal ATPase 
activity (especially with low EC50s) are very likely also high affinity transport inhibitors (Chufan 
et al., 2016) and act as chemosensitisers.   
Herein studied environmental chemicals modulating Danio rerio Abcb4 ATPase activity exhibited 
EC50s from below 10 µM up to several 100 µM and EC50s reached higher concentrations than for 
standard modulators. Effect strengths of environmental chemicals were similar to standard 
modulators for inhibition of stimulator co-treated ATPase activity and lower for stimulation of 
basal ATPase activity. Low EC50s can be interpreted as indicator for specific interaction with Abcb4 
(ATPase activity). Rather high EC50s and/or effects seen only at highest concentrations tested, 
could point to unspecific interactions of chemicals with Abcb4 and/or its membrane environment. 
Nonetheless, previous works emphasise the influence of membrane constituents on ABCB1 ATPase 
activity (Romsicki & Sharom, 1998; Sharom, 2014). 
The results of this work underline that ABCB1-like transporter (here Abcb4 and ABCB1) function is 
of (eco-)toxicological importance as several environmental chemicals were identified to inhibit 
basal and/or stimulator co-treated Abcb4 ATPase activity, which likely act as Abcb4 inhibitors 
(Chufan et al., 2016)/chemosensitisers on the one hand. On the other hand, chemicals stimulating 
basal ATPase activity/competitive substrates inhibiting stimulator co-treated ATPase activity are 
possibly transported (when they are not partitioning to the membrane immediately) (Glavinas et al. 
2008; Von Richter et al., 2009, Litman et al., 1997c). Moreover, among the surveyed environmental 
chemicals were stimulators and inhibitors with low EC50s indicating as specific interactions as 
seen for standard modulators from previous studies. High affinity inhibitors ABCB1 ATPase activity 
are very likely high affinity ABCB1 transport inhibitors (Chufan et al., 2016), and hence, Abcb4 
ATPase activity inhibitors exhibiting low EC50s are likely also high affinity Abcb4 mediated 
transport inhibitors. 
Obtained data and insights could contribute to the understanding of toxicokinetics of those 
compounds in the zebrafish. 
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Perspectives and challenges 
It is difficult to extrapolate from in vitro test results on ABCB1-like function to in vivo results 
(Sjöstedt et al., 2014) and more over to the wildlife scenario. ABCB1-like transporter levels are 
pretty high in artificial test systems, especially in (commercial) membrane preparations of 
ABCB1-like transporter expressing Sf9 cells (> 54 fmol/µg versus ≈ 1.3 fmol/µg in MDCKII-MDR 
cells [Zhang et al., 2011]). Vmax values and in some cases (equations to determine transport of a 
chemical) also Km values are reported to depend on the expression level of the ABCB1-like 
transporter, i.e. increase with increasing ABCB1-like transporter level (Shirasaka et al., 2006; 
Tachibana et al., 2010; Sjöstedt et al., 2014). By definition Km values are independent of the 
expression level. However, for some chemicals ABCB1 transporter mediated efflux depend on the 
expression level of ABCB1 (Troutman & Thakker, 2003). Nonetheless, ABCB1-like transporters are 
also effective at physiological levels, preventing substrate chemicals entering sanctuary tissues of 
the body (Schinkel et al., 1994; Schinkel et al., 1997; reviewed in Ayrton & Morgan, 2001; Leslie 
et al., 2005). Future works should assess at which concentrations of a chemical/at what abundance 
of ABCB1-like protein active transport by the ABCB1-like transporter is sufficient to dominate 
passive processes, for which chemicals. As it has been claimed that in studies on chemosensitisation 
by chemicals pretty high concentrations were tested being far above concentrations of these 
chemicals detected in the environment (Kurth et al., 2015), ABCB1-like transporter 
abundance/expression sufficient to overcome passive diffusion for a certain chemical could be 
related to environmental concentrations of this chemical and ABCB1-like transporter 
abundance/expression in wildlife organisms. This would help to evaluate to what extent Abcb4 or 
other ABC transporter mediated efflux is relevant at concentrations of chemicals found in the 
environment. Parameters from chemical ABC transporter interactions could be incorporated in 
pharmacokinetic modelling as PBPK (physiologically based pharmacokinetic modelling) to improve 
risk assessment of chemicals.  
Wildlife organisms are exposed to multiple stressors, amongst them various chemicals and thus 
combined effects related to MDR/MXR function are required to investigate further. Polar sediment 
fractions – representing mixtures of chemicals – were demonstrated to inhibit Poeciliopsis lucida 
Abcb1 ATPase activity and hence suggest chemosensitisation potential of these mixtures (Zaja et al., 
2013). Especially non-transported inhibitors could be ecotoxicologically relevant constituents of 
mixtures. First studies distinguishing effects by ABCB1-like and ABCC-like transporter inhibitors 
are available (Luckenbach et al., 2008; Faria et al.; 2016). 
In addition to ABCB1-like transporter mediated efflux, factors influencing toxicokinetics may be 
expression of further transporter proteins, metabolism by phase I and phase II enzymes, expression 
level of the transporter proteins in the test system on the one side and the type, concentration and 
quantity of modulating chemicals on the other side. A summary on further transport proteins 
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possibly affecting bioavailability can be found in Dobson & Kell (2008), Stein and Litman (2014) 
and are beyond the scope of this work.  
ABC transporters, and amongst them ABCB1-like transporters, seem to be involved also in 
developmental processes of sea urchin Strongylocentrotus purpuratus (Shipp & Hamdoun, 2012) 
and possibly in other species, increasing the number of targets MDR/MXR transporter inhibitors 
could be a threat to. 
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A APPENDIX 
A.1 NUCLEOTIDE SEQUENCE OF DANIO RERIO ABCB4 
https://www.ncbi.nlm.nih.gov/nuccore/NM_001316714 
 
A.2 PROTOCOL FOR RECOMBINANT PROTEIN PRODUCTION AND THE ATPASE ASSAY 
A.2.1 Sf9 cell culture  
Spodoptera frugiperda (Sf9), adapted to serum free conditions cells (Gibco life technology; Sf9 Cells; 
Cat No. 11496-015; Lot No 644282) were cultured according to the instructions in Sf-900 II SFM 
medium. Cells were used from passage 5 to 20 and were cultured in suspension of 25 to 50 ml 
volume in plain bottom bottles (Thermo Scientific, sterile disposable PETG Flasks; 125 ml) at 27 °C 
125 rpm in a GFL 3031 shaker (Gesellschaft für Labortechnik GmbH, Burgwedel, Germany). Large 
scale cultivation (200 ml volume) was performed in spinner flasks (Bellco Glass; BELL-FLO spinner 
flask complete 500 ml) used on a magnetic stirrer (Biomix 1; 2mag, München, Germany) in an 
incubator at 27 °C and 80 rpm.  
 
A.2.2 Transfection of Sf9 cells, generation of a P1 baculovirus stock, and virus 
propagation 
For transfection of Sf9 cells Cellfectin II (10362-100; Invitrogen) was used according to the 
manufacturer’s instructions (Invitrogen Bac-to-Bac baculovirus Expression System). Sf9 cells of a 
cell density of 1.5-2.5 x 106 cells/ml were seeded at a density of 0.8 ·106 cells/well in 2 ml Grace 
Insect media unsupplemented in 6-well-plates (Tissue Culture testplate 92406, TTP) and were 
transfected with 1 µg Bacmid DNA in Tris-EDTA (TE) - buffer (pH 8; Sambrook & Russell, 2000) 
using 8 µl of Cellfectin II in a total volume of 210 µl Grace Insect media unsupplemented. After five 
hours media was removed and 2 ml of Sf 900 II SFM media, containing 1% penicillin/streptomycin, 
were added. Cells were incubated 96 hours at 27 °C. Supernatant was collected and centrifuged at 
500 · g for 5 min. Virus stocks were stored at 4 °C in the dark, containing 2% FBS. 
Amplification of baculovirus stocks was performed as described in the Bac-to-Bac baculovirus 
Expression System manual. Briefly, 2 · 106 cells/ ml were inoculated with the P1 baculovirus stock 
at a multiplicity of infection (MOI) of 0.05 to 0.1. Sf9 cells with the respective inoculate were grown 
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in suspension for 120 h protected from light at 27 °C and 125 rpm (plain bottom bottles) and 80 
rpm (spinner flasks), respectively. The P2 baculovirus stock was harvested by centrifugation at 
500 · g for 5 min. To determine the titre of the new baculovirus stock a plaque assay was 
performed. P3 is the highest passage used. 
 
A.2.3 Determination baculovirus titres using the plaque Assay 
To determine the titre of the baculovirus stocks the protocol of the Bac-to-Bac baculovirus 
Expression System manual (Invitrogen, Version of September 2010) was used. 2 ml of a 0.5 · 106 
cells/ml Sf9 cell suspension were seeded in a 6-well-plate and incubated at 27 °C for 4 hours. 
Medium was removed and 1 ml of the baculovirus stock dilutions (1 · 10 -4 to 1 · 10-8) were added 
and cells were incubated for 1 h at 27 °C. Subsequently, the baculovirus inoculants were removed 
and 2 ml of 37 °C the plaquing medium [0.4 % low melting agarose in Sf 900 1.3x medium and 1 % 
penicillin/streptomycin, at 37 °C] were added carefully and plates were not moved for 30 min. 
Following 1 ml of Sf 900 II SFM media with 1% penicillin/streptomycin was added to prevent 
dehydration and the plated were incubated at 27 °C. After seven days the media on top was 
removed and 2 ml of 0.3 g/l Neutral red Solution in PBS with calcium/magnesium was added and 
incubated for 2 h at 27 °C. Hence, the Neutral red in PBS solution was removed; plates were dried 
bottom up overnight and plaques were counted.  
 
A.2.4 Production of recombinant wild-type Abcb4, mutant non-functional Abcb4, and 
ABCB1 proteins in Sf9 cells 
Exponentially growing Sf9 cells at passage 6-20 and a density of 2 - 2.5 · 106 cell/ml were infected 
with baculovirus at a MOI of ≈ 2.5 in a volume of 50 ml (plain bottom bottle) or 200 ml (spinner 
flask) and were cultivated protected from light for 68 to 72 hours (Fischer et al., 2013; Sarkadi 
et al., 1992) at 27 °C and 125 rpm and 80 rpm, respectively. The vitality of the Sf9 cells decreased to 
around 80 % and cells have a similar density as at the start of the infection. 
 
A.2.5 Crude membrane preparations 
Crude membrane preparations were obtained based on the protocol described in Germann (1998). 
Briefly, cells were pelleted in 50 ml falcon tubes by centrifugation at 1400 g for 10 min at 4 °C 
(Hermle ZK 380, Wehingen, Germany) and stored at -80 °C for at least 2 h and maximally 3 d. 
Pellets of 200 ml culture were resuspended in ice cold TMEP [50 mM Tris-HCl, pH7; 50 mM 
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D-Mannitol; 2 mM EGTA; 2 mM 2-Mercaptoethanol, 1 % protease inhibitor in MilliQ water] buffer. 
Cells were disrupted on ice using a tight-fitting dounce homogenator (15 ml Tissue Grinder, 
357544, Wheaton, Millville, USA]; 40 stokes; Fischer et al., 2013; Germann, 1998) or via nitrogen 
cavitation (Parr instrument company, 4635 cell disruption vessel) at 90 bar for 10 min (Keiter 
et al., 2016).  
The suspension was centrifuged at 500 g for 10 min at 4 °C and the resulting supernatant was 
ultracentrifuged at 100000 · g for 1 h at 4 °C (Beckmann Optima L-90k Ultracentrifuge, rotor 
Beckmann SW28, Krefeld, Germany). The pellets were resuspended in approximately 1 ml of ice 
cold TMEP buffer on ice, using syringes of different sizes (Braun, Melsungen: 20G (0.9 · 70 mm), 
and 27 G (0.4 · 20 mm) 90° bend and stored as aliquots at -80 °C until use. Differences to Germann 
(1998) were the use of protease inhibitor and cell disruption via nitrogen cavitation. Total protein 
concentration was determined using a bicinchoninic acid assay (BCA, Fischer Scientific BCA Kit) 
and bovine serum albumin (BSA) as standard. TMEP buffer was diluted 1:10 as solvent for BSA 
dilutions (0.06 mg/ml to 2 mg/ml) and to dilute samples 1:5 and 1:3, as pure TMEP buffer 
interfered with the measurement.  
 
A.2.6 Western blots to show presence of recombinant protein in membrane 
preparations 
Recombinant proteins in crude membrane preparation were verified using western blot analysis. 
Briefly 2 µg membrane protein per probe were loaded on a gel consisting of a resolving gel with 
7.5 % acrylamide and a stacking gel with 4 % acrylamide. Markers were a pre-stained marker (NEB, 
7-175 kDa.; P7708) and a biotinylated marker (Cell Signaling Technology, 7727). Proteins were 
blotted on a nitrocellulose membrane (Whatman Protras BA 83 nitrocellulose 9179735 0.2 µm). 
Antibodies were anti P-glycoprotein Mouse mAb C219 (Calbiochem Cat.No.517310; 1:500), goat 
anti mouse igG-HRP (sc-2005, Santa Cruz; 1:2000), and the anti-biotin antibody (#7075 P5, Cell 
Signaling Technology, 1:3333). Signals were detected using ECL select Western blotting detection 
reagent (GE health care, RPN 2235) and an Alpha Innotech Corp Fluorchem 8900 BioImaging 
system. 
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A.2.7 ATPase assay 
Reagent setup 
Rinse all vessels with bi-distilled water. 
 
 
Solutions Storage
1.7 M Tris
Dissolve 20.587 g of Tris in 100 ml distilled water
0.1 M MOPS-Tris
Dissolve 2.09 g of MOPS in 90 ml distilled water, adjust pH to 7.0 with 1.7 M Tris (about 2 
ml). Bring solution to 100 ml with distilled water.
100 mM EGTA-Tris pH 7.0
Dissolve 3.804 g of EGTA in about 10 ml of 1.7 M Tris. Add 80 ml of distilled water and 
adjust pH to 7.0 with 1.7 M Tris. Bring solution to 100 ml with distilled water.
1M KCl
Dissolve 7.46 g of KCl in 100 ml distilled water.
0,1 M Na-Azide
Dissolve 0.65 g of Na-azide in 100 ml of distilled water.
0.1 M DTT
Dissolve 0.3086 g of DTT in 20 ml of distilled water.
5% SDS 
Dissolve 5 g of SDS in 100 ml distilled water.
100 mM KH2PO4
Dissolve 0.1361 g of KH2PO4 in 10 ml distilled water.
Phosphate standard solutions
0.5 mM, 1 mM, 2 mM, 4 mM and 8 mM KH2PO4 prepared from 100 mM KH2PO4 stock in 
distilled water.
120 mM Na-orthovanadate
120 mM Na-Orthovanadate in distilled water. pH 10
0.2 M MgATP
Dissolve 2.2 g of ATP and 0.8 g MgCl2 in 10 ml od distilled water and adjust pH to 7.0 with 
1.7 M Tris. Bring solution to 20 ml with distilled water.
20 mM verapamil 
20 mM Verapamil in DMSO
15 mM zinc acetate
Dissolve 330 mg Zinc Acetate in 100 ml of distilled water.
35 mM ammonium molybdate in 15 mM zinc acetate pH 5.0
Dissolve 0.864 g of Ammonium Molybdate in 15 ml zinc Acetate and adjust pH to 5.0 
with HCl solution. Bring solution to 20 ml with 15 mM Zn Acetate. Store in a container 
wrapped with aluminum foil in the dark.
10 % ascorbic acid pH 5.0
Dissolve 1.6 g Ascorbic Acid in 16 ml distilled water and adjust pH to 5.0 with NaOH 
(prepared freshly).
4°C, 2 weeks
4°C, 1 week, 
dark
Prepare freshly
RT, > 1 year
-20°C in small 
aliquots
-20°C in small 
aliquots
-20°C in small 
aliquots
-20°C in small 
aliquots
-20°C in small 
aliquots
4°C, > 1 year
4°C, > 1 year
4°C, > 1 year
4°C, > 1 year
4°C, > 1 year
-20°C in small 
aliquots
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Procedure for the Danio rerio Abcb4 ATPase assay 
In each ATPase assay, two controls were included, representing basal ATPase activity of the protein 
in presence of 2% solvent (DMSO) and stimulator co-treated ATPase activity, caused by 40 µM 
verapamil (in accordance to Von Richter et al., 2009, Fekete et al., 2015)  
To calculate the liberated phosphate a phosphate standard curve was present on every test plate 
with 5, 10, 20, 40, and 80 nmol KH2PO4 in assay-mix without membrane protein.  
All tested chemicals (at least six different concentrations) and all controls were assayed in presence 
and absence of 0.25 mM and 0.3 mM sodium orthovanadate in ATPase assays, which is blocking the 
catalytic cycle of ABC transporter ATPase (Urbatsch et al., 1995, Ambudkar et al., 2003). Each 
concentration of tested chemicals and the controls with and without sodium orthovanadate were 
assayed at least in duplicate. 
 
• Thaw membrane preparation on ice 
• 96-well-plates, assay mix, membrane preparation, MgATP, sodium orthovanadate, and 
KH2PO4 are kept on ice 
• Prepare assay mix: 50 mM MOPS-Tris, pH 7; 50 mM KCl; 5 mM sodium azide; 0.1 mM EGTA-
Tris, pH 7; 2 mM DTT in bi-distilled water; 8 ml  
• Prepare 750 µl assay mix + 250 µl MgATP (0.2 M) 50 mM MgATP 
• Vortex dewed (on ice) membrane preparation for 1 min. Prepare assay-mix with 
membrane: 20 µg membrane protein in 4.2 ml assay mix.  
• 2 ml of assay mix with membrane + 4 µl DMSO or 4 µl 20 mM verapamil  basal (bA) or 
stimulator co-treated ATPase activitiy (cA; with 40 µM verapamil) 
• 0.9 ml of bA and cA + 2.25 µl bi-distilled water or 2.25 µl sodium orthovanadate (120 mM) 
 four tubes (Ctr. 1 to 4). 
• Spread 40 µl of the four different tubes on the 96-well-plate following the pipetting scheme 
figure A1 
• Spread 40 µl of assay mix without membrane in the wells for the phosphate standard curve, 
add 10 µl of the respective phosphate stock (8, 4, 2, 1, 0.5 mM KH2PO4); blank: 10 µl bi-
distilled water. 
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Fig. A.1 Pipetting scheme for ATPase assays 
Coloured areas code for common ingredients in squares (controls: ctr.1-4), plus test substance in the 
columns. Tested concentrations (A-H) were randomised. KH2PO4 standard with final concentrations of 5 to 
80 nmol Pi. 
 
• Add 1 µl of test chemical stock to the wells, 1 µl DMSO to the control bA, 1 µl of 2 mM 
verapamil to the control cA ( 40 µM); concentrations should be randomised.  
• Incubation of 96-well-plate at 27 °C for 10 min (water bath) 
• To prevent effects from handling during incubation (velocity of reaching incubation 
temperature and cooling down afterwards), wells with and without vanadate should be 
both either inside the plate or at the rim.  
• Para-film should be used to cover the plate from the bottom ensuring that wells are only 
warmed from below not from the rim. A water bath should be preferred to a table incubator 
because reactions and hence determined ATPase activities are time and temperature 
dependent (Temperature de/increase across the plate is faster using a water bath). 
• Reactions were started by addition of 10 µl 50 mM Mg ATP solution ( final concentration 
of 10 mM MgATP) in each well except of the phosphate standard curve 
• Place the 96-well-plate in a 27 °C water bath for 30 min  
• Reactions were stopped by addition of 40 µl 5% SDS and 200 µl of the freshly prepared 
detection reagent: 16 ml 10 % ascorbic acid + 5.33 ml ammonium molybdate tetrahydrate 
[8.33 % ascorbic acid, 5.83 mM ammonium molybdate tetrahydrate and 2.5 mM zinc 
acetate; pH 5].  
• Plates were incubated for 25 min at 37 °C in an incubator. 
• Cool down plate for 5 min 
• Measure absorption at 750 nm (MWG Biotech, Gesellschaft für angewandte Biotechnolgie 
GmbH, SpectraMax 250)  
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A (conc. B) (conc. B) (conc. B) (conc. B)
B conc. C conc. C conc. C conc. C
C conc. A conc. A conc. A conc. A
D conc. D conc. D conc. D conc. D
E conc. E conc. E conc. E conc. E
F conc. H conc. H conc. H conc. H
G conc. F conc. F conc. F conc. F
H (conc. G) (conc. G) (conc. G) (conc. G)
blank
20 nmol Pi
40 nmol Pi
80 nmol Pi
5 nmol Pi
10 nmol Pi
ctr.1 ctr.3
ctr.2 ctr.4
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ical + verapam
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chem
ical + verapam
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A.2.8 Re-Analysis of ATPase assay data from earlier pipetting scheme 
The example data to demonstrate re-analysis of ATPase assay data – obtained using the pipetting 
scheme in Fig. A.2 – were from Fischer et al. (2013) for verapamil (Fig. A.3 C). 
 
Fig. A.2 Pipetting scheme used in early ATPase assays 
Basal and control verapamil stimulated ATPase activities were calculated by subtracting vanadate treated 
samples (controls two and four) from samples without vanadate treatment (controls one and three), 
respectively. Basal and (control) verapamil stimulated ATPase activities served as controls. Chemical specific 
vanadate sensitive ATPase activities were obtained by subtraction of values from vanadate treated samples 
from non-treated samples, analogously to calculation of the controls. 
 
In Fig. A.3 A and C results were shown for verapamil, obtained with the early pipetting scheme, 
before re-analysis. When the well-plates were put in the 27 °C or 37 °C water bath, the incubation 
temperatures were faster reached at the rim of the well-plates, and at the end of the incubation 
time higher amounts of Pi were obtained at the rim. If subtracting values from the rim from values 
from inside, the calculated vanadate sensitive ATPase activities, were lower for basal, higher for 
verapamil stimulated ATPase activities of the controls, and further affect the ATPase activities 
evoked by the chemical tested along with the stimulator verapamil (co-treated). Subsequently, the 
concentration response curve of verapamil started above the level of basal ATPase activity (Fig. A.3 
C). Figure Fig. A.3 B and D showed results for verapamil after re-analysing. Re-analysis: Values to 
calculate vanadate-sensitive ATPase activities from wells with different reaction conditions 
(incubation temperature) were excluded (crossed out, in white background, compared to figure A.4 
A), that finally only values from either the rim or inside (which had the same reaction conditions) 
were passed to account for a final value (vanadate sensitive ATPase activity), depicted in Fig. 
A.4 (B).  
1 2 3 4 5 6 7 8 9 10 11 12
A blank ctr.3
chem
ical
conc. A
chem
ical + van
conc. A chem
ical + verapam
il
conc. A chem
ical + verapam
il + 
vanadate
conc. A
B 5 nmol Pi conc. B conc. B conc. B conc. B
C 10 nmol Pi conc. C conc. C conc. C conc. C
D 20 nmol Pi ctr.4 conc. D conc. D conc. D conc. D
E 40 nmol Pi conc. E conc. E conc. E conc. E
F 80 nmol Pi conc. F conc. F conc. F conc. F
G ctr.1 conc. G conc. G conc. G conc. G
H ctr.2 conc. H conc. H conc. H conc. H
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Fig. A.3 Early ATPase assay data before and after re-analysis 
Sections A and C show verapamil data before re-analysis (from Fischer et al., 2013) and sections B and D after 
re-analysis. Values to calculate vanadate-sensitive ATPase activities from wells with different reaction 
conditions (incubation temperature) were excluded, that finally only values from wells were used which had 
the same reaction conditions (see Fig. A.4). A/B, ATPase activity given in nmol Pi for all four controls and 
chemical treated samples indicated in A.3 – with and without vanadate. C/D, vanadate sensitive ATPase 
activities in nmol Pi/min/mg. Basal (bA) and verapamil stimulated (sA) Abcb4 ATPase activities and 
modulation of basal (modulation of bA) and modulation of stimulator co-treated (modulation of cA) Abcb4 
ATPase activities by verapamil. 
 
 
Fig. A.4 Re-analysis of example data 
Early pipetting scheme used e.g. in Fischer et al. (2013) (A) and values which were excluded (crossed out, 
white background) that finally only values from wells were used which had the same reaction conditions (B). 
 
A
B
1 2 3 4 5 6 7 8 9 10 11 12
A blank ctr.3
chem
ical
conc. A
chem
ical + van
conc. A chem
ical + verapam
il
conc. A chem
ical + verapam
il + 
vanadate
conc. A
B 5 nmol Pi conc. B conc. B conc. B conc. B
C 10 nmol Pi conc. C conc. C conc. C conc. C
D 20 nmol Pi ctr.4 conc. D conc. D conc. D conc. D
E 40 nmol Pi conc. E conc. E conc. E conc. E
F 80 nmol Pi conc. F conc. F conc. F conc. F
G ctr.1 conc. G conc. G conc. G conc. G
H ctr.2 conc. H conc. H conc. H conc. H
0.164 0.156 0.154 0.827 0.853 0.849 0.578 0.56 0.843 0.833 0.561 0.599
0.278 0.269 0.264 0.765 0.825 0.826 0.522 0.513 0.793 0.815 0.545 0.571
0.382 0.368 0.36 0.719 0.773 0.799 0.501 0.495 0.758 0.788 0.528 0.563
0.593 0.574 0.566 0.477 0.729 0.742 0.498 0.493 0.763 0.776 0.535 0.559
1.046 1.031 0.998 0.472 0.69 0.691 0.494 0.497 0.765 0.771 0.535 0.572
1.954 1.872 1.842 0.479 0.637 0.657 0.503 0.502 0.775 0.785 0.532 0.531
0.719 0.665 0.621 0.606 0.649 0.669 0.527 0.516 0.785 0.793 0.553 0.575
0.641 0.596 0.568 0.649 0.676 0.676 0.57 0.546 0.825 0.843 0.587 0.594
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A.2.9 Constraints in concentration response relationship modelling 
Whenever possible, measured values were used to fit concentration response relationships to the 
data points. Values of the controls – verapamil stimulated and basal ATPase activity – were 
constrained to max and min values, respectively and measured values of the treatments were 
constrained to the respective counterparts – min and max values. When no fit was possible or the 
fit was ambiguous with this procedure – usually when treatment values were not exactly at the 
level of control values or slopes were too slight or steep – only the max or min values were 
constrained. If this was still not resulting in a reasonable fit (narrow confidence intervals for EC50s, 
low r²) default settings (curve fit without constraints) were used. 
 
A.3 SUPPLEMENTAL TABLES AND FIGURES 
A.3.1 Primer sequences 
Table A.1 Primer sequences 
Number Primer name Primer sequence 5’ to 3’ 
1 Dr_abcb4_3 ATGGGCAAGAAATCCAAACTCAAAGTGTC 
2 Dr_abcb4_4 TCAGTGGCTCATCTGTGAGGTGACAAG 
3 Abcb4_a1609g_g1610c_for CAGGGGAACCCAGATGGCTGGCGGACAAAAGCAG 
4 Abcb4_a1609g_g1610c_rev CTGCTTTTGTCCGCCAGCCATCTGGGTTCCCCTG 
5 Abcb4_a1682c_for CCTTCTTCTCGATGCGGCTACCTCTGCCC 
6 Abcb4_a1682c_rev GGGCAGAGGTAGCCGCATCGAGAAGAAGG 
 
A.3.2 Sf9 membrane preparations with recombinant Danio rerio Abcb4 and Homo 
sapiens ABCB1  
 
Fig. A.5 Western blots from seven membrane preparations of Abcb4 and ABCB1 each 
2 µg of membrane proteins were subjected to SDS-PAGE and blotted to nitrocellulose membranes. Proteins 
were detected using C219 antibody. Concentrations of the primary and secondary antibodies were 1:500 and 
1:1000, respectively. Lanes 1 to 7 (A) showed Abcb4 at around 140kDa and lanes 8 to 14 (B) ABCB1 at 
around 120 kDa.  
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A.3.3 Recombinant Danio rerio Abcb4 in baculovirus infected Sf9 cell membranes 
after different infection duration  
 
Fig. A.6 Western blots of protein extracts from Sf9 cells with recombinant Abcb4 
Recombinant proteins were obtained with the baculovirus expression system. For protein detection we used 
the C219 antibody which was raised against a conserved epitope in mammalian Abcb1. Total protein of 
baculovirus-infected Sf9 cells was isolated at three different time points, subjected to SDS-PAGE and blotted 
to nitrocellulose membranes. Concentrations of the primary and secondary antibodies were 1:500 and 
1:1000, respectively. Lanes 1, 3 and 5 on each blot show negative controls (protein from non-infected Sf9 
cells isolated in parallel to protein from infected cells), lanes 2, 4 and 6 show the blots of isolates from Abcb4 
baculovirus-infected cells. The size of the intact Abcb4 protein is ca.140 kDa. Each lane was loaded with 2 µg 
protein. The figure and text was taken from Fischer et al. (2013), S5 from supplemental material. 
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A.3.4 Parameters for concentration response relationships 
Table A.2 MgATP modulating basal and 22.2 µM verapamil stimulated ABCB1 and Abcb4 ATPase activities. 
 
 
Table A.3 Verapamil and cyclosprorin A modulating basal and verapamil co-treated Abcb4 ATPase   
activities. A, verapamil. B, Cyclosporin A. 
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Fig. A.7 Modulation of ABCB1 ATPase activity by colchicine and verapamil 
Colchicine (A,B) and verapamil (C,D) were tested to modulate basal ABCB1 ATPase activity. Data analyses 
using the Michaelis-Menten equation – for which subtraction of basal ATPase activities was needed (A,C) – 
and the four parameter logistic equation – with and without subtraction of basal ATPase activities – (B,D) 
were compared.   
 
 
Fig. A.8 Endosulfan modulating stimulator co-treated Abcb4 ATPase activity 
Endosulfan inhibited stimulator co-treated Abcb4 ATPase activity (modulation of cA) in two replicates (I and 
II) indicated in blue and red. bA/sA, basal and 50 µM verapamil stimulated Abcb4 ATPase activity. 
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